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ABSTRACT 
Background: Prevention of Mother-to-child transmission (PMTCT) of human 
immunodeficiency virus (HIV) remains a significant challenge in resource-poor settings 
despite the advances in antiretroviral (ARV) treatment. HIV-1 infected individuals are able to 
achieve viral control naturally, however the underlying mechanisms of immunological 
control in children remains poorly understood. This study was conducted from 2006 to 2010 
to investigate correlates of immune control in HIV-1 clade C infected mother-child pairs in 
the absence of ARVs. Genotypic and phenotypic viral characteristics, cellular immune 
responses to HIV-1 and host genetics were characterized and correlated with clinical markers 
of disease progression. 
Materials and Methods: To achieve the objectives of the study, three cohorts of mother-
child pairs were investigated. The first cohort included 60 untreated mother-child pairs and a 
further ten uninfected children as controls. The second cohort comprised of ARV treated 
pairs (n=60). The third cohort consisted of 374 mothers and 374 children (infected, exposed 
uninfected, HIV negative). Plasma viral loads and absolute CD4+ T cell counts were 
routinely performed in all three cohorts. HIV-specific CD8+ T cell responses were analyzed 
by interferon gamma (IFN-γ) enzyme linked immunosorbent spot (ELISpot) assays. Viral 
replicative fitness was assessed using a green fluorescent protein reporter cell line (GFP). 
Multi-parameter flowcytometry allowed for the investigation of T cell regulation, exhaustion 
and activation using CD127/CD25, TIM-3/PD-1 and HLA-DR/CD38 markers respectively. 
IL-10 promoter single nucleotide polymorphisms (SNPs) at positions -592 and -1082 were 
determined by TaqMan allelic discrimination assays. Plasma IL-10 levels were measured 
using a luminex assay.  
Results:  To describe the CTL responses elicited to various regions of the HIV proteome in 
HIV-infected treatment naïve children. Sixty children under one year of age in the untreated 
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cohort were analyzed for CTL responses spanning the HIV genome, for which only 30 had 
detectable responses.  There was no significant difference in viral load between responders 
and non-responders (p=0.2799). The responders predominantly targeted Nef (49%), Gag 
(17%) and Env (14%) regions. Markers of T cell exhaustion and regulation and their 
relationship to markers of disease progression, were next investigated as these parameters 
may explain the inability of T cells to effectively control HIV infection. T cell phenotyping 
compared treated, untreated and uninfected subgroups. In infected children, CD8+ T cells 
were significantly higher for both the inhibitory marker TIM-3 (p=0.001) and exhaustion 
marker PD-1 (p=0.0001) compared to uninfected children. Median expression of TIM-3 was 
higher on CD8+ T cells (46%) compared to CD4+ T cells (20%). TIM-3 and PD-1 expression 
on T cells were maintained at high levels over time. The frequency of absolute Tregs 
(p=0.0225) were found to be significantly higher in untreated compared to treated children. 
HLA-DR+CD38+ on CD8+ T cells were significantly up-regulated in untreated children 
compared to treated (p=0.002) and uninfected children (p=0.0177). HLA-DR+CD38+ was 
also significantly higher in children less than 6 months compared to older children on CD4+ 
(p=0.0437) and CD8+ T cells (p=0.00276). Interestingly, we observed a significant negative 
correlation between magnitude of CTL response and CD25+CD127- (p=0.0202; r=-0.7333) 
as well as HLA-DR+CD38+ (p=0.0408; r=-0.5516) on CD8+ T cells. IL-10 is an important 
immunoregulatory cytokine that has been shown to affect the outcome of chronic viral 
infections.  IL-10 polymorphisms have previously been associated with IL-10 levels and 
HIV-1 outcomes in adults. Polymorphisms associated with different levels of IL-10 
production and their relationship with transmission, markers of disease progression and 
immune responses were next investigated in this mother-child HIV transmission setting. 
Genetic analysis of IL-10 in cohort three revealed that HIV-1 acquisition was not associated 
with either IL10 -592 (AA/CA vs CC) or IL10 -1082 (AA/AG vs GG) single nucleotide 
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polymorphisms (SNPSs). There was a significant association between IL10 -1082 and HIV-1 
transmission (p=0.0012). No correlation was observed between IL10 -592 (p=0.4279) or 
IL10 -1082 SNPs (p=0.6361) and mortality rates in children. IL10 -592C was associated with 
an elevated magnitude of IFN-γ CD8+ T cell response compared to IL10 -529A (p=0.0071). 
We found a significant positive correlation between IL-10 plasma levels and viral loads 
(p=0.0068; r=0.4759) and the ages of the children (p=0.0312; r=0.1737).  
Conclusion: CD8+ T cell responses and viral fitness did not explain differences in disease 
progression in selected HIV-1 untreated clade C transmission pairs.  T cell activation and 
regulatory markers influence CTL immune responses resulting in poor clinical outcome. IL10 
-1082 polymorphisms may be used as a predictor of HIV-1 transmission. The association 
between increased IL-10 plasma levels and high viral loads suggest that IL-10 contributes to 
immune dysfunction in paediatric HIV-1 infection. This study has extended our 
understanding of immunological and genetic correlates of mother-to-child transmission and 
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CHAPTER 1 
Overview of the interplay between HIV-1, T cells and host genetics 
 
1.1 INTRODUCTION: Why Human Immunodeficiency Virus (HIV)?  
Our immune system is always at work, enabling us to survive the threat of infectious agents. The 
human immunodeficiency virus (HIV) is a virus that directly attacks the normal functioning of 
the human immune system. While many other viruses can be controlled, and infections can be 
cleared by the immune system, HIV targets and infects the very same critical immune defense 
cells. HIV preferentially infects activated CD4 cells. As the virus replicates the virions damage 
the immune system resulting in CD4 decline. Loss of CD4+ T cells and the progressive inability 
to defend the body ultimately result in Acquired Immune Deficiency Syndrome (AIDS). This 
inevitably leads to the weakening of the immune system (Sattentau, 1989). HIV destroys cell 
functionality which predisposes the host to opportunistic infections. 
  
Evidence suggests that 40% of untreated HIV-infected infants die before they reach the first year 
of life and, if left unidentified and untreated, up to 50-60% die by age two (Newell et al., 2004). 
Possible eradication of paediatric HIV-1 infection lies in the development of an infant vaccine 
that can be administered at birth that would theoretically provide protection from infancy, 
through the adolescence period, and into adulthood. An overall understanding of the exact 
mechanism that drives HIV-1 disease pathogenesis is restricted due to the apparent multifactorial 
impact of the virus.  
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1.1.1 Etiology and Epidemiology of HIV/AIDS: Global and local perspectives  
June 2011 marks 30 years since the discovery of HIV. Thirty years later, this devastating disease 
has claimed over 30 million lives. AIDS was first reported in 1981 as unusual infections and 
cancers such as Kaposi’s Sarcoma (KS) and Pneumocystis carinii pneumonia (PCP) in young 
homosexual men in New York (Gottlieb et al., 1981, Levy, 2009). Two years later HIV was 
established as the causative agent of AIDS by the depletion of CD4+ T cells (Barre-Sinoussi et 
al., 1983). Today, 33.3 million people worldwide are still infected and living with HIV (Fig 1.1). 
In 2009, an estimated 2.6 million people were newly infected with HIV of which 370,000 
infections were in children under the age of fifteen. In the same year, 1.8 million people died 
from AIDS of which 260,000 were under the age of fifteen. Since the beginning of the HIV 
epidemic, more than 60 million people have contracted HIV and more than 25 million have died 
of AIDS-related causes (UNAIDS). 
Figure 1.1 Estimated number of people living with HIV/AIDS in 2009 (UNAIDS & WHO 
report on global AIDS epidemic, 2010).   
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More than two-thirds, 22.5 million of all people living with HIV, live in sub-Saharan Africa-
including 92 percent of the world’s HIV-positive children. In 2009, an estimated 1.8 million 
people in the region became newly infected. South Africa has one of the highest infection rates 
in the world. Statistics South Africa's (StatsSA, 2011) reported the overall HIV-prevalence as 11 
percent, one of the highest in sub-Saharan Africa and among the highest in the world. 
Approximately one-fifth of South African women in their reproductive ages are HIV positive. 
Life expectancy at birth had declined between 2001 and 2005, but had since increased partly due 
to the roll-out of antiretroviral therapy. More importantly, the report showed the elevation in the 
total number of people living with HIV from 2001 (4.10 million) to 2010 (5.24 million), 
represented in Table 1.1. 
Table 1.1 HIV prevalence estimates of number of people living with HIV from 2001-2010, in 
South Africa (adapted from statssa.gov.za). 
Year Population                 15-49 years 
% Women               % Population 
% of the total 
population 
Total number of 
people living with HIV 
(in millions) 
2001 18.7 15.4 9.4 4.10 
2002 19.2 15.8 9.6 4.38 
2003 19.4 16.1 9.8 4.53 
2004 19.6 16.3 9.9 4.64 
2005 19.7 16.5 10.0 4.74 
2006 19.7 16.6 10.1 4.85 
2007 19.7 16.7 10.2 4.93 
2008 19.7 16.9 10.3 5.02 
2009 19.6 17.0 10.3 5.11 
2010 19.7 17.3 10.5 5.24 
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A related study stratified the HIV prevalence rate according to the different provinces in South 
Africa (Stats SA, 2011). KwaZulu-Natal (KZN), Mpumalanga and Free State had the highest 
HIV prevalence. The province of KZN showed an astounding prevalence of 15.8% averaged 
between 2002 and 2008.  Adult mortality based on death notification data in South Africa: 1997-
2004 revealed that the death rate among men aged 30-39 doubled, while that among women aged 
25-34 more than quadrupled. In 2008, children aged between 0 and 9 years of age showed an 
increase in mortality to over 65,000 deaths when compared to older children (35,000).  This 
elevation in child mortality number was largely attributed to HIV-1 Mother to Child transmission 
(MTCT). Prior to this report, another South African study stratified HIV incidence by children’s 
age group revealing that children under the age of two had the highest number of new infections 
(Table 1.2). This high HIV incidence was attributed to increase in MTCT (Rehle et al., 2007).     
Table 1.2 HIV incidence and number of new infections by age group, South Africa, 2005 
Numbers rounded off to the nearest thousand (Rehle et al., 2007). 
Age 
Group 
          (years) 
  Weighted                 HIV incidence 
          Sample                      per year 
             (n)                               %  
Estimated number  of new 
infections per year 
(n) 
<2 44 513 000 1.4 571,000 
2-14 13 253 000 0.5 69,000 
5-9 4 820 000 1.1 49,000 
15-24 9 616 000 2.2 192,000 




5 | C h a p t e r  1 :  L i t e r a t u r e  R e v i e w  
 
1.1.2 HIV: Diversity, structure, replication and impact of antiretroviral drugs (ARVs) 
Diversity  
There are two types of HIV: HIV-1 and HIV-2. Both HIV-1 and HIV-2 are members of the 
retrovirus family which are characterized by viruses that are capable of copying RNA into DNA. 
Furthermore, HIV-1 and HIV-2 are lentiviruses.  Lentiviruses are unique in comparison to other 
members of the retrovirus family in that, they a) deliver a large amount of genetic information 
into the DNA of the host cell, b) are able to replicate in non-dividing cells (one of the most 
efficient methods of transfer of genetic information) finally, lentivirus translates into the term 
'slow virus' as these type of viruses slowly adversely affect the body.  
 
HIV can be phylogenetically classified into four groups: group M (main); group O (outlier) and 
two new groups, N and P (Plantier et al., 2009). The classification of these groups is based on 
their discovery and likeness to simian immunodeficiency virus (SIV).  Group O and Group P are 
rare HIV-1 strains and appear to be restricted to west-central Africa. The HIV-2 strain is very 
closely related to a strain of SIV found in sooty mangabees and African green monkeys (Hirsch 
et al., 1989, Li et al., 1989). The groups N and M are more infectious HIV-1 strains in 
comparison to HIV-2. More than 90% of HIV-1 infections belong to the HIV-1 group M, which 
can be divided into subtypes (Pieniazek et al., 2000).  
 
To date, there are nine subtypes or clades. These clades have been assigned to letters A, B, C, D, 
F, G, H, J and K (Takebe, 2000). Certain clades are more prominent in some regions of the world 
in comparison to others. However, in regions where more than one clade is prevalent, clades can 
merge and viral recombination occurs. These mixtures of clades are referred to as circulating 
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recombinant forms (CRF’s) (Gillies and Grossman, 1985). Figure 1.2 describes the distribution 
of the various clades worldwide. 
 Clade A and CRF A/G predominate in West and Central Africa, with clade A causing 
much of the Russian HIV-1 epidemic (Gao et al., 1998). 
 Historically, clade B was the most common clade/CRF in Europe however, other clades 
have emerged accounting for at least 25% of new HIV infections in Europe (Graf et al., 
1998, Monaco et al., Steinrigl et al., Rangel et al., 2009, Lai et al.).  
 Clade C is predominant in Southern and East Africa, India and Nepal. It has caused the 
world's worst HIV epidemics and is responsible for around half of all infections 
worldwide (Katzenstein, 2006, Khan et al., 2007, Jacobs et al., 2009).  
 Clade D is generally limited to East and Central Africa. CRF A/E is prevalent in South-
East Asia, but originated from Central Africa (Herbeck et al., 2007, Leitner et al., 1995).  
 Clade F has been found in Central Africa, South America and Eastern Europe (Triques et 
al., 1999).  
 Clade G and CRF A/G have been observed in West and East Africa and Central Europe 
(Ojesina et al., 2008, Ljungberg et al., 2002).  
 Clade H has only been found in Central Africa; J only in Central America; and K only in 
the Democratic Republic of Congo and Cameroon (Vidal et al., 2000).  
The HIV-1 and HIV-2 subtypes differ in transmission efficiency and pathogenicity (Levy, 
2009). HIV-2 is also less virulent in comparison to HIV-1. HIV-1 clades differ by 20–50% 
(Gao et al., 1994) and are associated with varying disease progression (Ng et al., 2011, 
Kiwanuka et al., 2008, Cohen, 2000, Kanki et al., 1999). These clades may also differ in 
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immune responses elicited. Therefore, researchers worldwide are gathering data across 
different clades to develop an AIDS vaccine candidate that offers the broadest possible 




Figure 1.2 The distribution of the HIV clades and CRF’s worldwide, Francine E. McCutchan, 
Henry M. Jackson Foundation (Rockville, Maryland). 
 
Structure 
HIV is different in structure from other retroviruses. Most virus sizes are defined by their internal 
structures however, as the HIV virions are variable in size, HIV is defined by its spherical 
morphology. The external surface structure of HIV virions (Fig 1.3) are formed when the capsid 
buds from the host cell, taking some of the host-cell membrane with it to form cone-shaped 
capsid particles. The external envelope membrane includes the two glycoproteins gp120 and 
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gp41. The genome encodes three structural proteins, three enzymes, and six accessory proteins 
(Turner and Summers, 1999, Andrea Rubbert, 2007).      
 
HIV has two exact copies of single-stranded RNA (ribonucleic acid) as its basic genetic material 
which are located in the center of the organism. The RNA is tightly bound to the nucleocapsid 
proteins, p6 and p7, and enzymes such as reverse transcriptase and integrase. All of these are 
important for the development of the virion as shown by Figure 1.4  (Kuby, 2007). The virion 
particle also contains Vif, Vpr, Nef, p7 and viral Protease (Kuby, 2007). 
 
HIV has nine genes that encode for its proteins as represented in Fig 1.3A (Hunt, Levy, 1993): 
 Envelope: The Envelope is cleaved into proteins namely, gp120 which mediates viral 
binding to the cell, and gp41 which facilitates fusion of the viral and cellular membranes. 
 Gag (Group-specific Antigen): Gag is an important core protein encoded by the HIV gag 
gene. Gag is the building block of the HIV particle core. HIV-seropositive individuals 
mount a significant immune response to Gag p24 supporting the use of Enzyme linked 
immunosorbant assay (ELISA) and Western blot assays for diagnosing HIV. 
 Pol: Pol encodes several enzymes including reverse transcriptase and protease. Retroviral 
proteins are encoded by the pol gene. Pol and Gag are translated into large proteins 
which can be synthesized as protein precursors (polyproteins). These proteins are 
subsequently cleaved into final products that include reverse transcriptase, 
endonuclease/integrase and viral protease. 
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 Vif (Virion Infectivity Factor): The vif gene is essential in HIV infection. Vif is important 
during late stages of virus production and promotes stable reverse transcriptase 
complexes. Vif functions by suppressing innate anti-viral activities in T cells and 
macrophages. In the absence of Vif, HIV is not infectious in primary human T cells (De 
Cock et al., 2000).  
 Tat (Trans-Activator of Transcription): The tat gene codes for the protein that enhances 
viral RNA transcription and promotes CD4+ T cell activation. Tat enables transcription 
as it binds to the HIV LTR region. It is a positive regulator of protein synthesis. 
 Vpu (Viral Protein U): The Vpu protein promotes the proteolysis of the CD4 antigen of 
the host cell as virions are produced. The CD4 antigen and gp120 are synthesized in the 
endoplasmic reticulum of the same cell, making it more likely for them to bind one to 
another before reaching the plasma membrane. The Vpu protein prevents the degradation 
of this complex.  
 Vpr (Viral Protein R): The Vpr protein promotes cell-cycle arrest and facilitates infection 
of macrophages, thereby contributing to the pathogenesis of HIV. 
 Rev (Regulator of Virion expression): The Rev protein regulates viral RNA nuclear 
export and binds to a component found only in the mRNA for structural proteins 
(Gag/Pol/Env).  Rev regulates the ratio of structural to non-structural protein (Tat/Rev) 
synthesis. Once Rev is expressed at elevated levels, structural protein synthesis increases. 
 Nef (Negative Regulatory Factor): The Nef protein is synthesized early in infection. Nef 
promotes CD4 activation, enhances infectivity, prevents apoptosis and is associated with 
disease HIV progression. The translation of the Nef protein is a result of the virus’ first 
influence on the internalization of the CD4 antigen from the surface of the cell.  












Figure 1.3 Schematic of A) HIV-1 genome, B) virion organization and C) viral attachment, 
indicating fusion receptors, the nine structural proteins, their encoding enzymes and coat proteins 
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Replication  
HIV begins its cycle by infecting susceptible host cells, preferentially white blood cells 
expressing the CD4 receptor. It binds to the CD4 receptor (Pudney and Song, 1994) which is 
present on the surface of T lymphocytes and macrophages.  Both these types of white blood cells 
form a critical part of the immune system. During infection, HIV first attaches to the CD4 
receptor and then to the chemokine co-receptors (CXCR4, CCR5) and other cell-surface proteins 
as indicated in Fig 1.3 B/C. 
 
The gp120 protein on the HIV virion binds to CD4 and undergoes conformational change 
exposing the V3 loop, which facilitates binding to CCR5 (Rabehi et al., 1998). In individuals 
with the CCR5 delta 32 mutation (Martinson et al., 1997), the second step is impeded, therefore 
HIV cannot enter the macrophage after binding to CD4. However in normal individuals 
expressing CCR5, viral entry occurs unhindered. Upon entry, the genetic material of HIV (RNA) 
is released and undergoes reverse transcription into DNA (deoxyribonucleic acid) by the enzyme 
reverse transcriptase. The converted viral DNA enters the host cell nucleus. It is integrated into 
the genetic material of the cell by the presence of the enzyme integrase. Integration allows HIV 
to latently persist in the host cells for many years. However, activation of the host cells results in 
transcription of viral DNA into messenger RNA (mRNA). The new viral RNA forms the genetic 
material of the next generation of viruses. During translation the enzyme protease cleaves the 
viral RNA into useful viral proteins. The viral RNA and viral proteins assemble at the cell 
membrane and bud out of the cell forming a new fully functional virus. This cycle can be 
visualized in Figure 1.4 (Levy, 1998). 
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Impact of ARV on the lifecycle of HIV  
The different phases of the HIV lifecycle can be interrupted through the use of antiretroviral 
therapy (ART).  ART can be stratified into classes or groups based on the phase of the HIV 
lifecycle that they target.  These groups are namely: entry inhibitors; nucleoside and nucleotide 
reverse transcriptase inhibitors; non-nucleoside reverse transcriptase inhibitors; protease 
inhibitors; integrase inhibitors and attachment inhibitors. Figure 1.4 demonstrates the inhibitors 
available, the phase in replication cycle that they inhibit and the sites of ART activity.  
  
 
Figure 1.4 The HIV replication cycle (adapted (Levy, 1998); http://www.kaetc.org/slides/SEK-
Dental-Study-Club-1-21-09.pdf). 
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1.2. Mother to child transmission (MTCT)  
Transmission of HIV is dependent on various etiological factors, some of which are the 
concentration of HIV in bodily fluids and the nature of the host susceptibility, both at the cellular 
and immunological levels (Levy, 2009). HIV can be transmitted in many different ways. 
However, the most common ways that infections occur are through sexual intercourse, sharing of 
needles by drug users, blood transfusions and vertical transmission referred to as mother-to-child 
transmission (Jaffe et al., 1983).  
 
Mother-to-child transmission of HIV occurs when an HIV infected pregnant woman transmits 
HIV to her unborn baby either before (intrauterine) or during birth (intrapartum/early 
postpartum), or after birth during breastfeeding (late postpartum). Although the mechanisms of 
in utero and intrapartum transmission are not well understood, it has been suggested that risk 
factors for in utero transmission probably include differences in cell mediated immunity and 
cells targeted. Additional, immunological or biological factors might protect the baby against 
infections in the uterus. Differences in maternal factors of viral load, CD4+ T-lymphocyte count 
may possibly play a role.  Mechanisms underlying peripartum infection could be related to 
maternal viral load, by direct contact with blood or secretions.    
 
 1.2.1 MTCT epidemiology 
The first cases of HIV/AIDS in children were described in 1982, where the link between infected 
mothers and their infants was established (CDC, 1982). Today, mother-to-child transmission of 
HIV still remains a global health problem. Acquisition of HIV is one of the main sources of 
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paediatric deaths, particularly in sub-Saharan Africa (Rehle et al., 2007). In 2009, WHO reported 
that around 400,000 children under 15 became infected with HIV, mainly through mother to 
child transmission, and most of these MTCT infections occurred in Africa. In the absence of 
ARV interventions, MTCT transmission rates range from 15-45% (WHO, 2011). This rate can 
be reduced to levels below 5% with effective treatment interventions (WHO, 2011). In 2010, the 
UNAIDS reported that MTCT infection rates had declined by 26% from 2001 to 2009 
(UNAIDS, 2011). The South African (SA) AIDS conference recently held in Durban, KZN 
(International Conference Centre; 2011) reported a dramatic decrease in the rate of HIV mother-
to-child transmission to 3.5% (HATP; 2011). Researchers propose the possible elimination of 
vertical HIV transmission by 2015 (Medical research council (SA), June 2011). 
 
1.2.2 Intrauterine transmission 
Of all the mother-infant infections in a non-breastfeeding population in the absence of ARV’s 
approximately 30% occur as intrauterine and 70% intrapartum infections. Intrauterine HIV-1 
infection is detected in fetal tissue by the presence of HIV on culture or PCR (polymerase chain 
reaction- a qualitative or quantitative laboratory method in which the genetic material, DNA or 
RNA, of a virus is detected and amplified). However, these types of tests are impractical. 
Intrauterine HIV-1 infection is more commonly defined as an infant with the first positive HIV-1 
peripheral blood mononuclear cell culture and/or PCR at seven days of age or younger. Delivery 
of premature babies is a further risk of intrauterine transmission (Fawzi et al., 2001, Magder et 
al., 2005).  
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1.2.3 Intrapartum transmission 
Intrapartum HIV transmission rate is as high as 60% in a non-breastfeeding, untreated infant 
population (Fleming et al., 2000, De Cock et al., 2000). Intrapartum infections occur when 
infants are diagnosed as HIV negative during the first seven days of birth and subsequently 
become HIV PCR positive within 28 days. Intrapartum infections occur when neonates are 
exposed to a large volume of HIV infected maternal blood during gestation and/or delivery. 
(Fawzi et al., 2001, Magder et al., 2005). 
 
1.2.4 Transmission through breastfeeding 
In the absence of ART, there is a 10-14% transmission rate during breastfeeding (Fleming et al., 
2000, De Cock et al., 2000). Breastfeeding is an uncommon route of HIV transmission in 
developed countries, occurring at four to six weeks post-delivery. In resource poor settings 
however, the benefit of breast feeding outweighs the risk of HIV transmission (Coutsoudis, 2001, 
John-Stewart, 2007, Kakuma, 2002). The risk through breastfeeding is cumulative-the longer the 
HIV-infected mother breastfeeds, the greater the additional risk of transmission through 
breastfeeding. WHO and other research groups recommend exclusive breastfeeding for the first 
six months of life (Coutsoudis, 2001, John-Stewart, 2007, Kakuma, 2002). Flash heating and the 
use of donor breast milk has been shown to be feasible as a supply to infants in resource limited 
countries (Coutsoudis et al., 2011a, Coutsoudis et al., 2011b). The actual mechanism of HIV 
transmission by breast milk is not fully understood. However, as neonatal mucus membranes  are 
not able to effectively prevent HIV infection and thus exposure to HIV in breast milk may result 
in viral infection directly through oral and gastric mucosa  (Nduati et al., 2000). Cell-free and 
cell-associated virus transmissions may occur. 
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1.3 Clinical diagnostics and staging 
The presence of the virus is evaluated by HIV antibody, PCR and p24 antigen tests. An antigen 
test detects the protein found on foreign particles that invade the body and trigger the production 
of antibodies in the body. When an individual immunity is compromised, their body produces 
specific antibodies to target the virus, which is detectable in an individual’s bodily fluids. HIV 
antibody tests diagnose HIV infection by detecting such antibodies directed against HIV-1 
antigens like Gag and Env. HIV antibody tests are accurate and reliable for routine diagnosis of 
HIV among adults.  However, diagnosis by antibodies are challenging in infants, as these tests do 
not differentiate the maternally-derived antibodies from the infant-derived antibodies. Maternal 
antibodies can persist in the newborn’s blood for up to 18 months. Therefore, rapid PCR DNA 
tests are used to diagnose HIV infection in the infant. 
 
Once HIV infection is confirmed, the clinical course of HIV is monitored by absolute CD4+ T 
cell counts and viral load tests. The absolute CD4+ T cell count measures the number of disease 
fighting cells per milliliter of blood. It is an adequate indicator of the overall immune health of 
an individual and signifies the progression of HIV infection. The number of absolute CD4+ T 
cells determines whether an individual should initiate ART. In the developed countries WHO 
recommends initiation of ART as soon as an individual’s absolute CD4+
 
T cell decline to below 
350 cells/μl (EACS, 2009), and recently, similar guidelines have been adopted in SA (WHO, 
2006). In adults, the absolute CD4+ T cell count indicates the degree of immune suppression. In 
children, the immune system is immature (Stewart et al., 1996, Ziegler et al., 1996) and the 
percentage of CD4+ T cells as a total of all lymphocytes is the best indicator of immune 
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suppression (WHO, 2007). The HIV viral load test measures the amount of the virus present in 
the bodily fluids of an individual and quantifies HIV RNA copies per mL. Both the viral load 
and the absolute CD4+ T cell count are used to assess HIV progression and suppression in 
individuals on ART (DOH, 2010). 
The course of HIV infection is described as the duration from time of HIV acquisition to the 
development of opportunistic infections and ultimately (AIDS). HIV progression eventually 
leads to HIV pathogenesis (disease causing) (Levy, 2009). The stages of HIV infection differs 
clinically/symptomatically from one individual to another. The clinical course of HIV-1 infection 
generally includes three stages: primary infection, clinical latency and AIDS (Fig 1.5). HIV-
infected individuals can remain asymptomatic during the primary infection phase (Hollander, 
1988, McCutchan, 1990), but may show flu-like symptoms. Recently, many individuals have 
been found to exhibit symptoms in the primary stages of infection which manifests as rashes, 
fever and fatigue (Sudarshi et al., 2008). The clinical latency phase begins with a temporary 
decrease in viral load and an increase in absolute CD4+ T cells. However, due to the inability of 
the immune system to regenerate the absolute CD4+ T cells, a slow and constant decline in 
absolute CD4+ T cell count is observed. At this stage symptoms are moderately manifested. 
When the absolute CD4+ T cell count drops further the immune system is no longer capable of 
controlling the virus and other pathogens, resulting in AIDS-defining opportunistic infections. 
The following guidelines are suggested for HIV management by The Department of Health in 
South Africa (DOH; 2011): 
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 Adults with an absolute CD4+ T cell count <350cells/mm
3
 irrespective of their clinical 
stage.   
 Nevirapine to be administered to HIV positive pregnant women at 28 weeks and mothers 
are placed in a PMTCT programme. 
 Mothers who did not receive any ART before or during delivery to receive daily for at 
least six weeks, and continued for as long the child is under one year of age. Mothers are 
advised to exclusively breastfeed children for the first six months.  
 Children aged between one and five with clinical staging three/four, or absolute CD4+ T 
cell percentage of 25 or below, or an absolute CD4+ T cell count < 750.  
 Children aged 5-15 years with clinical staging three/four, or CD4+ T cell < 350. 
The initiation of prophylaxis using ARVs can reduce morbidity and mortality in HIV infected 
individuals and may provide benefits in prevention of transmission. 
 
Evidence suggests that 40% of untreated HIV-infected infants die before they reach the first year 
of life and, if left unidentified and untreated, up to 50-60% die by age two (Newell et al., 2004). 
HIV-related mortality in children can be attributed to the damage of the immune system, 
occurring in the first six months of HIV infection and/or HIV associated illnesses. In adults, HIV 
pathology is attributed to extensive damage of the immune system over time. However, other 
research has shown that the immune system can be impacted greatly during acute HIV and SIV 
infection (Grossman et al., 2006, Picker and Watkins, 2005).  
 
 
19 | C h a p t e r  1 :  L i t e r a t u r e  R e v i e w  
 
1.4 The natural course and pathogenesis of HIV: Adult vs Paediatric 
HIV is a rapidly spreading disease. HIV progression eventually leads to HIV pathogenesis  
(Levy, 2009). The stages of HIV infection differs clinically/symptomatically from one individual 
to another. Adults and children significantly differ in viral burden and therefore exhibit varying 
clinical outcomes (Holland et al., 2000, Resino et al., 2002b, Resino et al., 2002a). Vertically 
transmitted HIV progresses more rapidly in children, compared to HIV acquired in adults. (Ruiz 
Contreras, 1998, Walker, 1995, Cigielski, 1988). Unlike adults, in paediatric HIV-1 infection 
there is no rapid decline in viraemia after acquisition, and the viral burden in children remains 
elevated for the first year of life.  This could be attributed to many reasons-the immune system of 
children is not fully developed; therefore they are particularly vulnerable to HIV and other 
common pediatric infections. HIV infected children cannot fight off infections as effectively as 
uninfected children or adults. Common infections in HIV-positive children include ear and sinus 
infections, sepsis, pneumonia, urinary tract infections, intestinal illness, skin disease and 
meningitis (Canosa, 1991, Scarlatti, 1996). In less developed countries, tuberculosis, diarrhea, 
and respiratory illnesses take precedence (Bobat et al., 1990, Jeena et al., 1998).  
 
HIV-1 pathogenesis, chronic asymptomatic infection normally span from 3 to 20 years 
depending on the individual’s rate of disease progression (Levy, 2009). About 10 to 15 % 
progress to AIDS within two to five years (rapid progressors), while long-term non-progressors 
(LTNP) , < 5% remain asymptomatic for at least 10 years (Curran et al., 1988). LTNP and elite 
controllers or slow progressors, gradually progress to AIDS. One of the main differences 
between a slow progressor and a rapid progressor is their ability to maintain a robust CTL 
response (Fig 1.5 (Goulder et al., 2001b, Altfeld et al., 2001, Hay and Rosenberg, 1998)). 
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Untreated HIV-1 infected children exhibit an elevated viral load within the first year of life. A 
slow decrease in viral replication is only visible over 2-3 years of age (Richardson et al., 2003, 
Shearer et al., 1997) which may be attributed to a mature strengthened, robust and more durable 
T cell response  as demonstrated in Fig 1.6.  
 
Figure 1.5 Schematic illustration of the course of HIV infection (Goulder et al., 2001b). 
 
One of the main challenges in paediatric HIV-1 infection is the inability of the immune system to 
generate a sustainable immune response, particularly following vertical transmission.  The CD8+ 
T cell response (CTL) has been documented to play a critical role in maintaining suppression of 
the virus (Borrow et al., 1994, Hay and Rosenberg, 1998, Kalams and Walker, 1994, Kaul et al., 
Papasavvas et al., 2003, Walker and Plata, 1990), particularly in primary infection (Fig 1.5/6). 
Accumulating evidence indicates that the immune system is potentially capable of effective 
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control of HIV infection and, events occurring in acute infection critically determine the final 
outcome (Paranjape, 2005, Borrow and Bhardwaj, 2008). The initial containment of HIV after 












Figure 1.6 Schematic comparison of the kinetics of HIV disease progression in a) adults 
(adapted from (Paranjape, 2005, Borrow and Bhardwaj, 2008)) and b) children adapted (Goulder 
et al., 2001b). 
 
Children fail at controlling HIV, firstly because of their immature immune system and inability 
to mount a significant immune response (Stewart et al., 1996, Ziegler et al., 1996). The next 
complication lies with the transmitted virus. As children share their parent’s genetic make-up, 
the human leukocyte allele (HLA) inherited by a child may affect his/her capability to control the 
virus. The study of transmission pairs provides information of both donor and recipient virus.  
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Knowledge of the transmitted virus, sequence changes in the virus itself, innate genetic host 
factors, and host immune responses to HIV will direct our understanding of the correlates of 
protection and/or viral control. 
 
Our review will cover the following in the sections to follow. 
1) The virus and host interaction:  host HLA and immune response, and virus 
escape/fitness,  
2) The cells: immune activation (HLA-DR and CD38) and regulatory response: T 
cell immunoglobulin mucin protein (TIM-3); T regulatory cells (Tregs); 
Programmed death-1 (PD-1).  
3) The host:  immunogenetic regulatory factor (Interleukin-10).  
 
1.4.1 HIV pathogenesis: The virus and host interaction 
HIV-specific T cells play a crucial role in HIV control (Edwards et al., 2002, Kiepiela et al., 
2007, Masemola et al., 2004, Novitsky et al., 2003). The negative correlation of strong HIV-1 
specific CD4+ T helper (TH1) cell responses and viral load, indicates that CD4+ T helper cells 
play an important role in the immune response to HIV-1(Rosenberg et al., 1997). In particular, 
CD4+ T cells have repeatedly been described to impact viral control and disease progression, by 
secreting cytokines and other effector molecules that are essential in the orchestration of a potent 
antiviral CD8+ T cell mediated immune response (Rosenberg et al., 1997, Pitcher et al., 1999, 
Janssen et al., 2003, Shedlock and Shen, 2003, Snell, 1979).  
HIV-specific cellular responses mediated by CD8+ T cells, are a major component of the host 
adaptive immunity and, have been implicated in the containment of viral load (Borrow et al., 
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1994, Hay and Rosenberg, 1998, Kalams and Walker, 1994, Kaul et al., Papasavvas et al., 2003, 
Walker and Plata, 1990). CTL recognizes the infected cells through the signal produced by the 
processed portion of viral proteins on the infected cell surface. The T cell receptor (TCR) is 
somewhat promiscuous with respect to peptide binding as it is able to recognize and target 
multiple epitopes. CTLs with broad breadth can either be immunodominant or subdominant 
(Newman et al., 2002, Rolland et al., 2008) and if effective-should be considered in vaccine 
design.  
 
The targeting of certain HLA restricted epitopes and viral protein regions successfully impacts 
viral set point (Kaul et al., Lyles et al., 2000, Mellors et al., 2007, Vidal et al., 1998), and have 
been associated with a dramatic decline in viremia in adults (Borrow et al., 1994, Altfeld et al., 
2001, Goulder et al., 2001a, Streeck et al., 2009, Yang, 2004, Lindback et al., 2000). A similar 
outcome (Fig 1.6) was noted in paediatric studies (Feeney, 2004, Feeney et al., 2005, Goulder et 
al., 2001b, Goulder et al., 2001c, Thobakgale et al., 2009b, Thobakgale et al., 2007).  
 
Recognition by CTL of epitopes derived from the HIV-specific protein coding genes, have been 
found to influence viral control. The conserved gene product, Gag has been associated with a 
decline in viremia in the primary and asymptomatic chronic period of infection. In adults, Gag-
specific responses have been associated with low viremia, while Env-specific responses have 
been associated with higher viremia (Kiepiela et al., 2007). This suggests that in adult HIV-1 
infection, immune responses to Gag play an important role in viral control while Env-directed 
responses may be associated with a detrimental outcome.  
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Very few studies have investigated cellular immune responses in paediatric infection or, the 
trends of protein recognition within mother-child pairs. Lohman et al. investigated HIV-1-
specific IFN-γ responses over the first year of life. The infants demonstrated a diverse pattern of 
immune recognition and viral replication. Some infants completely lacked detectable responses 
while others demonstrated strengthening and broadening responses to HIV-1 over time (Lohman 
et al., 2005). In another study (Thobakgale et al., 2007), envelope specific responses were found 
to be frequently targeted  in acutely infected infants, compared to chronically infected children. 
Gag-specific CD4+ T cell responses were undetectable during the earlier months of paediatric 
infection. The study revealed that some infants maintained suppression of the virus, partially 
attributable to CTL response (Thobakgale et al., 2007).  
 
The HLA system is heterogeneous and is made up of a cluster of genes that influence immune 
functioning (McCusker and Singal, 1990, Scripcaru and Plesa, 1978). More than 300,000,000 
genetically different individuals can be represented by HLA-A; -B and -C combinations 
(Bodmer, 1979, Bodmer and Bodmer, 1978). A distinct few HLA have been found to play a 
more influential role in clade C. HLA-B appears to have the strongest impact on viral load. More 
specifically, HLA-B*57; B*8101 and B*5801 had the strongest significant association with low 
viral load while HLA-B*5802 and HLA-B*1801 were documented to be associated with higher 
viral load (Fig 1.7 (Kiepiela et al., 2004)).  CTL responses (epitopes) restricted by HLA-B alleles 
were further investigated in children.  If the child or their mother possesses one of the protective 
HLA-B alleles, they progress slowly. Slow progressors tend to make more cellular T cell 
responses to Gag epitopes (Thobakgale et al., 2009a).  












Figure 1.7 Impact of HLA-B on viral load (Kiepiela et al., 2004) Coloured bars denote epitopes 
previously found to significantly impact viral load.  
 
Figure 1.8 Global distribution of influential MHC class 1 HLA-B (Goulder and Watkins, 2008). 
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CTL studies provide information for the development of epitope-based vaccines. CTLs target 
different regions of the HIV genome across the different clades, posing variable targets for 
vaccine design (Newman et al., 2002, Cao et al., 1997, Cao et al., 2000).  An effective global 
CTL-based vaccine is one likely to induce CTL responses that can suppress the virus across 
clades. HLA-B itself is similarly heterogeneous, varying in frequency across regions worldwide 
(Fig 1.8 (Goulder and Watkins, 2008)). Different HLA may be associated with strikingly 
different clinical outcomes.  HLA-B*5801 has been shown to be associated with low viral loads 
while, HLA-B*5802 has been linked to high viral loads. (Ngumbela et al., 2008).  
 
Transmission pairs provide information regarding donor and recipient virus.  Knowledge of the 
sequence changes that subsequently occur during transmission, may direct us to protein 
sequences that play a role in viral containment. Mutational escape represents the major driving 
force for viral diversification. In adult HIV-1 transmission, transmitted escape variants may be 
associated with lower viral load in recipients. A significant association has been documented 
between the number of Gag escape mutations, and low viral loads in linked recipients. In HLA- 
B*5703 common Gag p24 mutations were found in epitopes IW-9; KF-11 and TW-10. Similarly, 
in HLA- B*5801, mutations were found in TW-10 and KF-9 (Goepfert et al., 2008). 
Accumulation of the three B*5703-associated Gag p24 escape mutations in succession, reduces 
viral replicative capacity in vitro (Crawford et al., 2009).   
 
MTCT pairs represent an interesting cohort for investigation, as pairs share a partially matched 
genetic environment.  The HLA inherited by a child will affect his/her capability to control the 
virus. In clade B investigations, HLA-B*27 has been strongly associated with low viral loads. In 
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adults, Gag specific CTL escape variants restricted by HLA-B*27, result in the loss of CTL 
recognition and disease progression. Accumulated CTL escape variants revert in the absence of 
the evolutionary pressure that originally selected the mutation (Leslie et al., 2004, Goepfert et al., 
2008, Goulder et al., 2001b, Goulder et al., 2001c, Pillay et al., 2005). 
 
HLA may drive the virus to a less fit state and thus influence clinical outcome. HIV-1 fitness is 
associated with, and contributes to, the rate of transmission and disease progression (Biesinger 
and Kimata, 2008, Chopera et al., 2008, Duda et al., 2009, Lal et al., 2005, Miura et al., 2009a, 
Miura et al., 2009b, Wright et al., Wright et al.). Viral fitness can be explored using a novel 
method that uses target cells that enable the entry of both CXCR4 and CCR5 tropic HIV-1 
strains (Brockman et al., 2006, Wright et al., 2010, Wright et al.). This novel method measured 
replication capacity of  the virus using an HIV-1 inducible green fluorescent protein
 
reporter cell 
line (Brockman et al., 2006). The replication capacities of patient-derived Gag-protease 
recombinant viruses have been shown to positively correlate with
 
viral load and negatively with 
absolute CD4+ T cell count in chronically infected individuals (Wright et al., 2010). However, 
the rate of decline demonstrated no influence over time. The protective allele HLA-B*81 seemed 
to play a significant role in driving
 
sequence changes in the conserved regions of Gag, and may 
impact viral fitness (Wright et al.). These findings were associated to early HIV infection 
(Wright et al., 2011). Replication capacities did not correlate with viral
 
load set points but were 
significantly lower in individuals
 
with low viral load set points. Transmission
 
or early Gag 
escape variants seem to result in reduced early CD8+ T cell responses and higher
 
viral load set 
points. HIV disease
 
progression is influenced by the ability to mount
 
effective Gag CTL 
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responses, as well as the replication capacity
 
of the transmitted virus (Wright et al., 2010, Wright 
et al., 2011). 
 
Taken together, cellular immune responses provide at least partial success in mediating viral 
control, particularly when restricted by protective HLA. Certain HLA are associated with 
reduced viral replicative capacity. However, a better understanding of immune control in slow 
progressor survivors naturally containing viral load, may direct us to the underlying determinants 
of protective immunity. The broad scientific goal of our study was to explore HIV pathogenesis 
in genetically matched transmission pairs and/or children, in order to further contribute to 
understanding of the correlates of successful immune control in paediatric HIV-1 infection. The 
paediatric population is vulnerable to HIV owing to the immaturity of their immune system. In 
the absence of antiretroviral therapy, HIV-1 infected children die within the first two years of life 
(Shim et al., 2012, Bobat et al., 1999, Bobat et al., 1990, Goulder et al., 2001b, Newell et al., 
2004, Ruiz Contreras, 1998, Prendergast et al., 2007, Mphatswe et al., 2007). 
 
1.4.2 HIV pathogenesis: “The cells” 
In neonates, components of the immune system are unable to function as maturely as the adult 
immune system. Understanding the difference in immunopathogenesis in children and adults, 
may provide further insights into the mechanisms leading to effective immune control. T cell 
immune response plays a role in immune control (Dyer et al., 2008, Kalams and Walker, 1994, 
Kaul et al., Liu et al., Paranjape, 2005, Rolland et al., 2008, Walker and Plata, 1990, Altfeld et 
al., 2002, Edwards et al., 2002, Huang et al., 2008, Prendergast et al., 2011, Ramduth et al., 
2009, Wright et al., 2010, Wright et al., 2011) unless viral escape occurs (Autran et al., 1996, 
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Draenert et al., 2004). The sequence changes of escape variants make it hard for CTL to 
recognize and target them, often leading to the loss of immune control (Crawford et al., 2009, 
Thobakgale et al., 2009b). Many HIV infected infants seem to exhibit virus specific CD4+ and 
CD8+ T cell  immune responses that appear to be functionally impaired and therefore, are unable 
to effectively control viral replication (Papasavvas et al., 2003). Previous adult cohort studies 
have shown that clinical outcome is further influenced by the functionality of T cells. In other 
words, the mere presence of T cells is not sufficient because, it is the level of functionality of 
these T cells that effectively mediate host immunity.   
 
Functionality of T cell subsets can be investigated by the phenotypic characterization of 
lymphocyte subsets, and may contribute to the understanding of HIV disease pathogenesis and 
progression. There is variation in T cell frequency for T cells having phenotypes associated with 
T cell regulation and activation (Ssewanyana et al., 2009). T cell frequency differs during the 
course of infection, and may also differ between children and adults.  The disparity between viral 
loads in infants compared to adults is considered to be a major contributing factor to observed 
clinical difference (Fig 1.6B). Unlike adults, the levels of plasma viremia in infected infants are 
persistently high, with declines seen only in the second year of life (Shearer et al., 1997).  
Approximately 25-40% of untreated infants will progress to AIDS within the first year of life 
(Newell et al., 2004).  It is assumed that these neonates have ineffective T cell immunity, which 
may be attributed to T cell exhaustion, which can be measured by the increased expression of 
certain surface markers. However no studies have investigated this assumption in African 
children hence the need for our study.  
30 | C h a p t e r  1 :  L i t e r a t u r e  R e v i e w  
 
Phenotypic evaluation of lymphocyte subpopulations can determine their maturational and 
functional capabilities. Activated specific CD8+ T cells present during virus replication 
frequently express activation markers CD38 and HLA-DR. CD38 is a surface marker of cell 
activation. In HIV negative individuals, CD38 is expressed in relatively greater numbers by 
naïve lymphocytes, while in HIV infected individuals, CD8+ memory T cells express more 
CD38 (Benito et al., 2005). HLA-DR is another cell surface receptor. The CD4+ HLA+DR 
CD38+ phenotype identifies activated lymphocytes and is increased in HIV-infected adults. 
However, the CD4+ T lymphocyte population may be different in children compared to adults.  
When lymphocyte activation in healthy infants are compared to that of HIV exposed uninfected 
infants, the proportions of activated CD4+ HLA-DR+ and CD38+ are  increased in the exposed 
infants (Jennings et al., 1994). 
 
CD4+ cells co-expressing CD38+ and HLA-DR+  have been found to be significantly higher in 
clade B HIV infected children compared to uninfected children(Plaeger-Marshall et al., 1994). 
When the CD4+ cells were compared between these uninfected and infected by age, the CD4
+
 
cells of the uninfected vs infected children exhibited a mean expression of 2 vs 6% for < 2 years 
of age, 3 vs 11% for 2-3 years, 2 vs 8% for > or = 4 years). There was a striking and significant 
increase in the proportion of CD8+ T cells co-expressing CD38 and HLA-DR  with a mean of 5 
vs. 25% for < 2 years, 10 vs 41% for 2-3 years, 6 vs 31% for > or = 4 years being exhibited for 
uninfected vs infected children, denoting the effect of immune activation on immune response 
(Gallagher et al., 1997, Plaeger-Marshall et al., 1994). Immune activation in children receiving 
ART may vary, depending on the viral load. The percentage of CD8+ CD38+HLA-DR+ T cells 
of children with VL ≥ 400 copies/ml was significantly higher than that of patients with VL < 400 
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copies/ml, suggesting that successful ART could significantly decrease immune activation in 
children (Jin et al., 2011).  
 
T cell activation has also been found to be regulated by the suppressive ability of regulatory T 
cells (Treg). In humans, quantitative identification and viable enrichment of natural regulatory T 
cells are problematic. There exists a need to facilitate the analysis of these cells in disease states. 
Tregs are identified as being CD4+, with high levels of cell-surface expression of CD25, and can 
also be identified by their expression of the forkhead winged-helix transcription factor FOXP3 
(forkhead box P3). Treg identification using these markers is not consistently accurate, as it is 
unable to uniquely define this specialized T cell subset in humans (Fehervari and Sakaguchi, 
2004). Nevertheless, Tregs are critical regulators of immune tolerance. They prevent the 
generation of self-reactive T cells which are capable of generating autoimmune disease in the 
host.  
Treg’s suppressive ability may limit the magnitude of effector response, poorly contributing to 
viral control; but it may also suppress chronic immune activation, thus preventing disease 
progression. Immune activation during chronic HIV infection is a strong clinical
 
predictor of 
death, and may mediate Treg depletion. Treg
 
number is strongly correlated with both CD4+ and 
CD8+ T cell
 
activation in adults (Eggena et al., 2004). In HIV-1 infected children, there has been 
an association between the number of activated CD8+CD38+ T cells and the viral load. In 
addition, the proportion of Tregs correlated positively with HIV-1 viral load and CD8+CD38+, 
but correlated inversely with CD4+ T cells. This suggests that the suppressive activity of Tregs 
may be sometimes unsuccessful in limiting immune activation (Freguja et al.).  
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CD4+ Tregs, mediated by the CTLA-4 pathway have been found to play a role in CD8+ T cell 
suppression in vivo (Sakaguchi et al., 2009). Stronger robust CD4+ and CD8+ effector T cell 
responses are important for control of HIV replication. After Tregs in vitro were sorted and 
removed, an increased HIV-specific effector T cell response was observed (Aandahl et al., 2004, 
Oswald-Richter et al., 2004, Weiss et al., 2004). Tregs may suppress the HIV-specific cytolytic 
antiviral response of CD8+ T cells (Kinter et al., 2007).  Most of these studies examined the 
effect of Treg depletion on T cell proliferation and/or IFN- γ production, after stimulation with 
HIV antigens.   
 
Another marker found to be associated with T cell regulation is the T cell immunoglobulin 
mucin (TIM) proteins. The TIM proteins are membrane surface glycoproteins that are expressed 
on T cells and exhibit common structural motifs. TIM-1 appears to be an activation molecule for 
all T cells. TIM-2 molecules function by negatively regulating T helper or TH2 immune 
responses, while TIM-3 is activated by galectin-9 and is specifically expressed on TH1 cells in 
both mice and humans. TIM-4 expression occurs in dendritic cells (DC) and promotes DC 
maturation, which plays an important role in the initiation of TH2 polarization.  
 
Our investigation focused on the TIM-3, which to date has not been described in HIV-1 infected 
children and, of which no data is available in the context of HIV-1 clade C infection. TIM-3 has 
previously been associated with immune dysregulation of T helper cell responses (Hafler and 
Kuchroo, 2008, Koguchi et al., 2006, Kuchroo et al., 2006, Sakuishi et al., 2011, Sanchez-Fueyo 
et al., 2003, Zhu et al., 2011). TH1 cells represent the body’s first line of defense against foreign 
microbes. When TH1 cells are activated, they help to initiate an attack and guard against 
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infection. However these TH1 cells can become counterproductively aggressive in their attack, 
leading to autoimmune diseases, and thus optimal TIM-3 function is needed (Anderson et al., 
2007, Meyers et al., 2005, Sanchez-Fueyo et al., 2003). TIM-3 plays a role in controlling TH1 
dependent immune responses by balancing aggressive responses, regulating immune tolerance 
(Hastings et al., 2009, Kuchroo et al., 2006, Sanchez-Fueyo et al., 2003). By increasing TIM-3 
signal, the response of TH1 cells can be diminished. When the TIM-3 pathway is blocked and 
the TIM-3 signal decreased, the TH1 responses could be amplified, creating aggressive immune 
responses (Jones et al., 2008, Monney et al., 2002). In addition, TIM-3 signaling events exhibited 
differential expression on the innate naïve dendritic cells in comparison to adaptive immune cells 
(Anderson and Anderson, 2006).  
 
TIM-3 fusion proteins could lead to hyper-proliferation and increased production on TH1 type 
cytokines, indicating that the function of TIM-3 may be to dampen effector responses (Sabatos et 
al., 2003). Conversely, a blockade of the TIM-3 pathway accelerated the onset of autoimmune 
disease in mice (Sanchez-Fueyo et al., 2003) The blockade of PD-1 together with TIM-3 
pathway has been shown to rescue T cell immune responses in hepatitis (Golden-Mason et al., 
2009, Callendret and Walker); leukemia (Zhou et al.) and HIV (Sakuishi et al.). These dually 
expressing T cells may also play a role in T cell exhaustion. No studies have investigated the role 
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1.4.3 HIV pathogenesis-The host: Role of Interleukin-10 
HIV pathogenesis and susceptibility is strongly reliant on host-pathogen interplay. How does 
genetic susceptibility translate into control or the lack thereof in children? Does genetic 
susceptibility in children affect immune responses as T cells and regulatory cells (Tregs) have 
been found to do? The immunoregulatory factor, interleukin-10 (IL-10), is a cytokine produced 
by lymphoid cells. IL-10 plays a key role in promoting viral persistence, possibly by inhibiting 
activation and effector functions of particular T cell and macrophage subsets (Brooks et al., 
2008, Brooks et al., 2006). Thus immune activation appears to be a driving force in HIV 
pathogenesis, indicating a major role for IL-10 in this process. 
 
Genetic polymorphisms within the IL-10 promoter region may influence the levels of IL-10 
produced from various cells of the immune system (Ejrnaes et al., 2006, Lazarus et al., 2006, 
Turner et al., 2002). Our investigation focused on two single nucleotide polymorphisms (SNPs) 
found in the proximal promoter region at positions -1082 (A to G transition) and -592 (C to A 
transversion) of the 36-kDa IL-10 gene. The IL-10 gene has been mapped to human chromosome 
1, between 1q31 and 1q32 and its promoter SNPs have been associated with different levels of 
IL-10 production (Kamali-Sarvestani et al., 2006, Lan et al., 2006) as shown in Fig 1.9.  
 
IL-10 has also been shown to inhibit HIV-1 replication directly in macrophages and monocytes 
by blocking entry and/or post entry, and also suppressing and down regulating cyclin T1 and 
consequently Tat function (Wang and Rice, 2006). Lymphocytic choriomeningitis virus (LCMV) 
infection in mice is a model of chronic viral infections, and suggests that during the early phases 
of infection, IL-10 plays a critical role in the disruption of effector immune responses and viral 
35 | C h a p t e r  1 :  L i t e r a t u r e  R e v i e w  
 
persistence (Brooks et al., 2006). The blockade of the IL-10 pathway allowed a DNA vaccine to 
further stimulate T cell responses and restore IFN-γ secretion, resulting in viral clearance. This 
suggests that a single immunoregulatory molecule can have a significant role in determining the 
outcome of persistent viral infection in mice (Brooks et al., 2006)  There is a need for these 
studies to be extended to HIV-1, the most significant persistent viral infection in the human 
population. This will enable a better understanding of mechanisms that underlie immune 
dysfunction in HIV-1 infection.  
Figure 1.9 Location of -1082 and -592 SNPs on proximal promoter region of IL-10 gene on 
human chromosome 1 (adapted D. Naicker).  
 
Polymorphic variants are likely to regulate susceptibility or resistance to HIV infection.  Each of 
the genotypes of these SNPs is associated with different levels of IL-10 production (Kamali-
Sarvestani et al., 2006, Lan et al., 2006).   Polymorphisms associated with decreased IL-10 
production have been associated with increased likelihood of HIV-1 acquisition, suggesting that 
high IL-10 production may reduce susceptibility to HIV-1 infection and protect against disease 
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progression. IL-10 genotypes do not appear to play a significant role in HIV pathogenesis.  In 
HIV-1 CRF01_AE-infected northern Thais, IL10 promoter SNPs IL10-1082 (with the commonly 
expressed IL10-AA genotype and A allele) was not associated with CD4+ or CD8+ absolute T 
cell counts or viral load  (Kingkeow et al.).  
 
In African women at high risk for HIV-1 infection, a C to A transversion mutation at promoter 
position -592 (relative to the transcriptional start site) can be linked to increased likelihood of 
HIV-1 acquisition (Naicker D, 2009). On the other hand, A to G transition mutation at position -
1082 showed a trend towards increased likelihood of HIV-1 acquisition. Thus genotypes linked 
to high IL-10 production may have a protective effect against HIV-1 infection.  However, 
individuals with high IL-10 producer genotypes have exhibited significantly higher median 
plasma viral loads or lower absolute CD4+ T cell counts during the acute phase (≤3 months post 
infection). As HIV-1 infection progresses, the allele effect on median viral load or CD4+ T cell 
pattern reverses or may be lost (Naicker D, 2009). In carriers of IL-10 1082G, an allele linked to 
increased IL-10 production could be associated with decreased rates of mortality, and CD4+ T 
cells decrease may well be attenuated compared with non-carriers (Erikstrup et al., 2007). Taken 
together, these studies suggest that IL-10 promoter variants may influence susceptibility to HIV-
1. 
 
The IL-10 cytokine may have beneficial anti-HIV-1 effects. IL-10 promoter variants associated 
with different levels of IL-10 production may also affect markers of disease progression such as 
viral load and absolute CD4+ T cell counts, depending on the stage of infection. Pro-
inflammatory cytokines have been found to induce transcription of latent HIV-1, and regulatory 
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cytokines play a role in suppressing type 1 cytokines. It is important to investigate functional 
levels of pro-inflammatory and anti-inflammatory cytokines; honing in on their levels of 
association with IL-10 promoter polymorphisms, clinical markers of disease progression, age 
and HIV-pathogenesis.   
 
In acute HIV infection, up regulation of certain cytokines such as IFN-α, TNF-α (von Sydow et 
al., 1991) and IL-10 (Norris et al., 2006) have been reported.  Furthermore, hepatitis studies 
revealed that a broad array of cytokine expression lead to eventual viral clearance in a majority 
of infected participants (Stacey et al., 2009). Recently, the association between plasma cytokine 
concentrations during primary acute infection, with clinical markers of HIV disease progression, 
such as absolute CD4+ T cell count and viral load measurements, has also been described 
(Roberts et al., 2010). Cytokines IL-12p40, IL-12p70, IFN-γ, IL-7 and IL-15 were able to predict 
66% of the variation in viral load set-point 12 months post infection. Lower viral loads were 
significantly associated with IL-12p40, IL-12p70 and IFN-γ, whereas IL-7 and IL-15 were 
associated with a higher viral load. Moreover, IL-7 was associated with more rapid CD4 loss 
(Roberts et al., 2010).  The investigators Jones et al., 2005 are one of the very few investigators 
to have attempted to profile cytokines and their levels of production in HIV-1 infected children. 
Cytokine production, CD4+ T cell count and viral loads were monitored in HIV-1 infected 
children in Hong Kong (Jones, 2005) however, they did not find any conclusive correlations. 
 
1.5 Study rationale: Hypothesis and specific aims 
Our investigation was initiated in 2006 under previous ART guidelines when ART rollout was 
not widespread. The ART guidelines have since been revised (WHO/DOH; 2011) to ensure that 
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all pregnant mothers and HIV-1 infected infants are started on highly active antiretroviral 
therapy (HAART) to improve clinical outcomes, as was demonstrated by the CHER study 
(Violari et al., 2008). Unfortunately the limitation of resources in less developed countries still 
daunts HIV related MTCT. Possible eradication of paediatric HIV-1 infection lies in the 
development of an infant vaccine that can be administered at birth, providing protection from 
infancy, through the adolescence period, and into adulthood. Our investigation aimed to provide 
information that could aid and advance vaccine development. 
 
The broad scientific goal of the study was to explore HIV pathogenesis in genetically matched 
transmission pairs, in order to further contribute to understanding of the correlates of successful 
immune control in paediatric HIV-1 infection. 
 
1.5.1 CTL-Virus interplay 
1.5.1.1 Hypothesis: 
HIV-specific CTL responses in mothers or infants restricted by the protective HLA-B*27, 
B*5703, are associated with slow progression. We hypothesized that if a child carrying a 
protective allele is able to mount significant CTL responses, and/or if escape occurs-which 
lowers viral fitness-then the child is more likely to progress slowly. However, viral control may 
be lost if escape results in abrogation of immune responses, if  the immune response was the 
actual underlying mechanism involved in viral containment. Alternatively, we hypothesize that a 
child will not mount an immune response because they inherit an escape variant, and therefore 
there will be no control, particularly if the child shares protective alleles with the mother. We 
tested these hypotheses in the following specific aims: 
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1.5.1.2   Specific Aims: 
1.  To describe the CTL responses elicited within various regions of the HIV proteome 
targeted by HIV-infected treatment naïve children using ELISpot assays.  
 2.  To describe HLA restricted sequence changes and viral fitness of donor and                      
               transmitted virus within selected HLA matched cases. 
 
1.5.2 T cell activation and regulation 
1.5.2.1   Hypothesis: 
Generalized T cell activation is the hallmark of adult HIV-1 infection, and is associated with 
CD4+ T cell loss and HIV disease progression. We hypothesize that T cell activation is elevated 
in HIV-1 infected infants, and contributes to T cell exhaustion and failure to control HIV 
viremia. We further hypothesize that regulatory T cell frequencies are elevated in HIV-1 infected 
infants, and can impact generalized immune activation, but also suppress HIV-1 specific 
immunity. We tested these hypotheses in the following two specific aims: 
 
1.5.2.2  Specific Aims: 
1. To investigate the expression of the markers of T cell exhaustion TIM-3 and PD-1 and             
their relationship to markers of disease progression such as absolute CD4+ T cell count 
and HIV-1 plasma viral load in a cohort of HIV-1 infected, exposed uninfected infants, 
ARV treated. 
 2. To assess the impact of regulatory T cell frequencies and T cell activation measured      
    using multi-parameter flow cytometry on markers of disease progression such as   
    absolute CD4+  T cell count and HIV-1 plasma viral load in a cohort of HIV-1       
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              infected, exposed uninfected and ARV treated infants. 
 
1.5.3 Host-pathogen interplay 
1.5.3.1   Hypothesis: 
Polymorphisms associated with increased IL-10 production are associated with a decreased risk 
of HIV-1 acquisition in infants-either after exposure, in utero or intrapartum. Furthermore, 
during paediatric HIV-1 infection, individuals possessing IL-10 polymorphisms associated with 
increased IL-10 production will display higher viral loads and lower absolute CD4+ T cell %. 
We tested these hypotheses using the following specific aims: 
 
1.5.3.2   Specific Aims: 
1. To assess the impact of genetic polymorphisms in the IL-10 promoter gene on the    
    risk of HIV-1 acquisition among children and the risk of transmission among mothers.  
2. To describe the associations between IL-10 promoter variants related to the breadth         
    and/or magnitude of T cell immune responses. 
3. To assess the impact of long term biomarkers of disease progression, such as            
absolute CD4+ T cell count and HIV-1 plasma viral load on cytokine levels, within 
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CHAPTER TWO 
The influence of CD8+ T cell responses on HIV-1 pathogenesis in clade C infected 
treatment naive African mother-child transmission pairs. 
 
ABSTRACT 
Background: MTCT represents a significant proportion of HIV/AIDS burden in KZN, South 
Africa. The failure of the STEP vaccine trials and the partial success of the Thai trial have 
increased the urgency to extend HIV-1 vaccine development and design initiatives. An 
effective T cell vaccine against HIV-1 may need to elicit strong virus-specific T cell responses 
against functionally essential regions of viral proteins where escape mutations may result in 
significant fitness cost to the virus.  HIV infected mother-child pairs have a partially matched 
genetic background and therefore offer a unique opportunity to study viral adaptation to host 
immune pressure. This study aimed to 1) characterize specific HIV-specific CTL responses in 
HIV-1 infected children 2) describe HIV-specific CTL responses in B*27 and B*57 and to 
characterize pathways of immune escape in mother-child transmission pairs.  
Materials and Methods: One hundred and nineteen mother-child pairs were recruited from 
clinics in Durban, South Africa of which only 60 mother-child pairs met the inclusion criteria 
for the current sub-study. Ages of mothers ranged from 17-42 years while children ranged from 
0.3-11 years. During follow-up, viral load measurement and absolute T cell CD4+ counts were 
performed at 3-6 month intervals. High resolution  human leukocyte antigen (HLA) typing and 
comprehensive screening of HIV-1 specific CTL responses was performed by an interferon-
gamma enzyme-linked immunosorbent spot (ELISpot) assay using pools of overlapping 
peptides (18mers) spanning the HIV genome. Subsequently, we studied HIV-1 clade C Gag 
from mother-child transmission pairs. A viral replication assay using an HIV-1-inducible green 




reporter cell line was used to investigate replication capacity of plasma-
derived
 
Gag-protease from the virus of selected transmission pairs.  
Results: HIV-1 plasma viral load of mothers ranged from 1,170 to 750,000 copies/mL, while 
children ranged from 1,320 to 1,000,0000 copies/mL. Children exhibited a CD4+ T cell 
percentage ranging between 8-57% (median 24%). The viral regions targeted by children in 
order of frequency of expression were Nef (49%), Gag (17%), Env (14%) and Acc/Reg/Pol 
(6%). Mothers presented with a broad range of CTL responses which were predominantly 
different from children. CTL responses restricted by the possession of selected protective HLA 
alleles (HLA-B*2705 and B*5703), viral sequences and viral replicative capacities were 
described in 4 mother-child pairs. Magnitude of CTL responses was not associated with lower 
viral loads among mothers or children in this cohort.  
Conclusion:  HLA, CTL or viral fitness alone are not individual players as correlates of 
successful control.  
 
Key words: CTL; viral proteins; CD8+ T cells; HLA; paediatric; children; HIV-1 and disease 
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2.1 INTRODUCTION 
The UNAIDS has reported remarkable progress in combating infection rates among children 
born to mothers living with HIV over the past decade (UNAIDS, 2010). Infection rates have 
declined by 26% from 2001 to 2009 (UNAIDS, 2011). However, despite HIV-1 PMTCT 
efforts in reducing new infections in children, there were an estimated 370,000 new paediatric 
HIV infections in 2009, with almost 65% HIV-1 exposed infants not receiving PMTCT drugs.  
There is urgency for more to be done to prevent mothers and babies from morbidity and 
mortality incurred by HIV-1 infection. Adults and children differ significantly in viral burden 
and clinical outcome (Holland et al., 2000, Resino et al., 2002b, Resino et al., 2002a) as HIV-1 
infection progresses rapidly in children compared to adults (Ruiz Contreras, 1998, 
Apostolopoulos et al., 1995, Takiguchi, 1994). To date, HIV immunopathogenesis in children 
remains poorly understood. Much of our understanding of paediatric infection and 
pathogenesis are drawn from adult studies and the underlying mechanisms may not always 
hold for paediatrics.  
 
In HIV-1 infection, there appears to be a rapid decline in viraemia after HIV-1 acquisition. A 
slow decrease in viral replication is only visible over 2-3 years of age (Richardson et al., 2003, 
Soh et al., 2003). In the absence of antiretroviral treatment, children typically progress to 
AIDS or death within the first 2 years of life (Goulder et al., 2001b, Thobakgale et al., 2007). 
However, a minority group of children seem to progress relatively slowly to HIV disease, 
which is predicted to be attributed to a stronger and durable immune response. Several vaccine 
efforts are directed towards enhancing the induction of virus-specific T cell responses that are 
directed towards the early suppression of HIV. More so, the eradication of paediatric HIV-1 
infection lies in the development of an infant vaccine that can be administered at birth that 
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would theoretically provide protection from infancy, through the adolescence period, and onto 
adulthood.  
 
Virus-specific cytotoxic T lymphocyte (CTL) or CD8+ T cell responses play a significant role 
in viral control and the emergence of these responses in primary HIV-1 infection is associated 
with a decline in viremia (Rosenberg, 2000). Of the nine HIV proteins,  Gag directed CTL 
responses have been largely associated with a beneficial role in HIV-1 containment (Zhou et 
al., 1993, Anderson et al., 1992, Geldmacher et al., 2007, Otto O. Yang, 2011, Kiepiela et al., 
2007, Rolland et al., 2008). The CD8+ T cell recognition of multiple epitopes within specific 
Gag regions is associated with maintenance of a low steady-state viremia in HIV seropositive 
participants (Anderson et al., 1992). The breadth of these Gag-specific responses is found to be 
associated with decreasing viremia (Kiepiela et al., 2007, Rolland et al., 2008). Gag-specific 
responses have been shown to be most associated with low viremia, the Env-specific responses 
have been associated with higher viremia in a clade C infected cohort in KwaZulu-Natal 
(Kiepiela et al., 2007) but this influence have been recently documented to not be intrinsically 
inferior to Gag responses investigated across several cohorts (Chen et al., 2011). Taken 
together these studies suggest that in adult HIV-1 infection, immune responses directed to Gag 
play an important role in viral control.  
 
CTL recognize short peptide proteins presented by corresponding HLA (A, B and C), which 
are encoded by the major histocompatibility complex (MHC) (Townsend and Bodmer, 1989). 
Selected HLAs have been documented to be influential in viral containment more than others 
(Crawford et al., 2009, Goulder et al., 1997, Kiepiela et al., 2007, Kiepiela et al., 2004, 
Thobakgale et al., 2009b, Winchester et al., 2004). The heterogeneous HLA system contains a 
cluster of genes that influence immune functioning. More than 300, 000,000 genetically 
different individuals can be formed by HLA-A, B and C combinations (Bodmer, 1979, Bodmer 
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and Bodmer, 1978). HLA-B has the most influential impact on viral load (Leslie et al., 2010, 
Serwanga et al., 2009, Salgado et al., 2011, Kiepiela et al., 2007, Leslie et al., 2004). For 
example HLA B*57; B*8101 and B*5801 had the strongest association with low viral load 
while HLA B*5802 has been documented to be associated with higher viral load in clade C 
HIV infection (Kiepiela et al., 2004). Moreover, certain HLA alleles documented to be more 
associated with slower disease progression, tend to preferentially target the HIV Gag capsid 
(Borghans et al., 2007).   
 
The presence of multiple subtypes of HIV-1 worldwide has created further challenges in the 
investigation of viral control of HIV-1 infection. HLA that may have been found be influential 
in certain clades may not be as influential in other clades. Investigation of HLA alleles 
associated with protection in both adults and children will benefit vaccine research. In clade B 
investigations HLA-B*27 has been strongly implicated in viral load associations. HLA B*27 
has been shown to be associated with slow disease progression and accumulation of Gag 
escape variants result in loss of viral control in both adults and children in clade B infection 
(Leslie et al., 2004, Goepfert et al., 2008, Goulder et al., 2001b, Goulder et al., 2001c, Pillay et 
al., 2005). However the role of HLA-B*27 has not been assessed in clade C HIV-1 infection 
and hence we attempted to describe this role.  
 
Adult studies suggest that protective HLA molecules associated with lower HIV-1 viral load 
and slow disease progression tend to present epitopes that predominantly target Gag. Very few 
studies have investigated cellular immune responses in paediatric infection and trends of 
protein recognition within mother-child pair context. These studies have been hampered by the 
difficulty of obtaining paediatric samples and by the early introduction of HAART (Highly 
Active Anti-Retroviral Therapy) to prevent mother-to-child transmission in developed 
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countries. Therapy naïve children demonstrate that HIV-specific CD8+ T cell immune 
responses are detectable during early life, however they may not offer immediate clinical 
benefit in the majority of infants (Lohman et al., 2005, Thobakgale et al., 2007). Furthermore, 
the role of CD4+ T cells in HIV-1 infection is controversial showing either lack of adequate 
responses or effective CD8+ T cell maintenance during early infancy (Feeney et al., 2003, 
Huang et al., 2008, Thobakgale et al., 2007, Wasik et al., 2000). More recently Gag-specific 
CD4+ T cell responses were detectable and correlated inversely with viral load in older 
children (Prendergast et al., 2011, Nqoko et al., 2011). It is encouraging to note that a small 
group of children could spontaneously control the virus without ART. Studies on rare 
controller cases are needed to further understand factors that mediate control in children. 
 
Mother-child pairs represent a partially genetically matched environment and hence are a 
valuable cohort to study. These transmission pairs offer an opportunity to gather valuable 
information because unlike most studies, the source of the transmitted virus is known and can 
also be further studied. Knowledge of the sequence changes that subsequently occur during 
transmission will direct us to epitopes that may or may not impact viral control. The biggest 
obstacle to CTL based vaccine initiatives remains HLA associated polymorphisms called CTL 
escape variants.  In the first years of life, many children are able to mount functional HLA 
driven immune responses that are able to influence immune escape (Feeney et al., 2005, Tang 
et al., 2010).  The transmission of these HLA–B associated escape variants has been 
documented to be correlated to a lower viral load in recipients (Goepfert et al., 2008). 
Successive control seems to be significantly attributed to selective cellular responses within the 
protective HLA-B*27, HLA-B*57 and HLA-B*5801 whom have been implicated with slow 
progression to disease. Protective Gag driven HLA class I alleles select Gag escape mutations 
that benefit the mother/adult and child in clade C HIV-1 infection. Slow progression in children 
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have been significantly associated with the mother or a child possessing a protective allele 
(B*5702, B*5703, B*5801, or B*8101) (Thobakgale et al., 2009a). If the mother possesses a 
protective allele, she may transmit Gag variants that reduce viral fitness to children who lacked 
the HLA allele. Subsequently, the accumulation of certain mutations in a specific order seem to 
further reduce viral replicative capacity (Crawford et al., 2009); denoting the interplay between 
the cellular and viral components.  
 
HLA may also drive the virus to a less fit state and thus influence clinical outcome. Studies 
have associated HIV fitness with the rate of transmission and disease progression (Duda et al., 
2009, Biesinger and Kimata, 2008, Brockman et al., 2007). HIV evolves with its host in the 
attempt to avoid different immune responses, manipulating the fitness of the virus. The fitness 
of the virus similarly contributes to immune control or disease progression (Brockman et al., 
2007). Viral fitness can be explored using a novel method that uses target cells that enable the 
entry through both CXCR4 and CCR5 tropic HIV-1 strains. The growth kinetics of a HIV-1-
inducible green fluorescent protein
 
reporter cell line GFP is measured to describe the 
replication capacity of  the virus in clade B infection (Brockman et al., 2006). In chronically 
infected clade C participants, viral replication capacity (utilizing similar methodology) 
correlated positively with viral load and negatively with CD4+ absolute T cell count (Wright et 
al., 2010). However, no correlation was noted with viral loads in patients with early infection 
(Wright et al., 2011). 
 
The precise location of the mutation in the viral genome sequence may influence the efficacy 
of certain CTL specificities to reduce viral fitness, hence relevant to vaccine design (Goulder 
and Watkins, 2004). The present study aims to try to identify the determinants of viral control 
so as to be able to provide information that could aid in therapeutic and ultimately protective 
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vaccine design. We aimed to describe HIV-specific CD8+ T cell responses, within the nine 
regions with the HIV genome, targeted by HIV-1 infected treatment naive children from a sub-
group of a cohort of treatment mother-child pairs using ELISpot assays. We hypothesized that 
HIV-specific CTL responses restricted by the protective HLA- B*5703 and HLA-B*2705 will 
be associated with slow progression and/or a less fit virus in children.  We also describe four 
case series of HLA-B*5703 and HLA-B*27 restricted sequence changes and viral fitness of 
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2.2 PARTICIPANTS, MATERIALS AND METHODS 
2.2.1 Description of cohort and study sites 
A cohort of treatment naive HIV-1 infected mother child transmission pairs was established in 
Durban, KwaZulu-Natal, to understand T cell immunity and HLA genetic associations with 
viral control. The study began recruitment in 2006 prior to the initiation of current PMTCT 
guidelines to prevent HIV-1 transmission from mothers to children. The guidelines at the time 
required that single dose of nevirapine be given to HIV-1 seropositive mothers during the last 
trimester of pregnancy and during labour. The infant received a single dose of nevirapine 
within 48 hrs of birth, according to the HIVNET-012 protocol, as previously described (Guay 
et al., 1999, Jackson et al., 2003).  
 
A subgroup of 60 mother-child pair participants (Fig 2.1) from Zulu/Xhosa ethnic origin, with 
clade C HIV-1 infection were recruited at clinics in KwaZulu-Natal, Durban, South Africa. The 
recruitment clinic sites included King Edward Hospital; McCord Hospital; Saint Mary’s 
Hospital and Prince Mshiyeni Hospital. At the study sites, transmission pairs were screened 
and mother-child pairs who met the inclusion criteria of HAART naïve mother-child treatment 
pairs and a child with PCR positive DNA results from birth were recruited. The inclusion 
criteria were further revised to include an age restriction of children aged three months of age 
having a confirmed positive DNA PCR result. Mothers and their children who were on ART 
were excluded from the study. Mothers provided written informed consent for their and their 
children participation into the study.  For the case study, four transmission pairs in which either 
the mother or child carried HLA-B*27 or B*57 to study, and/or pairs which retrospectively 
sparked interest (i.e. family or siblings etc) as case studies. The research protocol was approved 
by the Biomedical Research Ethics Committee of the University of KwaZulu-Natal, and the 
participating hospital review boards. 
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2.2.2 HIV Pathogenesis Programme (HPP) 
All research (Fig 2.1) was conducted at the Doris Duke Medical Research Institute, Nelson 
Mandela School of Medicine (http://hpp.ukzn.ac.za) except for the Gag sequencing assay 
which was carried out at the Department of Pediatrics, Nuffield Department of Medicine, 
Oxford, UK. All assays except for the Gag sequencing assay, routine viral loads and CD4s 
were carried out by the candidate.  
Figure 2.1 CP (Chronic Pairs) mother-child study design: Sites, participants and assays 
performed. 
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The blood samples were drawn at the clinic sites and transported at room temperature to the 
HPP lab. A single EDTA vial of 10 mL volume was drawn from children while three 10 mL 
EDTA vials were drawn from adults. Upon arrival at HPP, the blood sample were logged and 










Figure 2.2 Summary of experimental procedures undertaken routinely at HPP. 
 
2.2.3 Plasma viral load  
HIV-1 plasma viral load was amplified and quantified using the Cobas Amplification HIV-1 
Monitor Test, version 1.5 (Roche Diagnostics) and the Cobas Amplicor
TM
 Analyzer which can 
detect a limit of 50 HIV-1 RNA copies/mL plasma, according to  manufacturer’s instructions. 
The Amplicor HIV-1 Monitor Test Kit included three controls (Negative, Low positive and 
High positive control) at a specified threshold, and nine test samples. If controls failed the 
assay was repeated. Both test and control sample preparation were initiated by dispensing 
100μl of HIV-1 Mn
2+ 
(Manganese ion) solution to a vial of the HIV-1 matrix solution and 
mixed by inversion. 50 μl of this working stock was added to 12 A-tubes of an A-ring. The A-
ring was stored at 4°C for a time maximum of 4 hours.  
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Subsequently, RNA was transcribed (reverse transcription) into cDNA using the following 
steps. The Lysis Buffer was first prepared by adding 100 μl of HIV-1 Monitor Quantitation 
Standard (HIV-1 QS) to the vial of HIV-1 Monitor Lysis Reagent. The Lysis Buffer was mixed 
well and 600μl was dispensed into test and control tubes. A volume of 200 μl of normal human 
plasma (NHP), together with 50 μl of patient plasma was added to control tubes while 200μl of 
patient’s plasma was added to test samples. The sample tubes were vortexed and incubated for 
10 minutes. 800 µl of 100% iso-propanol was added to each tube which was vortexed and 
centrifuged for 20 minutes. The supernatant was discarded and the pellet was washed with 1 
mL of fresh 70% ethanol, vortexed and centrifuged for 5 minutes. The supernatant was 
discarded and the pellet was clearly visible. A volume of 400 μl of HIV-1 Monitor Specimen 
Diluent was added to each tube, followed by 50 μl of each processed controls and specimen 
into the MMX solution of the tubes of the A-ring, which was previously been stored at 4°C. 
Next, the A-ring was transferred to the Roche Cobas Amplicor where the amplification, 
hybridization and detection steps were performed. HIV-1 viral RNA was validated using the 
HIV-1 Quantitation Standard which was added to the test specimen of a specific concentration. 
The results of the controls and test samples were exported in exponential log format. 
 
2.2.4 Absolute CD4+ T cell measurement 
Absolute CD4+ T cell counts and CD4+ T cells percentages were determined from fresh whole 
blood using Multitest four colour TruCount as previously described according to the 
manufacturer’s instructions (Beckton Dickonson Technology). The technology that underlies 
the TruCount method uses specialized tubes which contain a pellet of a known quantity of 
fluorescent beads. A specific quantity of whole blood was added to the tubes, and the 
lymphocytes were stained with MultiTEST monoclonal antibodies (mAb). We assayed the 
absolute T cell counts of a full lymphocyte subset profile (CD3+, CD3+CD4+, CD3+CD8+, 
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CD3-CD19+, CD3-CD16/56+). The ratio of region events for each subset to bead event was 
calculated using the BD Biosciences MultiSET software. 
 
2.2.5 Isolation of Peripheral Blood Mononuclear Cells (PBMCs) from whole     blood 
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood using the Ficoll-
Histopaque (Sigma, St Louis, Mo) density gradient centrifugation, which allowed for the 
formation of a distinct opaque layer of mononuclear cells between the plasma/ histopaque 
stratum and Phosphate buffered saline (PBS)+R10 medium. Blood specimens were collected in 
EDTA tubes and processed within 6hrs of collection using the following steps.   
 
The blood was diluted with PBS containing antibiotics in a 1:1 dilution and slowly layered 
over Histopaque 1077 using pipette aid (Drummond) in a second 50 mL Sterlin tube. The 
diluted blood was slowly pipetted at a 45 degree angle onto the Histopaque layer. The tube was 
centrifuged at 1,500 rpm for 30 minutes at room temperature. A Pasteur pipette was used to 
aspirate off the opaque interface containing the mononuclear cells. The mononuclear cells were 
transferred to a clean 50 mL Sterilin tube. The tube was topped with 40 mL of PBS containing 
antibiotics, and centrifuged to a pellet at 1,500 rpm for 10 minutes at room temperature. The 
supernatant was discarded and the pellet of cells were re-suspended, and washed with 40 mL of 
PBS containing antibiotics, at 1,500 rpm for 10 minutes at room temperature. The supernatant 
was discarded and the remaining pellet was gently re-suspended with R10 media (10mL). The 
PBMCs were incubated at 37
o
C in a CO2 incubator pending cell count and re-suspension to 1 
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2.2.6 Lymphocyte cell counting 
To standardize cell quantification, the automated Guava cell counter laser technology (Guava 
Technologies, Guava PCA System) was used instead of the classical manual hemocytometer 
counting method. The Guava cell counter technology is based on the differentiation of 
permeability DNA-binding dyes; the nuclear dye binds DNA in all cells, whilst the viability 
dye exclusively binds DNA of dead cells.  A Guava check kit containing calibration beads and 
diluents (room temperature) were used for routine calibration. The calibration beads were 
vortexed. Volumes of 25 μl calibration beads and 475 μl of diluent were pooled in a 1:20 
dilution and ran on the machine. Test PMBCs were uniformly prepared using the Guava 
viacount assay by adding 20 μl cells to 180 μl Guava Counting Solution in a 1:10 dilution. The 
mixture was incubated for 8 minutes in the dark. PBMCs were then read on the Guava cell 
counter in a sterile microcentrifuge for cell counting to reveal final cell concentration. Samples 
were re-suspended for use in immunological assays. 
 
PBMCs were used fresh in ELISpot assays and the remaining PBMCs were cryopreserved in 
90% Fetal Bovine Serum (Sigma-Aldrich), 10% DMSO prior to storage in liquid nitrogen for 
subsequent Multiparameter Flow staining and immunophenotyping expression analyses 
(Chapter 3 and 4). 
 
2.2.7 Cryo-preservation of cells 
As any other cells PBMCs do not have a long life span and thus need to be frozen if they are 
not to be used immediately. These cells were centrifuged at 1,500 rpm for 10 minutes at 4 
o
C 
after which the supernatant was discarded. The pellet of cells was slowly re-suspended using a 
pasteur pipette tip and clumps were dissolved.  The tube containing cells was transferred onto 
ice.  A maximum concentration of 10 million cells per 1.8 mL volume was frozen in a cryovial. 
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A volume of 500 μl of fetal calf serum (FCS) was added to the resuspended cells and the 
mixture was gently mixed.   A volume of 500 μl of FCS with 20% DMSO (dimethyl sulfoxide) 
was further added to the mixture dispensing a single drop at a time.  The cryovial of cells were 
transferred to specialized freezing containers (Nalgene Mr. Frosty’s).  The freezing containers 
had iso-propanol at their base which allowed the temperature of the cryovial of cells to be 
lowered at a rate of 1 
o
C per minute when stored in the -80 
o
C freezer. Within 24hours, the 
cryovial of cells were transferred and logged into location in the long term liquid nitrogen 
storage freezer. 
 
2.2.8 Deoxyribonucleic acid (DNA) extraction 
DNA was isolated from whole blood using the Puregene
TM
 DNA Isolation Kit (Gentra 
Systems, Minneaplois, USA). The blood was first lysed by adding 9 mL of RBC lysis solution 
to approximately 3 mL of the blood. Steriline tubes were inverted and left to incubate for 10 
minutes at room temperature. The mixture was centrifuged for 10 minutes at 2,000 rpm and the 
supernatant was discarded. This step was repeated after which cells lysis occurred. During the 
cell lysis step, excess supernatant was removed with a pasteur pipette. The DNA pellet was re-
suspended with 3 mL of cell lysis solution and left to incubate for a minimum time of 24 hours. 
The proteins were precipitated by the addition of 1 mL protein precipitation solution to the cell 
lysate.  This mixture was vortexed and centrifuged for 10 minutes at 2,000 rpm.   Next, the 
supernatant containing DNA was transferred with a pasteur pipette into a sterile tube 
containing 3 mL of 100% iso-propanol. The steriline tube was inverted until strands of DNA 
formed. The tube was centrifuged for 3 minutes at 2,000 rpm.  The supernatant was discarded 
and the pellet was washed with 70% ethanol solution. The supernatant was discarded once 
more and the DNA pellet was left to air dry. Finally, a volume of 50 µl of DNA hydration 
solution was added to the DNA pellet and the tube was stored at 4
0
C.The following day the 
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hydrated solution was mixed and aliquoted into 1.5 mL eppendorf tubes which were stored in 
at -20
0
C until assayed. DNA was quantified by pipetting 1 µl of DNA onto the sample port of a 
Nanodrop reader (ND-1000 Spectrophotometer - Inqababiotec™, Pretoria, South Africa).  The 
sample was quantified at 260/280nm at a purity ratio of 1.8-2.  
 
2.2.9 Human Leukocyte Antigen (HLA) typing   
Human Leukocyte Antigen (HLA) typing is a DNA based genetic method that used the Dynal 
RELITM reverse Sequence Specific Oligonucleotide (SSO) kit to type HLA-A, HLA-B, and 
HLA-C loci (Dynal Biotech).  HLA alleles were discriminated using the Dynal Biotech 
sequence-specific priming kits in conjunction with the previous SSO kit.  Undetermined alleles 
were defined using sequence specific primers. The assay was performed at the transplant 
laboratory of the South African Blood Transfusion Services (Pinetown, Durban).  
 
2.2.10 Synthetic HIV-1 Peptides 
The HIV-specific peptides used for the ELISpot assays were either 410 overlapping individual 
peptides or a matrix of 408 peptides (18mers with a 10-amino acid overlap).These HIV 
peptides were synthesized from clade C consensus sequences using an automated peptide 
synthesizer (MBS 396, Advanced ChemTech). 
 
2.2.11 Enzyme-linked immunosorbent spot (ELISpot) technique 
CD8+ T cell responses were characterized using using HIV-specific individual peptides or a 
matrix of peptide pools as shown in Fig 2.3 and as previously described (Thobakgale et al., 
2007) in an Interferon-  Enzyme-linked immunosorbent spot (ELISpot) assay as per 
manufacturer’s instructions (MAIP S45; Millipore).  
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Peptides representing each of the nine viral proteins regions were pooled into a matrix system 
consisting of Gag (66), Nef (27), Rev (13), Tat (12), Vpu (9), Pol (133), Vpr (11), Env (113), 
and Vif  (24) were pooled together as previously described (Addo et al., 2003). Rows A, C and 
E contained respective proteins, which were then confirmed by matching wells to rows B, D 
and F. All positive pool responses were then traced to individual peptides by performing the 
secondary confirmatory ELISpot assay using individual peptides. Testing of individual 
peptides overlapping peptides (OLP) or HLA optimal epitopes were performed on a few 
participants depending on the paucity of cells.  
 
 
Figure 2.3 Representation of ELISpot matrix design of HIV-specific peptide pools testing all 
nine regions of the HIV genome. Rows A, C, E had individual peptides from each of the nine 
regions. Rows B, D, F were confirmatory with peptide pools (Adapted P.Kiepiela). 
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Briefly, a 96-well polyvinylidene diflouride-backed (PVDF) culture plate was coated with 100 
µl of anti-human IFN-  capture antibody (0.5µg/mL, 1-D1k, Mabtech) and stored for a 
minimum of 24 hours at 4°C. On the day of setup, the wells of the plate were washed five 
times with PBS. A volume of 50 µl of R10 medium was added prior to the addition of 10 µl of 
individual HIV-specific peptides (2 µg/mL) or 50µl of matrix of HIV-specific peptides (200 
µg/mL) to all except control wells. The three negative controls contained R10 media, while the 
two positive controls contained 10 µl of a 200 µg/mL concentration of phytohaemoagglutinin 
(PHA) wells. Next, a volume of 100 µl of R10 medium containing either 50,000 or 100,000 
PBMCs was added to each well of the ELISpot plate. The plate was incubated in an incubator 
at  37 
0
C, 5% CO2 overnight. The next day the plate was processed by six washes with cold 
PBS, followed by the addition of PBS containing the secondary biotinylated IFN-γ monoclonal 
antibody (0.5 μg/mL, 7-B6-1, Mabtech) and 90 minute room temperature incubation. The plate 
was further washed with cold PBS, followed by addition of PBS containing the streptavidin-
alkaline phosphatase conjugate antibody (0.5μg/mL, Mabtech) and incubated at 45 minutes at 
room temperature.  Finally IFN- γ producing cells were stained with a substrate combination 
(Bio-Rad) of NBT (nitro-blue tetrazolium chloride) and BCIP (5-bromo-4-chloro-3'-
indolyphosphate p-toluidine salt), which reacted with alkaline phosphatase to yield a black-
purple colour, which allowed for visualization of IFN-  T lymphocyte cells within 5 to 10 
minutes of staining.   The IFN-  T lymphocyte cells were quantified by automated counting of 
spots per well using the Aid ELISpot plate reader (Autoimmun Diagnostika GmbH, Strasburg, 
Germany).  The output was exported as the number of spots forming cells (SFC) per well using 
the ELISpot plate reader software. A response was defined as positive if it was above 100 
SFC/million PBMC and above 3x standard deviations above the mean for the four background 
wells using previously adopted criteria (Addo et al., 2003, Kiepiela et al., 2004, Kiepiela et al., 
2007). 
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2.2.12 RNA extraction 
To investigate the HIV, RNA was extracted from patient plasma using the Qiagen QIAmp viral 
RNA extraction kit (Qiagen) as Fig 2.4 
Figure 2.4 Viral RNA extraction protocol (adapted Qiagen protocols).   
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2.2.13 Sequencing of proviral DNA and viral RNA 
Following genomic DNA extraction from PBMC, we set out to investigate patient Gag-specific 
sequences. The Gag-specific sequences were amplified and sequenced from DNA using a 
nested PCR as previously described (Leslie et al., 2004) at the Department of Pediatrics, 
Nuffield Department of Medicine, Oxford, UK. PCR primer for Gag specific amplification 
were 5`-CTAGCAGTGGCGCCCGAACA-3`and 5`-ACAGTCTTTCA TTTGGTGT CCTTC-
3`(MWG Biotech, Germany) for first round PCR and 5`-TTCTCTCGACGCAGGACTC-3` 
and 5`-TTTTCCACATTTCCAACA GCC-3`(MWG Biotech, Germany) for second round PCR 
(Leslie et al., 2004). For amplification of Gag-specific sequences mastermixes (Bioline) were 
generated for the first and second round PCR amplification reaction (Appendix).  
 
Following PCR amplification, 5 µl of the PCR product was loaded onto a 1% agarose gel 
[Sigma, St. Louis, MO] in TBE buffer (Tris-borate-EDTA, Promega). Ethidium bromide was 
added at 5µl/400mL gel. To determine the size of the amplified fragment, samples were run in 
parallel with Hyperladder I (Bioline) (Leslie et al., 2004). After running at 200V for 35 
minutes, bands were visualized under UV light.  
 
The PCR product was purified using ExoSAP-IT, containing Exonuclease I and Shrimp 
Alkaline Phosphatase, (GE Healthcare Life Sciences)  as previously described as per 
manufacturer’s instructions (Leslie et al., 2004).  
 
The PCR product was directly sequenced using sequencing primers as per Table 2.1 and the 
BigDyeTerminator version v3.0 ready reaction mix (Applied Biosystems, Foster City, CA). 
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Table 2.1 Sequencing primers for HIV Gag regions p17 and p24) (Leslie et al., 2004).  
          Primer                     Sequence 





   Frag1_3IP TTTTCCACATTTCCAACAGCC 
 
2.2.14 Viral replicative assay 
The viral replication assay was performed to assess the replication capacities of the virus as 
previously described (Miura et al., 2009a). RNA was extracted from patient plasma. Gag-
protease was amplified by a two round PCR reaction. Gag was selected based on its 
demonstrated role in viral containment, while protease was included due to its interaction with 
Gag by cleavage of the Gag polyprotein. The Gag protease was inserted into the plasmid NL4-
3 Gag-Protease, co-transfected, cultured, harvested and finally assessed viral fitness using an 
HIV-1-inducible GFP reporter cell line.  
 
After RNA extraction reverse transcription-PCR (RT-PCR) was performed using a Superscript 
III One-Step RT-PCR kit (Invitrogen, Carlsbad, CA) and the Gag-protease-specific primers: 5'-
CACTGCTTAAGCCTCAATAAAGCTTGCC-3` (HXB2 nucleotides 512 to 539) and 5'-
TTTAACCCTGCTGGGTGTGGTATYCCT -3` (nucleotides 2851 to 2825) (Miura et al., 




GCTTTTATTTTTTCTTCTGTCAATGGCCATTGTTTAACTTTTG-3` (Wright et al., 2010, 
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Wright et al., 2011, Brockman et al., 2006, Miura et al., 2009a), which was exactly 
complementary to NL4-3 on either side of Gag-protease using the TaKaRa Ex Taq HS enzyme 
kit (Takara, Shiga, Japan). Two PCR reaction mixtures were prepared for each sample, 
comprising 37 µl diethyl pyrocarbonate (DEPC)-treated water, 5 µl, 10x Ex Taq buffer, 4 µl of 
deoxynucleoside triphosphates (dNTPs), 0.8 µl forward primer (10 µM), 0.8 µl reverse primer 
(10 µM), 0.25 µl Ex Taq, and 2 µl of the first round RT-PCR product. (Miura et al., 2009a). 
Amplification conditions were as follows: 94°C for 2 min; 40 cycles of 94°C for 30 s, 60°C for 
30 s, and 72°C for 2 min; and 72°C for 7 min. PCR products from two reaction mixtures were 
pooled while 10 µl was reserved for sequencing (Wright et al., 2010, Wright et al., 2011). 
 
The recombinant viruses Gag-protease deleted pNL4-3 plasmid was amplified from a stock of 
STBL3 cells that were previously heat shocked and co-transfected with plasmid (Brockman et 
al., 2006, Miura et al., 2009a, Wright et al., 2010, Wright et al., 2011). A volume of 200 mL 
LB (Luria Bertani or L-Broth) media was inoculated with 17.5 µl of STBL3 competent cells 
containing pNL4-3 Gag-Protease.  Following overnight culturing at 37
o
C in a shaking 
incubator the DNA plasmids were harvested and prepared using the Qiagen plasmid DNA 
purification maxi kit. Plasmids were selected from the culture colony. The bacterial cells were 
harvested and centrifuged at 6,000 g for 15 min at 4°C. The bacterial cell pellet was 
resuspended in 4 mL of Buffer P1 (RNase A solution). A volume of 10 mL Buffer P2 (aid 
precipitation) was mixed and incubated at room temperature for 5 minutes. After adding Buffer 
P3 the solution was mixed and filtered using QIAfilters. The cleared lysate was washed with 30 
mL Buffer QC. Solution was eluted with 15 mL Buffer QF. DNA was further precipitated by 
adding 10.5 mL isopropanol, Precipitated DNA was washed with 70% ethanol and centrifuged 
at 15,000 g for 10 minutes. The pellet was air dried and re-dissolved in TE (Tris and 
Ethylenediaminetetraacetic acid buffer). 
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 Bacterial cultures were stored at -85°C using a 30% glycerol-LB solution. The glycerol was 
mixed with bacterial culture solution at 1:2 and stored at –80 
o
C. To confirm specificity of the 
maxiprepped product a Hind III digest was performed as Table 2.2. 
 
Table 2.2 Confirmation of plasmid transfection using Hind III digest. 
Reagent Volume (µl) 
Hind III 












The plasmid NL4-3 Gag-Protease and the wild type pNL43 were digested for 1 hour at 37 
o
C 
after which they were visualized on a 1% agarose gel [Sigma, St. Louis, MO] in TBE buffer.  
Plasmid was represented by 4 gel bands while the wild type control by 5 gel bands. Prior to co-
transfection we went on to prepare a digest reaction with circular pNL4-3 Gag-Pro plasmid 
(Table 2.2) and we digested this for 2 hours at 60 
o
C in waterbath.  
 
Table 2.3 Generation of chimeric pNL43 Gag-Protease viruses. 
Reagent Volume (µl) 
Plasmid (amplified) 
10x Buffer (Promega BSTEII kit) 
100X BSA 
Enzyme (BSTEII from Promega) 
Water(to make up balance of final volume (400) 
           *10 µg per sample 
40 (1/10 reaction volume) 
4 (1/100 reaction volume) 
        2 U per µg plasmid 
         400µl-all above 
*Plasmid concentration (c1v1=c2v2) 
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To generate the chimeric viruses (Table 2.3), we co-transfected the CEMGXR25 cells with 
digested pNL4-3 Gag-Pro plasmid (Brockman et al., 2006, Miura et al., 2009a, Wright et al., 
2010, Wright et al., 2011) and the second round PCR product while maintaining CEMGXR25 
cells in culture every 2-3 days by feeding them with RPMI1640; containing 5mL 1M Hepes  
(Gibco); 5mL of 200mM L-glut (Sigma); 5mL of 5000U/mL Penstrep (Gibco) and 50mL 10% 
FBS  (Gibco) (Brockman et al., 2006, Miura et al., 2009a, Wright et al., 2010, Wright et al., 
2011). Concentrations of 2 million cells GXR cells were prepared per sample by spinning them 
at 1,500 rpm for 10 minutes at 20 
o
C. Supernatent was aspirated. A volume of 800 L of cells, 
80 L of second round PCR product and a concentration of 10ug digested plasmid were 
combined in a cluster tube. After mixing, the solution was transferred to labelled 
electroporation cuvettes and they were electroporated at settings of 300 V; 500 F; R=  ∞ and 
4mm BioRad GenePulsar II. Cuvettes were left to incubate for an hour to allow cell 
membranes to restructure themselves following co-transfection of product to plasmid. The 
solution was transferred to 25 mL flasks containing 4 mL media and incubated for 5 days. A 
volume of 5 mL R10 media was added to flasks and the flasks were further incubated. At day 
12 samples were assessed using a flow cytometer to determine the percentage infected cells.  
The sample was run every second day until reaching a percentage of 30-40% infectivity and 
were then harvested and frozen. 
 
Finally titration and viral replication capacities were (Brockman et al., 2006, Miura et al., 
2009a, Wright et al., 2010, Wright et al., 2011) using a multiplicity of infection (MOI) of 
0.0003. Viruses were thawed and based on their % infectivity they were added in different 
amounts to achieve 0.3% infection on day 2. The concentration of virus added ( L) = [0.3/ (% 
total cells fluorescing on day 2 of titre experiment)] * final volume (400 L). This volume was 
subtracted from final volume of 400 L to determine how much media to add. The solution and 
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contents were added to 100 L of GXR cells containing 1 million cells which was transferred 
to a well of a 24 well culture plate and the plate was left to incubate overnight (Sigma). The 
following day 1 mL of media was added to the well. The day thereafter 500 L sample was 
collected and acquired at 25,000 events on a flow cytometer. A volume of 500 L of media 
was added to replace acquired sample. This process was repeated until day 6. Replication 
assays were performed at least in duplicate, and results were averaged. 
 
2.2.15 Statistical analysis 
Sequence data were analysed using Sequencher v.4.8 (Gene Codes Corporation). Nucleotides 
residues were matched and aligned against the HXB reference sequence manually in Se-Al 
v.2.0a11 (A. Rambaut, Department of Zoology, University of Oxford) or automatically in 
BioEdit Sequence Aligner Programme version 7.0.0(IBIS Biosciences, CA). Phylogenetic trees 
were derived from aligned nucleotide consensus sequences. Neighbour joining (NJ) trees were 
computed using ClustalX (Multiple sequence alignment tools). Bootstrap resampling (1000 
replicates) was performed to validate individual nodes on a tree (Felsenstein, 1985). Flow data 
was analyzed with FlowJo software version 7.5 for PC. Microsoft Excel was utilized to transfer 
data and subtract FMO background values. Microsoft Excel was also used to calculate the 
mean slope of exponential growth for the viral replication assay from days 3 to 6 using the 
semi-log method [=ln(LOGEST({x1,x2,x3,{y1,y2,y3},0,0)))], which was divided by the slope 
of growth of the wild-type NL4-3 control that was included in each assay to generate a 
normalized measure of replication capacity. Nonparametric testing with the Mann Whitney U 
test was undertaken for a less than two group comparison and the Kruskal Wallis was 
performed for more than two group comparisons. Post test analysis was performed using 
Dunns Multiple Comparison Test. Normalization and subset discrimination and gating of data 
was performed using Flow Jo. The mean fluorescent intensity and % response per event was 
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calculated using the Wilcoxon-Mann-Whitney-U test. Significance levels were indicated using 
Mann Whitney U (P<0.05). Correlations were performed using Spearman rank tests (p and r 
values). This analysis was performed and graphically represented using Prism software 
(GraphPad, version 5).  
 
2.3 RESULTS  
2.3.1. Cohort Characteristics 
A total of sixty HIV-1 infected mothers and children (mother-child pairs) were recruited for 
this study based on inclusion criteria (Appendix) as described in previous section.  
 
2.3.2. Clinical characteristics (Absolute CD4+ T cell count and plasma viral load). 
The investigators denoted CD4 counts as cells/mm
3
 for 
mothers and % for babies as per WHO criteria which use these parameters as measures of 
immune deficiency in adults and children respectively. CD4% in children provides a 
more accurate indicator of a child’s health compared to absolute CD4 counts.  
 
The median CD4 percentage in HIV infected children was 24% (range, 11-46%) while the 





), Table 2.9. The median age of the children studied was 12 months and ranged 
between 3 months-10 years, while the median age of mothers was 29 (17-34 years). 
 
Table 2.4 Overall clinical characteristics of study cohort.   
                                                         Mothers  Children 
N 60 60 
Median Age in years (IQR) 29 (17-34) 1 (0.3-10) 







As expected, the median viral load in the children (260,000 copies/mL) was significantly 
higher than the mothers (59,550 copies/mL) (p<0.0001, Mann-Whitney U test) as represented 














Median Absolute CD4+ T cell count  
cells/mm3 (IQR) 
304 (24-905)  - 
Median CD4% (IQR) - 24 (11-46) 
Median Viral Load (copies/mL) 
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Figure 2.5 Comparison of A) Viral load (copies/mL) between mothers and children B) plasma 
viral load and) % CD4 T cell between children stratified by age. 
 
As neonates have been shown to exhibit an elevated viral load in comparison to older children 
and CD4% has been documented to better depict HIV-1 infection in children clinically, we 
next sought to further describe HIV-1 infection by stratifying the children into groups based on 
their age (Fig 2.5). The younger group of children had a trend towards higher viral loads and 
lower CD4% in comparison to the older children.  
  
2.3.3 CTL responses and viral loads in responder and non-responder children 
We hypothesized that the presence of CTL responses in HIV-1 infected children would 
decrease on HIV-1 viral load and therefore HIV plasma Viral loads were compared between 
children who made CTL responses compared to non-responders. A total of 30 children made 
responses to at least one of the peptide pools and were thus responders, many children did not 
make any CTL responses (non-responders). Comparison of viral load between responders and 
non-responder showed no significant differences between the two groups. Although the non-
responders had a higher median viral load (535,000 copies/ml) than the responders (375,000 
copies/ml), the differences were not significant as per Mann-Whitney U (p=0.2799).  
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2.3.4 Specificity of the CTL response in children less than 12 months 
Sixty children were investigated in this sub-study of which many infants did not make any 
detectable responses using the standard confirmatory ELISpot. The remaining 30 infants who 
did make detectable responses were older than 12 months and were not included in this 
investigation. As documented certain regions of the nine HIV proteins are targeted frequently 
at different stages of HIV-1 infection in comparison to other viral proteins. HIV-specific CD8+ 
T cell function in children have been documented to be critically influenced by age (Sandberg 
et al., 2003) and data on CTL responses in infants are scarce. Hence, the HIV regions targeted 
by children at different disease stages were assessed using ELISPOT. A previous study of 
infants in the same setting reported that the specificity of the response in the first month of life 
is directed to Env and accessory proteins RTVVV (Reg,Tat, Vif,Vpr, Vpu)  (Thobakgale et al., 
2007). Due to the paucity of samples in infants, we tested the ELISpot assay in a matrix pool 
approach (cut off 100 SFCs) in order to determine the HIV regions targeted by children 
between the ages of 3-12 months as previously described (Thobakgale et al., 2007) (Fig 2.6). 
This method did not confirm responses as the responses were low and not detected by day 2.  
Due to the low responses the magnitude of these responses could not be tested as this method is 
not comparable to the routine confirmatory ELISpots. All the infants under 12 months of age 
were tested using day 1 ELISpot pooled matrix results to ensure comparable results. There 
were a few infants that did show low level detectable responses in the original  day 2 
confirmatory ELISpot but for uniformity these infants were also analyzed using methodology 
described by (Thobakgale et al., 2007).  Children aged less than 3 months of age dominantly 
targeted Nef. Gag was targeted next by children between 3 months to 9 months of age. Env was 
targeted less frequently in comparison to Nef and Gag in children between 3-12 months of age. 
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Figure 2.6 Contribution of HIV-specific protein response to overall response in 30 children 
using a matrix system (Thobakgale et al., 2007) in children aged 3-12 months. Nine proteins of 
the HIV proteome were tested with each colour representing the protein region described in the 
legend. 
 
As observed in Table 2.5 and Fig 2.6 children less than a year of age targeted Nef, Gag and 
Env respectively. As children matured in age and stabilized in viral load-responders tend to 
target Gag more frequently than any other viral protein.  
 








Age Region most frequently targeted 
1-2years (n=4) Gag;Integrase Pol 
2-3years (n=4) Nef 
3-5 years (n=8) Gag;Nef 
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2.3.5 Frequency of distribution of HLA-B and impact of HLA-B on disease in mother-
child HIV-1 infected transmission pairs. 
Due to the heterogeneity of HLA, genetic studies should ideally be performed in a large sample 
size to validate findings. As previously described in clade B, we next compared the distribution 
of HLA alleles in mother-child pairs (Kuhn et al., 2004). As T cell immune responses are 
restricted by different types of class I molecules designated HLA-A, HLA-B, and HLA-C, we 
next described the frequency of distribution of selected HLA-B restricted that have been found 
to be influential clade C HIV-1 infection. HLA-B*07/41/81, are similar alleles (epitopes target 
all 3 alleles) which were frequently distributed at 19% in children and 21% in mothers (Fig 
2.7). Next HLA-B*5802 and B*15 were expressed in both mothers (17,17%) and children (17, 
16%) respectively within this clade C cohort. 
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Figure 2.7 Frequency of distribution of HLA-B in transmission pairs A) children and B) 
mothers. 
 
Based on the previous investigations that reported HLA-B alleles to be influential in viral 
control, we also investigated Gag-specific responses restricted by HLA-B alleles reported to be 
protective in children. Based on specific HLA-B allele findings related to the protective effect 
of HLA-B*27 and HLA*B57 in transmission pairs, we identified four transmission pairs in 
which either the mother or child carried HLA-B*27 or B*57 to study, and/or pairs which 
retrospectively sparked interest (i.e. family or siblings etc) as case studies. We investigated the 
mechanisms underlying viral control, viral escape a fitness in relation to HLA-B restricted Gag 
CD8+ T cell epitopes. The Gag epitopes in the positions highlighted in Figure 2.8 are the 
epitopes commonly targeted by HLA-B*27 and B*57. However, we focused our study on 
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B*27-IK9/KK10 in two HLA-B*2705 HLA transmission pairs and epitopes B*57-




















Figure 2.8 Illustration of epitope map (our study participant) of common HLA-B*27 and 
HLA-B*57 restricted Gag-specific CD8+ T cell epitopes and possible clade C related 
compensatory mutations. 
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2.3.6. A description of the protective HLA-B*27 in mother-child HIV-1 infected 
transmission pair 
HLA-B*27 is a common allele in the Caucasian population in which clade B HIV-1 infection is 
the predominant subtype. HLA-B*2705, more specifically a Gag p24 KK10 response, has been 
previously associated with effective viral control in children (Schneidewind et al., 2007, 
Kelleher et al., 2001). However, the KK10 response is lost with the emergence of R264K 
mutant. If the transmitted virus carries an escape mutations in any key Gag epitopes HLA*27 
tends to lose its protective effect (Kuhn et al., 2004). As documented by Goulder et al.(2001), 
infected children who carry B*2705 or B*5703 are able to effectively control the HIV infection 
particularly if the transmitted virus is not pre-adapted to either of these alleles hence if mothers 
or children do not share a protective allele they are likely to maintain viral control (Goulder et 
al., 2001a, Goulder et al., 2001b). We selected the only two HLA-B27 restricted transmission 
pairs in our cohort. In transmission pair CP3-005, only the mother carried HLA-B*2705 (Fig 
2.9 A) while in transmission pair CP3-024, only the child carried HLA-B*2705 (Fig 2.9 A). In 
transmission pair CP3-005 the father volunteered his blood for testing so we were able to run 
tests on a single time point of the father as well.   
 
As the mother carried HLA-B*27 we hypothesized that the mother would progress slowly, if 
she has effective CTL responses– but would progress rapidly following escape – unless escape 
lowers fitness and other responses can still control an attenuated virus. As the child did not 
carry HLA-B*27 we hypothesized that child would progress slowly if the virus in the child is 
less fit than the virus of the mother.  
 
Clinically, the father required immediate treatment as had a viral load 510,918 copies/mL and 
an absolute CD4 T cell count of 129 cells/mm
3
. The mother and child had stable viral loads and 
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relatively stable CD4 tests over 33 months of investigation (Fig 2.9 B). The mother exhibited 
an average absolute CD4 T cell count of 214 cells/mm
3
 (Fig 2.9 C) however as time of 
infection was unknown it was difficult to identify if progression was slow or related to the 
possession of HLA-B*27. However, as the child was 8 months of age upon enrolment, we 
assumed a slower level of progression, as child consistently exhibited a CD4% ranging 
between 27-45% throughout investigation. A dip in CD4% was observed in children however 
we did not have clinical or co-infections data to further extrapolate.  The data is presented as 
acquired. (Fig 2.9 C).  
 
Based on the association of Gag-specific epitopes with slow progression, we next went on to 
investigate the role of HLA-B*27 restricted Gag-specific responses in transmission pair CP3-
005 (Fig 2.9 D/E). CD8 T cell responses in this pair showed that the mother targeted Gag p17 
(OLP 11) at low levels while no Gag-specific responses were detected in the child. A 
predominant B*27 restricted response to Nef (OLP 81) was detected at high levels in the child 
from the first till the last 15 month time point test. At the mother’s 15 month timepoint it seems 
asif the assay may have been problematic as the positive control is not fully developed. We 
speculate the plate development stage may have not been fully completed. CTL data for this 
timepoint has been removed from analysis.  
 
We next investigated whether the failure to generate effective Gag-specific responses was 
related to sequence changes by the transmission of variants from mother to child, based on the 
evidence of MTCT escape variants influencing CTL responses.  We investigated the role of 
escape variant within the KK10 epitope as an effective KK10 response has been associated 
with slow progression in HLA-B *27 carriers and conversely late escape from KK10 as been 
linked to progression. In addition, as documented in clade B infection the R264K/R264G 
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mutation has been associated with the development of rare compensatory mutations, S173A 
and E260D.  Our sequencing results showed that epitope B*27-IP9 was present as a wildtype 
in all family members, while epitope KK10 showed 3 sequence changes in position 264, 268 
and 271 (Fig 2.9 G). In clade C infection we observed the appearance of a T173A variant. 
Interestingly as child and mum also possessed HLA-B*5802 we observed the presence of 
S165N/V168I in both B*58-KF11 and TW10 epitopes.  
 
Based on the interplay between CTL response viral adaptation and viral fitness, we next 
compared the fitness of earliest timepoint to later timepoints and to the donor viruses within the 
family CP3-005. As CTL responses and viral adaption did not explain good clinical outcome, 
we expected viral fitness to play an influential role. However, we found no significant 
difference in viral replicative capacity between the virus of the mother, father or child (Fig 2.9 
F). Furthermore, we found no difference in viral replicative capacity over a 21 month 
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Figure 2.9 A) HLA, B) Viral load, C) CD4% and Absolute CD4 T cell count, D) CTL 
response of mother, E) CTL response of child, F) Viral replicative capacity and G) Sequence 
changes in epitope IK9 and KK10 of transmission family CP3-005 (C=child etc). 
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We next went on to investigate the role of B*27 in another transmission pair, CP3-024 in 
which the child carried HLA-B*2705 (Fig 2.10 A).  As the child carried HLA-B*27 we 
hypothesized that the child would progress slowly, if he/she has and maintains an effective 
CTL response. As the mother did not carry HLA-B*27 we hypothesized that she would 
progress rapidly. 
 
Clinically, the mother and child have stable viral loads and relatively stable CD4 tests months 
(Fig 2.10 B). The mother had an average absolute CD4 T cell count of 200 cells/mm
3
 (Fig 2.10 
C) warranting ART soon after recruitment. The child was 7 months of age upon enrolment and 
consistently exhibited a CD4% ranging between 26-37% throughout 15 months of 
investigation, assumed to be related to the possession of HLA-B*27 (Fig 2.10 C).  
 
We assessed the association of HLA-B*27 restricted Gag-specific responses with slow 
progression in transmission pair CP3-024 (Fig 2.10 D/E). The mother targeted Gag p24 (25) at 
high levels at a three month interval time, while the child had no detectable responses at first 
ELISpot assay and a low level response to Gag p17 (OLP 3-IK9) and integrase (Pol).  
 
As previously documented the transmission of escape variants within B*27-KK10 in children 
could results in lack of response, which in turn could be associated with rapid progression 
(Goulder et al., 2001a). We next investigated sequence changes in the transmission variants 
from mother to child focusing on HLA-B *27 restricted KK10 (OLP 36) and IK9 (OLP 3) 
epitopes compensatory mutations, S173A and E260D.  Our sequencing results showed no 
changes in epitope B*27-IP9 in the mother but a variant change in position 2 of B*27-IP9 in 
the child. The epitope KK10 showed two sequence changes in position 264, and 268 (Fig 2.10 
G). Similarly as in CP3-024, the variant T173A was present in contrast to S173A as in clade B 
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infection. We next compared the replicative capacity of the transmitted virus and found no 
significant difference in viral replicative capacity between the virus of the mother or child (Fig 
2.10 F).  
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Figure 2.10 A)HLA, B)Viral load, C)CD4% and Absolute CD4 T cell count, D)CTL response 
of mother, E)CTL response of child, F) Viral replicative capacity and G)Sequence changes in 
epitope IK9 and KK10 of transmission pair CP3-024. 
 
2.3.7. A description of HLA-B*5703 in mother-child HIV-1 infected transmission pairs 
We next went on to investigate the impact of the HLA-B*5703 allele in HIV infection, as they 
have been reported to be most strongly associated with low viral loads and high CD4 counts in 
a clade C cohort (Kiepiela et al., 2004, Leslie et al., 2010). HLA-B*5703 also presents Gag-
specific CD8+ T cell epitopes such as KF11, TW10 respectively and conversely escape 
mutations within these epitopes has been found to reduce the replicative capacity of HIV 
(Brockman et al., 2007, Crawford et al., 2009, Goepfert et al., 2008).    
 
In order to describe the role of HLA-B*57 in clade C HIV-1 infection we investigated two 
transmission pairs. In transmission pair CP3-052 the mother carried HLA-B*5703 (Fig 2.11 A) 
while in transmission pairs CP1-002 two siblings carried HLA-B*5703 (Fig 2.11 A). The CP1-
002 children were enrolled by the mother at different visits. The younger child was enrolled 
first and based on low CD4% was awaiting ARV treatment, while the older sibling joined the 
study a few months later but was still clinically stable.   
 
We first investigated the mother who carried HLA-B*57 hypothesizing that the mother would 
progress slowly, if she has effective CTL responses and the correct succession of variants 
escaping. As the child did not carry HLA-B*57 we hypothesized that child would progress 
faster but that progression will also depend on the variants transmitted and/or the fitness of the 
transmitted virus. 
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Clinically, upon enrolment the mother and child were doing well but the child progressed 
rapidly after first visit and was disenrolled from our study and referred for treatment (Fig 2.11 
C). The mother was doing well as she maintained an absolute CD4 T cell count of 583 
cells/mm
3
(Fig 2.11C). As the child was 5 months of age upon enrolment, the child seemed to 
be a rapid progressor requiring early treatment by second visit.  
 
As the child rapidly progressed between 5 and 8 months of age from a CD4% of 40-25% we 
next investigated the child’s HIV-specific responses (Fig 2.11 E). The child had one 
predominant B*7 restricted response to Nef (OLP 76). The mother also targeted Nef (OLP 76), 
together with Gag p17 (OLP 3-5) and Gag p24 (22) at higher levels. 
  
Based on the previous evidence of the association of B*57 MTCT escape variants on viral 
escape and viral fitness we next investigated whether rapid progression in the child was related 
to the child’s inability to generate effective responses was related to sequence changes by the 
transmission of variants from mother to child. Do children benefit from transmission of escape 
variant within unmatched pairs and is its effect compensated by reversion (Thobakgale et al., 
2009b)?  We next investigated the role of escape variant Gag T242N escape mutation in Gag, 
which is known to decrease viral fitness early in the course of HIV infection, associated with 
TW10 epitope and the emergence of upstream mutations at residues H219, I223, and M228. 
We further investigated sequence changes in the ISW9 and KF11 epitopes. Our sequencing 
results showed that a sequence change in the first position (I147L) in ISW9 for the mother but 
the child still showed the presence of the wildtype. In addition, the mother had a sequence 
change in position 247 (I247M) in TW10 while the child still carried the wildtype. The child 
carried variant V168I in the KF11 sequence while the mum carried the wildtype.   
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Interestingly we also observed the presence of possible compensatory mutations in 
A146P/A163G/ S165N and S252N.  
 
From the above observations it seemed possible that the child may have received a 
predominantly wildtype virus with ineffective compensatory mutations from the mother, hence 
we next compared the fitness of earliest transmitted virus of the child to the mother. We found 
no significant difference in viral replicative capacity between the virus of the mother, father or 
























































Figure 2.11 A)HLA, B)Viral load, C)CD4% and Absolute CD4 T cell count, D)CTL response 
of mother, E)CTL response of child, F) Viral replicative capacity of pair at first timepoint and 
G) Sequence changes in epitopes ISW9, KF11 and TW10 of transmission pair CP3-052 
(Child=C etc). 
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We next investigated the siblings who carried HLA-B*57 hypothesizing that these children 
would progress slowly depending on the transmitted variants and/or the fitness of the 
transmitted virus. 
 
Clinically, upon enrolment the mother had a stable viral load and an average absolute CD4 T 
cell count of 275cells/mm
3
 (Fig 2.12 B/C). At this visit, the mother enrolled her youngest child 
(3 years old). The child had a stable viral load and a low but relatively stable CD4% (Fig 2.12 
B/C). However, only after 18 months of follow up the mother agreed for her child to be 
referred for treatment.  After 9 months on the study, the mother also enrolled her older child (5 
years). Interestingly, unlike the younger child, the older child was doing very well 5 years after 
transmission. The child had a low viral load averaging 1967copies/mL with a high CD4% of 
43%. We next aimed to identify where the difference arose that enabled one child to progress 
and the other to control after both receiving the transmitted from the same donor but at 
different times. 
 
We next investigated if the children’s HIV-specific responses played a role in their diverse 
clinical outcomes (Fig 2.12 E). The youngest child made a single dominant B*57 restricted 
response to Gag (OLP 22), which was an optimally defined KF11 response (Fig 2.12 E2). The 
older child targeted Vif and Nef at low levels but did not target Gag. We confirmed this finding 
using optimal epitopes. The mother exhibited the highest magnitude of response when she 
targeted Nef (OLPS 81and 84), together with low magnitude of responses to Gag p17 (OLP 3) 
and Gag p24 (48) when initially screened. 
  
 Based on the association of B*57 MTCT escape variants on viral escape and viral fitness we 
next investigated whether the difference in clinical outcome in siblings were related to 
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sequence changes in the transmitted virus.   We next investigated the role of escape variant 
T242N escape mutation in Gag by investigating sequence changes in the TW10 epitope, and by 
further investigating sequence changes in the ISW9 and KF11 epitopes. Our sequencing results 
showed that no sequence changes in ISW9 for the mother and both children. Interestingly the 
mother carried the wildtype for all three epitopes while the children carried the same variant. 
The children carried a sequence change in position 242 (T242N) in TW10 and position 163 
(A163N).  
 
 We concluded the investigation by comparing the growth kinetics and fitness of earliest 
transmitted virus from the mum to the children. When investigating growth kinetics, all viruses 
seem to grow similarly for first four days, after day 5 the growth of the donor virus increased 
exponentially (Fig 2.12 F1). The difference in growth filtered through when investigating viral 
replicative capacity. The donor virus seemed to show a higher replicative capacity than the 
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Figure 2.12 A)HLA, B)Viral load, C)CD4% and Absolute CD4 T cell count, D)CTL response 
of mother, E1/E2)CTL responses of children, F1) Growth kinetics of virus F2) Viral replicative 
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capacity and G)Sequence changes in epitopes ISW9, KF11 and TW10 of transmission mother 
and siblings CP1-002. 
 
2.3.8 Phylogenetic comparison of sequences 
After sequence analysis it is imperative to identify if sequences correspond to clade C origin 
and are closely related to each other as expected with mother-child pairs. Our phylogenetic tree 
confirmed lineage which allowed and mother-child clusters which allowed investigators 
confidence to continue with successive implementation of viral replicative assays (Fig 2.13).  
 
2.4 DISCUSSION 
The majority of treatment naïve children typically progress to AIDS or death within the first 2 
years of life. However, a minority of children progress slowly to AIDS. Effective immunity in 
these children could be related to genetics (eg. IL-10, HLA etc), transmitted virus, effective 
humoral immune response, and/or effective cytokine secretory response and can be related to 
virus to cell surface interactions (eg CCR5, CXCR4 etc). The humoral immune response 
consists of two main arms of immunity namely antibody defense (B cells) and CTL defense (T 
cells). Our investigation focused on the T cell arm of immunity predominantly in children, 
whom appear to be in immunologically impaired during the first few years of their life.  
 
Our cross sectional evaluation of CTL responses in 60 treatment naive clade C infected 
children revealed that 50% of these children made low level responses that were not detectable 
when confirmed as individual pooled responses, while the remaining children had detectable 
responses. We found no difference in viral load between responders and non-responders 
(p=0.2799) in keeping with previous studies (Huang et al., 2008). Our analysis of responses 
104 | C h a p t e r  2 :  C D 8 +  T  c e l l  r e s p o n s e s  
 
confirmed that viral regions targeted by responder children in order of frequency as Nef (49%), 
Gag (17%), Env (14%) and Acc/Reg/Pol (6%). Interestingly, Nef which has been previously 
associated with different clinical outcomes (Gomez-Icazbalceta and Larralde, 2009), was 
dominantly targeted from 3 months to 10 years of age confirmed previous findings 
(Thobakgale et al., 2007, Huang et al., 2008).  
 
Knowledge of the known transmitted virus with an understanding of effective CTL responses 
may direct us to proteins that could impact viral control. Based on other studies that showed 
that HIV-1 infected adults (Goepfert et al., 2008, Matthews et al., 2009) and children (Feeney 
et al., 2005, Thobakgale et al., 2009b) benefit from exhibiting HLA-B restricted Gag-specific 
responses and from receiving transmitted escape mutations we next attempted to investigate the 
interplay between HLA, T cell and virus in a few MTCT transmission pairs. In the search for 
natural correlates of immune protection, our study was subsequently conducted in a rare 
untreated mother-child cohort. As protective HLA-B*27 (Goulder et al., 2001a, Schneidewind 
et al., 2007) and HLA-B*57 (Altfeld et al., 2003, Brockman et al., 2007, Crawford et al., 2009, 
Goulder et al., 2000, Leslie et al., 2004, Miura et al., 2009b, Feeney et al., 2005, Thobakgale et 
al., 2009b) restricted Gag-specific responses have been documented to play a role in slow 
disease progression within transmission pairs (Feeney et al., 2005, Thobakgale et al., 2009b, 
Goepfert et al., 2008), we focused on these HLA alleles.  
 
We hypothesized that HIV-specific CTL responses restricted by the protective HLA- B*2705 
and B*5703 would be associated with slow progression in children and/or sequence changes 
that may shape a less fit virus. However, our study was unable to relate specificity of any CTL 
targeting.  Furthermore, we were also unable to associate Gag-specific CD8+ T cell response 
with slow progression in the selected children in our cohort, in keeping with previous studies in 
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children (Froebel et al., 1997, Huang et al., 2008). We were unable to show an obvious benefit 
in adults carrying a protective allele. The mothers carrying protective alleles B*2705 (CP3-
024) and B*5703 (CP3-052) were doing well clinically but the study design was restricted in 
that we were unable to follow mothers or children from time of infection. In addition, mother 
CP3-052 defaulted once child was referred for treatment. Our study was restricted in that 
participants often defaulted after receiving clinical results, or once requiring ART as we were 
unable to provide treatment or aftercare based on funding constraints.    
 
HIV-specific CTL responses are able to target many viral variants across clades represent 
possible targets (Newman et al., 2002, Cao et al., 1997, Cao et al., 2000). Certain HLA –B 
associated escape variants have been documented to be correlated to a lower viral load in 
recipients (Brockman et al., 2007, Feeney et al., 2005, Leslie et al., 2004, Miura et al., 2009b). 
We hypothesized that loss of viral control may be associated with sequence changes in Gag 
that facilitate viral escape, leading to the loss of effective immune responses influencing viral 
fitness. We were limited only able to investigate Gag sequence changes. The limited targeting 
of Gag (Huang et al., 2008) ) could not explain why slow progressors, targeting Nef were still 
controlling HIV infection. As previously described, most chronically infected children 
frequently target Nef. We were unable to sequence Nef due to financial constraints.  
 
We next went on to investigate replicative capacities of the viruses. The replicative capacities 
differ in slow and rapid progressor children (Prado et al., 2010). Furthermore, a reduced viral 
replicative capacity has previously been documented to be associated with the presence of 
certain mutation and/or compensatory mutations (Brockman et al., 2007). In B*57 restricted 
transmission pairs we observed the presence of mutations and compensatory mutations 
associated with TW10. The mother who carried B*57 was clinically stable even though follow 
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up period was restricted. She did not carry the T242N mutation, which has previously been 
associated with lower fitness cost (Brockman et al., 2007) but still carried the S252N 
compensatory mutation. However, both mother and child’s virus had similar replicative 
capacities. The sibling carriers of B*5703 showed different clinical outcomes, which we 
presumed to be related to the changes in the virus that may have occurred between the time the 
mother transmitted to older and then younger child. However, the family was only recruited 
into our study many years after transmission, making it difficult to investigate the underlying 
mechanisms. Our investigation of sequences changes in this family revealed the presence of the 
T242N variants in both siblings at the time of investigation, however as we were unable to 
track sequence changes. We were thus unable to identify timing of sequence variants, and if 
changes were compensated in one child accounting for the difference in clinical outcome.  
 
CTL based studies provide information for the development of T cell based vaccines. Overall, 
our study was unable to investigate transmission pairs as rigorously as required ie. time of 
transmission, larger HLA cohort, detailed sequencing etc. The overall study design was further 
affected due to the much welcomed changes in PMTC guidelines. Nevertheless, our 
investigation concluded that children make low level or no responses following transmission 
which could explain why a majority of children are unable to control HIV-1 infection. To 
complement this finding, children who make responses tend to target Nef-specific epitopes, 
which have been associated with differential outcomes. We were unable to link the interplay 
between HLA, CTL responses, transmission of escape variants with overall viral fitness in the 
selected transmission pairs which may be related to study design or show that HLA and CTL 
data alone is not sufficient in determining what enables control. There exists a need to describe 
the role of the other arm of immune defence such as neutralizing antibodies, and innate 
immunity such as natural killer cells which to date has yet to be described in children.   
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CHAPTER THREE 
TIM-3 and PD-1 contribute to T cell exhaustion in HIV-1 clade C infected 
African children  
 
ABSTRACT 
Background: Inhibitory receptors such as the T cell immunoglobulin and mucin-3 domain 
molecule (TIM-3), and Programmed Death-1 (PD-1) play a crucial role in regulating T cell 
function during chronic viral infections. A study in HIV-1 clade B infected adults suggested 
TIM-3 expression on T cells to be elevated in chronic HIV infection, and correlate with 
markers of HIV disease progression. TIM-3 expressing T cells exhibited an “exhausted” 
phenotype with impaired functionality; however blockade of TIM-3 resulted in restoration of 
T cell effector activity such as cytokine secretion and proliferation. To date, no studies have 
been performed to investigate the role of TIM-3 in HIV-1 infected children and no data is 
available in the context of HIV-1 clade C infection. In this study, we assessed T cell 
exhaustion profiles in HIV-1 clade C infected children, and investigated their association 
with markers of disease progression.  
Materials and Methods: Our study investigated the expression profiles of the inhibitory 
molecules TIM-3 and PD-1 on CD4+ and CD8+ T cells in a cohort of 37 infected children, 
aged 24-942 days, and 9 HIV-1 seronegative children (controls) using multiparameter flow 
cytometry. 
Results: T cells from HIV-1 infected children expressed significantly higher levels of both 
TIM-3 (p=0.001) and PD-1 (p=0.0001) on CD8+ T cells derived from HIV-1 infected 
children in comparison to uninfected children. Expression of TIM-3 was higher on CD8+ T 
cells compared to CD4+ T cells (46% vs 20%), in line with previous studies, and TIM-3 
expression levels on CD4+ T cells and CD8+ T cells were positively correlated (r=0.45; 
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p=0.028). TIM-3 expression correlated with expression of PD-1 on CD4+ and CD8+ T cells. 
However, unlike adult HIV-1 infection, neither TIM-3 nor PD-1 correlated with HIV-1 viral 
load or absolute CD4+ T cell count. Longitudinal investigation revealed that TIM-3 and PD-1 
expression levels on T cells were maintained at high levels over time.  
Conclusion: We here demonstrate that the expression of the inhibitory molecules TIM-3 and 
PD-1 on T cells are elevated in paediatric HIV-1 infection. This elevated expression on T 
cells from vertically infected children suggests that both TIM-3 and PD-1 contribute to T cell 
exhaustion in children.  Of note, the highest expression levels were observed in infants less 
than 6 months of age, where HIV-1 specific T cell immunity is of lowest magnitude and 
breadth. TIM-3 in concert with other inhibitory molecules such as PD-1 may therefore 
promote or result in the failure to control viral load and to accelerate disease progression in 
the paediatric HIV patient population.  
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3.1 INTRODUCTION 
Acquisition of HIV remains a major source of paediatric death particularly in sub-Saharan 
Africa (Stats SA, 2011). Despite the revision of treatment guidelines in favour of early 
initiation of ART, the impact of the HIV epidemic has had a devastating effect on the 
mortality rates of children (WHO, 2010). Recent estimates by Statistics South Africa- a 
government agency, revealed that 43% of deaths in South African children were AIDS-
related (Stats SA, 2011). Clues obtained from studies of natural control of HIV on immune 
correlates may provide valuable information for vaccine design. Effector T cells such as 
CD8+ and CD4+ T cells have been implicated in successful viral control (Thobakgale et al., 
2007, Honeyborne et al., 2007, Kiepiela et al., 2007, Yu et al., 2007, Gamberg et al., 1999, 
Ramduth et al., 2009). Functional effector T cells are initially generated during the early 
stages of infection. However, robust immune responses have been shown to gradually 
diminish over time. This loss of effector function, including the inability to produce cytokines 
and proliferate renders effector cells ineffective in viral control. Chronic infections are often 
characterized by varying degrees of functional impairment of virus-specific T cell responses, 
and this defect is the principal reason why the host is not able to eliminate the persisting 
pathogen. As these cells are not able to function at their optimum we refer to them as 
dysfunctional and in a state of “functional exhaustion”. It has been demonstrated that by 
blocking the inhibitory pathways using antibodies against inhibitory molecules such as TIM-
and PD-1, the CD8+ T cell effector function can be restored (Day et al., 2007, Jin et al., Jones 
et al., 2008b).  
 
TIM-3 belong to the immunoglobulin super family, of which 4 molecules have been 
described in mice and humans (Kuchroo et al., 2003). TIM-1 appears to be an activation 
molecule for all T cells. TIM-2 molecules functions by negatively regulating TH2 immune 
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responses. TIM-4 expression in DCs promotes DC maturation, which plays an important role 
in the initiation of TH2 polarization. The present investigation focused on the TIM-3 
molecule, which is a type I membrane surface glycoprotein expressed on T cells (Mariat et 
al., 2005). Interestingly, TIM-3 has been shown to engage with its ligand galectin-9 and 
thereby negatively regulates IFN-γ secretion (Zhu et al., 2005) and TH1 responses in general 
(Wang et al., 2009, Wang et al., 2008). TIM-3 has previously been associated with immune 
dysregulation of T helper cell responses in other disease settings (Koguchi et al., 2006, Zhang 
et al., 2011).   
 
When TH1-helper cells are activated they help to initiate an attack thereby guarding against 
infection. However these T cells can also become overaggressive in their attack and thus their 
function needs to be kept in check. TIM-3 plays a role in controlling TH1 dependent immune 
responses by counterbalancing aggressive responses via interaction with its ligand galectin-9. 
Consequently, by increasing the TIM-3 signal the response of TH1 cells can be diminished, 
creating immune tolerance.  
 
TIM-3 induces T cell tolerance in both mice and man. The effects of blocking the TIM-3 
pathway were studied in mice who spontaneously develop insulin-dependent diabetes. A 
rapid onset of disease was observed in the mice treated with TIM-3-specific monoclonal 
antibodies. The study corroborated the role of TIM-3 in inhibiting autoimmune responses 
(Sanchez-Fueyo et al., 2003). The TIM-3 pathway blockade also played a role in other cells. 
TIM-3 was found to dampen the antigen-specific immunosuppressive function of 
CD4+CD25+ regulatory T cell populations (Anderson and Anderson, 2006, Sanchez-Fueyo 
et al., 2003, Wang et al., 2009). TIM-3 ligation has further been found to be associated with 
distinct signalling events exhibiting differential expression on the innate naïve dendritic cells 
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compared to adaptive immune cells (Anderson and Anderson, 2006, Kuchroo et al., 2008). 
Hence through differential
 
expression on innate versus adaptive immune cells, TIM-3 can
 
either promote or terminate TH1 immunity.
 
Taken together, data supports a key role for TIM-
3 in regulating immune responses in different disease settings. 
 
When TIM-3 pathway was blocked and TIM-3 signal was decreased, the TH1 responses 
could be amplified, creating strong immune responses which could play a role in autoimmune 
diseases (Jones et al., 2008a, Monney et al., 2002). A study in HIV-1 clade B infected adults 
suggested that TIM-3 expression on T cells was increased in chronic HIV infection and 
correlated with markers of HIV disease progression. The frequency of TIM-3 expressed on 
CD8+ T cells correlated positively with HIV-1 viral load and CD38 expression as a marker of 
immune activation, and correlated inversely with absolute CD4+ T cell count in HIV-1 
infected participants (Jones et al., 2008b). The highest TIM-3 expression was observed in 
HIV-1-specific CD8+ T cells. In addition, TIM-3 expressing T cells exhibited an exhausted 
phenotype (Sakuishi et al., 2011) with impaired functionality and blocking of TIM-3 
signaling restored proliferation and increased cytokine production in HIV-1-specific T cells 
(Jones et al., 2008b).  
 
Recent studies in the LCMV mouse model have documented CD8+ T cell exhaustion by co-
expression of TIM-3 and PD-1 (Jin et al., 2010). Day et al. investigated the role of the 
inhibitory molecule PD-1 in a chronic human viral infection by examining PD-1 expression 
on HIV-specific CD8+ T cells in 71 treatment naïve HIV-1 clade-C infected participants 
(Day et al., 2006). The study demonstrated that PD-1 was upregulated on the surface of HIV-
specific CD8+ T cells and that this expression was associated with increased T cell 
exhaustion and HIV disease progression (Day et al., 2006).  The study reported that PD-1 was 
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significantly upregulated, and expression correlated with impaired HIV-specific CD8+ T cell 
function as well as predictors of disease progression: positively with plasma viral load and 
inversely with absolute CD4+ T cell count.  In an additional blockade experiment of the PD-
1/PD-L1 pathway, an enhancement of HIV-specific CD4+ and CD8+ T cell function, and the 
reversal of the exhausted T cell phenotype was observed (Day et al., 2006).  
 
Even though there are a growing number of investigations on negative immuneregulators in 
adult study populations, the role of inhibitory molecules in paediatric HIV-1 infection has not 
been fully explored and no data exist on the expression of TIM-3 in children to date. A recent 
study demonstrated PD-1 to be a marked negative regulator of activated T cells in 93 HIV-1 
infected untreated children aged (10.8 years) (Prendergast et al., 2011). PD-1 expression on 
CD8+ T cells, was found to be higher in HIV-infected children than HIV-uninfected children 
(Prendergast et al., 2011). However, unlike what has been reported for adult HIV-1 infection, 
the study found no correlation between PD-1 and HIV viral load (R=0.11, P=0.40). 
Interestingly, PD-1 expression on CD8+ T cells positively correlated with activation on 
CD8+ T cells which was measured by co-expression of CD38 and HLA-DR. The study 
finally demonstrated that both CD8 activation and PD-1 expression on CD8+ T cells were 
partially driven or driving the magnitude of the HIV-specific CD8+ T cell response 
(Prendergast et al., 2011). 
 
Dual blockades of the TIM-3 and PD-1 pathway are able to rescue T cell immune responses 
in hepatitis C infection (Golden-Mason et al., 2009, Callendret and Walker), murine 
leukaemia (Zhou et al.), cancer (Sakuishi et al.), tuberculosis (Henao-Tamayo et al., 2011) 
and in LCMV infection (Jin et al., 2010). The LCMV study found that TIM-3 expression on 
CD8+ T cells was low after acute infection, but that TIM-3 was expressed at high levels 
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throughout chronic infection. Blockade of the TIM-3 pathway alone has also resulted in an 
improved T cell response. Interestingly as much as 80% of the LCMV-specific CD8+ T cells 
in lymphoid and non-lymphoid organs dually expressed TIM-3 and PD-1. The dual 
expression was associated with a severe exhaustion profile that was associated with the 
secretion of pro-inflammatory cytokines (Jin et al., 2010). In another study mice were 
infected with Mycobacterium tuberculosis (TB). The study documented that the exhaustion 
markers PD-1 and TIM-3, as well as the marker KLRG-1, were predominantly expressed on 
CD8+ T cells in 5 MTB infected mice. The expression levels of the exhaustion markers 
decreased upon treatment showing, changes as the bacterial load in the lungs dropped 
indicating a valuable marker to exploit therapeutically. The study further demonstrated the 
potential use of these markers for early detection of TB in comparison to conventional 
methods of screening TB (Henao-Tamayo et al., 2011).  
 
To date, no studies have been performed to investigate the role of TIM-3 in HIV-1 infected 
children and no data is available in the context of HIV-1 infection. Given the recently 
published data on PD-1 in children and co-regulation of PD-1 and TIM-3 in LCMV, our 
study investigated the mechanism underlying the association between progressive T cell 
exhaustion and HIV replication in an African cohort of HIV-1 clade C infected children. We 
sought to answer the following research questions: (1) Do TIM-3 and PD-1 T cell expression 
profiles differ in HIV-1 infected children and uninfected children (2) Do TIM-3 and PD-1 
expression correlate with markers of disease progression as observed within adult HIV-1 
clade B populations?  and (3)  What is the interplay between TIM-3 and PD-1 expression  in 
HIV-1 infected children? 
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3.2 PARTICIPANTS, MATERIALS AND METHODS 
3.2.1 Cohort description 
The study began recruitment in 2006 in South Africa, prior to the revision and initiation of 
the new ART guidelines. A cohort of untreated HIV-1 infected mother child pairs was 
established. The treatment guidelines at the time dictated that HIV-1 seropositive mothers 
during the last trimester of pregnancy received a single dose of Nevirapine during labour. The 
infant received a single dose of nevirapine within 48 hrs of birth, according to the HIVNET-
012 Protocol, as previously described (Guay et al., 1999, Jackson et al., 2003).  
 
The 46 study participants were recruited through clinics in KwaZulu-Natal, Durban, South 
Africa. The recruitment clinic sites included King Edward Hospital, McCord Hospital, Saint 
Mary’s Hospital and Prince Mshiyeni Hospital. Transmission pairs were screened and 
mother-child pairs who met the inclusion criteria of mother-child treatment naïve pairs and 
positive HIV-DNA PCR results from birth hospitals were recruited. The participants were 
selected for a preliminary cross-sectional analysis based on sample availability. The 
exclusion criteria for the chronically infected cohort included treated pairs (mothers and/or 
children). The untreated cohorts were part of the chronically infected pair cohort and 
represented initially falsely diagnosed HIV negative participants. This study retrospectively 
investigated 23 HIV-1 infected, 9 HIV-1 exposed uninfected and 13 HIV-1 treated children 
(Thobakgale et al., 2009, Thobakgale et al., 2007, Mphatswe et al., 2007) from Zulu/Xhosa 
ethnic origin with HIV-1 infection. Treated children who had an undetectable viral load for at 
least one or more timepoints were included for analysis. 
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 Written informed consent was obtained from all study participants and the research protocol 
for the study was approved by the Biomedical Research Ethics Committee of the University 
of KwaZulu-Natal, Durban, South Africa, and the Internal Review Board of Massachusetts 
General Hospital, Boston. 
 
3.2.2 Plasma viral Load and absolute CD4+ T cell measurement 
Plasma was isolated from whole blood after a single round of centrifugation. Plasma viral 
loads were assessed using the Cobas Amplicor Monitor Test version 1.5, detection limit of 50 
HIV-1 RNA copies/mL plasma according to the manufacturer’s instructions (Roche 
Diagnostics).  
 
Absolute CD4+ T cell counts and percentages of CD4+ T cells were determined from fresh 
whole blood using Multitest four colour TruCount as previously described (Gratama et al., 
2002) according to the manufacturer’s instructions (Beckton Dickinson Technology) at the 
HIV Pathogenesis Programme, Durban, KZN, South Africa. 
 
3.2.3 Isolation of PBMCs 
Blood specimens were collected in EDTA tubes and processed within 6hrs of collection.  
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood using the 
ficoll-histopaque (Sigma, St Louis, Mo) density gradient centrifugation. PBMCs were used 
fresh in ELISPOT assays. The remaining PBMCs were cryo-preserved in 90% fetal bovine 
serum (Sigma-Aldrich), 10% DMSO prior to storage in liquid nitrogen for subsequent 
multiparameter flowstaining and immunophenotyping expression analyses. 
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3.2.4 Multiparameter flow cytometry staining for TIM-3 and PD-1 expression on bulk 
CD4+ and CD8+ T cells 
3.2.4.1  Antibody titrations: Titrations were performed by staining (1x10
5
) PBMCs at 
a range of 2 to 25µl antibody (depending on volume and concentrations specified by 
manufacturer). Antibody dilutions were halved covering the above range. The final optimal 
concentration was subsequently used for immunophenotyping.  The optimal concentration 
was determined by choosing the dilution of the stain where the intensity plateau for the 
stained cells was most favourable.  
 
3.2.4.2  Thawing: Cryo-preserved PBMCs were thawed using a warming method. 
R10 media, made up of RPMI 1640 + 10% FBS, was warmed to 37°C in a 15 or 50 mL 
Sterilin tube. Firstly, 20 μl nuclease was added to 2 mL 37 
o
C warm R10 in a 15 mL Sterilin 
tube. Frozen PBMC vials were left to sit at room temperature for approximately 5 minutes 
until nearing liquid state. The cryovial was opened and the rim was quickly swabbed with 
70% ethanol before the icy cells were transferred into the 15 mL Sterilin tube containing 
nuclease and 2 mL of warm R10 media. An additional 8 mL of warm R10 was slowly added 
to the tubes and the mixture was spun down at 1,700rpm for 10 minutes. Supernatant was 
discarded removing all of the now toxic DMSO freezing solution and the cell pellet was re-
suspended and cells counted using an automated cell counting Guava viacount assay and read 
on the Guava cell counter (Guava Technologies, Guava PCA System). Cells were re-
suspended in R10 at a concentration of 1 million cells per mL. 
 
 3.2.4.3 Immunostaining: 1 million cells per mL were added to each experimental 
FACS tube and control Fluorescence Minus One (FMO) tubes. PBMC were first stained for 
viability in the dark, at room temperature, with 1µl of a 200 µl stock solution of 
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LIVE⁄DEAD® Fixable Violet Dead Cell Stain Kit (Invitrogen). After 15 minutes the dye was 
washed of using cold PBS (phosphate buffered saline) for 10 minutes at 1,500 rpm. PBMCs 
panels were stained (extracellular) as below (Table 3.1), at 4°C for 30 minutes. Due to the 
limitation of available fluorochromes for PD-1 and TIM-3 antibody staining at the time of 
investigation, single cell analysis could not be implemented.  
 










CD14 Peridinin Chlorophyll Protein PerCP (BD, 340660) 5 
CD19 Pacific Blue PacB (BD, 51-0199-73) 2 
CD3 Phycoerythrin-Cyanine 7 PE-Cy7(BD,clone L3T4) 2 
CD4 Allophycocyanin APC (BD, 340443) 3 
CD8 Alexa Fluor 700 Alexa Fluor 700 (BD, 557945) 2 
TIM-3 Phycoerythrin PE (R&D, FAB2365P) 8 
 
 
After the above mentioned staining of PBMCs, they were washed twice using cold PBS. 










CD14 Pacific Blue PacB (EBioscience, 48-0149-42) 2 
CD19 Pacific Blue PacB (EBioscience, 51-0199-73) 2.5 
CD3 Fluorescein Isothiocyanate FITC(EBioscience, SK7, 11-0036-42) 3 
CD4 Allophycocyanin APC (BD, 340443) 3 
CD8 Alexa Fluor 700 Alexa Fluor 700 (BD, 557945) 2 
PD-1 Phycoerythrin PE (EBioscience,clone MIH4,  558694) 10 
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setup and read to standardize assay.  Flow data were acquired on a LSR II flow cytometer 
(BD Biosciences). For the infant cohort, a minimum of 500,000 events were collected per 
participant, and a minimum of 250,000 events were collected for adult samples. Acquisition 
templates were drawn during acquisition to further confirm subset gating prior to analysis. 
The FMO control was used as the reference gate while the LIVE⁄DEAD® Fixable Violet 
Dead Cell Stain were used as an exclusion channel to eliminate dead PBMCs. 
 
3.2.5 Statistical analysis 
Flow data was analyzed with FlowJo software version 7.5 for PC. Microsoft Excel was used 
to transfer data and subtract fluorescence minus one (FMO) background values. Data was 
analyzed and graphically represented using Prism software (GraphPad; version 5). The Mann 
Whitney U test was performed when comparing less than two groups, Kruskal Wallis testing 
and ANOVA was performed when comparing more than two groups. Post-test analysis was 
performed using Dunns Multiple Comparison Test. Normalization and subset discrimination 
and gating of data including the mean fluorescent intensity and % response per event was 
performed using Flow Jo. Significance levels were indicated using Mann Whitney U 
(P<0.05).Correlations were performed using Spearman rank tests (p and r
2
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3.3 RESULTS 
3.3.1 Cohort Characteristics 
A total of forty six children were studied. As represented in Table 3.2 age range and clinical 
data shows that the HIV-1 uninfected children exhibit a median absolute CD4+ T cell count 
of 2,033 cells/mm
3
 and CD4+ T cell % of 34%. The infected untreated children had a median 
viral load of 55,700 copies/mL with a median absolute CD4+ T cell count of 1,838 cells/mm
3
 
and CD4+ T cell% of 30% while the treated children had a median viral load of 292 
copies/mL with an absolute CD4+ T cell count of 1,325 cells/mm
3
 and CD4 T cell of 29% 
(Figure 3.1).  The median ages of uninfected and infected untreated children were similar 
while the treated children were slightly older as represented in Table 3.2.  
 
Table 3.2 Age and clinical characteristics of study cohort.   
 
Figure 3.1 Graphical representation of the clinical characteristics of the cohort of children: 
A) Viral load (copies/mL), B) CD4+ T cell % and C) Absolute T cell count (cells/mm
3
).  
                                                          HIV-1 uninfected  HIV-1 untreated HIV-1 treated 
N 9 23 14 
Median Age in days (IQR) 61(62-945) 76(24-942) 1838(53-4025) 
Median Absolute CD4+ T cell count (IQR) 2033 (194-3433) 1838(173-5561) 1325(605-4291) 
Median CD4 T cell % (IQR) 34(24-61) 30(10-46) 29(16-54) 
Median Viral Load (copies/mL) 
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3.3.2 Representative gating scheme for the quantification of the expression of 
inhibitory molecules on CD4+ and CD8+ T cell subsets 
Gating schemes for the PD-1 and TIM-3 experiments are represented in Fig.3.2 and Fig.3.3 
In Fig 3.2/3A time represents a uniform flow rate. The live lymphocytes were then gated on 
removing doublets. Subsequently, gates were set to exclude dead cells (viability marker
+
), 
monocytes (CD14+) and B cells (CD19+). Fig 3.2B represents the gating strategy for 
quantification of TIM-3 expression. The gating for viable cells was followed by the gating of 
viable lymphocytes (CD3+) and CD4+ or CD8+ T cells. The TIM-3 FMO and PD-1 FMO 

























Figure 3.2 Representative flow cytometry gating scheme for the assessment of expression of 
TIM-3 for a single participant sample from the study cohort.  
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= 
Figure 3.3 Representative flow cytometry gating scheme for the assessment of expression of 
PD-1 for a single participant sample from the study cohort.  
 
3.3.3 Elevated expression of TIM-3 on CD4+ and CD8+ T cells of the HIV-1 infected 
children.  
We first evaluated TIM-3 expression levels on CD4+ T cells and CD8+ T cells as shown in 
Fig. 3.4 TIM-3 expression ranged from 8 to 87% for CD8+ T cells and 1 to 91% for CD4+ T 
cells. Median TIM-3 expression was higher on CD8+ T cells compared to CD4+ T cells. 
Moreover when comparing sub-groups median TIM-3 expression was higher on CD8+ T 
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cells from the group of treated children in comparison to uninfected children (p=0.0044). 
However untreated infected children had a broader expression range. The median TIM-3 
expression in untreated uninfected children differed significantly from uninfected children 
(p=0.0134) but not from treated children (p=0.2647). The uninfected group was removed 




Figure 3.4 Comparison of CD8+ TIM-3+ and CD4+ TIM-3+expression levels within sub-
groups: A) CD8+ TIM-3+ and B) CD4+ TIM-3+.  
 
3.3.4 No association observed between clinical markers of disease progression and 
TIM-3+ expression 
We subsequently examined the relationship between CD8+ TIM-3+ and viral load in 
untreated children. We decided not to examine this relationship in treated children as viral 
loads were undetectable and data may be conflicting due to age related differences. Noted, 
children on therapy may continue to express TIM-3 but have suppressed VL and relatively 
reconstituted CD4 counts, which could obscure correlations existing in children who were 
untreated. We found no relationship between CD8+ TIM-3+ and viral load. (p=0.6632, 
r=0.0763); absolute CD4+ T cell count (p=-0.3426, r=-0.1653) and CD4 T cell % (p=0.0842, 
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r=-0.2960) (Fig 3.5A/B/C.). The relationship between CD4+ TIM-3+ and viral load 
(p=0.4770, r=-0.1350); absolute CD4+ T cell count (p=0.7480, r=-0.0612 and CD4+ T cell % 
(p=0.2959, r=0.1973) showed insignificant associations (Fig 3.5D/E/F.) 
 
Figure 3.5 Correlation of clinical markers with expression of TIM-3 on CD8+ T cells: A) 
Viral load (copies/mL), B) Absolute T cell count (cells/mm
3
) and C) CD4 T cell % and CD4+ 
T cells D) Viral load (copies/mL), E) Absolute T cell count (cells/mm
3
) and F) CD4 T cell 
%.. 
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3.3.5 Increased expression of PD-1 on T cells from HIV-1 infected children  
We next investigated expression levels of PD-1 derived from HIV-1 infected children. A 
comparison of PD-1 expression on CD4+ T cells and CD8+ T cells reveals the following: 
PD-1 expression was elevated on CD8+ T cells in comparison to CD4+ T cells. When 
comparing the median of PD-1 expression across uninfected (5%), treated (19%) and 
uninfected (36%) sub-groups-PD-1 expression was elevated in the untreated children in 
comparison to treated children (p=0.02). In addition PD-1 expression was elevated in treated 
children in comparison to uninfected children (p=0.0348) and untreated children in 
comparison to uninfected children (p=0.0012) (Fig 3.6A). PD-1 expression on CD4+ T cells 
revealed that treated children exhibit a higher median of PD-1 expression in the untreated 
children (p=0.0074) and uninfected children (p=0.0002). PD-1 expression was significantly 
different between untreated and uninfected children (p=0.0058) on CD4+ T cells (Fig 3.6B). 
Additionally, PD-1 expression and TIM-3, were found to be expressed at higher levels in the 
children aged less than 6 months in comparison to older children  although this differences 
were not statistically significant (p=0.1266; data not shown). 
  
Figure 3.6 Comparison of expression levels of PD-1 on A) CD8+ T cells and B) CD4+ T 
cells between uninfected, treated and untreated children. 
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3.3.6 Correlations between clinical markers of expression and PD-1+ expression 
Based on findings from adults where PD-1 expression correlated with viral load, we 
examined the relationship between CD8+ PD-1 and viral load and found a significant 
relationship between PD-1 and viral load (p=0.0083, r=0.3974) but not absolute CD4+ T cell 
count (p=0.8347, r=0.00328) and CD4+ T cell % (p=0.1631, r=-0.2165) (Fig 3.7A/B/C.). The 
relationship between CD4+ revealed the following associations:  CD4+PD-1+ expression and 
plasma viral load (p=0.1526, r=-0.2304); absolute CD4+ T cell count (p=0.1370, r=-0.2305) 
and CD4 T cell % (p=-0.2910, r=0.0583) as represented in Fig 3.7D/E/F. 
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Figure 3.7 Correlation of clinical markers with expression of PD-1 on CD8+ T cells: A) 
Viral load (copies/mL), B) CD4 T cell % and C) Absolute T cell count (cells/mm
3
) and CD4+ 
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3.3.7 Expression of PD-1 and TIM-3  
A synergistic effect of PD-1 and TIM-3 blockades has been found to restore T cell 
exhaustion, we next investigated the expression of PD-1 and TIM-3on bulk cells. Based on 
the panel restrictions we were not able to correlate co-expression on identical cell. However, 
correlation analysis revealed positive correlation of CD4+ T cells and CD8+ T cells for PD-1 
(p<0.0001; r=0.6507) which could be related to compensation controls, antibody staining or 
variation in subset expression. TIM-3 expression correlation analysis revealed positive 
correlation (p=0.0131; r=0.4478). There was a positive correlation of TIM-3 and PD-1 
expression on CD8+ T cells (p=0.0483; r=0.2941) and no correlation of TIM-3 and PD-1 
expression (p=0.9737; r=-0.0006) on CD4+ T cells. 
Figure 3.8 Correlation of expression on exhaustion  markers A) CD4+ TIM-3+ and CD8+ 
TIM-3+ B) CD4+ PD-1+ and CD8+ PD-1+ C) CD8+ TIM-3+ and CD8+ PD-1+ and D) 
CD4+ TIM-3+ and CD4+ PD-1+. 
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3.3.8 Longitudinal follow-up: TIM-3 expression levels on T cells were maintained at 
high levels and tracked with HIV viral load. 
In order to complement our cross-sectional data we next had the unique opportunity to 
investigate expression of PD-1 and TIM-3 longitudinally in an HIV-1 infected child over a 20 
month period. PD-1 and TIM-3 expression on CD8+ T cells were maintained at high levels 
over time and in this participant appears to track positively with viral load and inversely with 
CD4 T cell %. Furthermore, expression of PD-1 and TIM-3 on CD4+ T cells track positively 




Figure 3.9 Longitudinal assessment of clinical markers and markers of exhaustion with A) 
CD8+ TIM-3+ and CD8+ PD-1+ and B) CD4+ TIM-3+ and CD4+ PD-1+. 
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3.4 DISCUSSION 
Studies on paediatric HIV patient populations are limited but crucial to our goal of an HIV-
free generation. There is an obvious difference in disease progression and immunology of 
children in reference to adults. Consequently, it is imperative not to extrapolate but rather to 
investigate the mechanisms underlying paediatric infection. To date no studies have been 
performed to investigate the role of TIM-3 in HIV-1 infected children and no data is available 
in the context of HIV-1 infection. The present study aimed to investigate the mechanism 
underlying the association between T cell progressive exhaustion and HIV replication in an 
African cohort of HIV-1 clade C infected children. Our results showed a significant 
difference in TIM-3 and PD-1 T cell expression profiles between HIV-1 infected children and 
uninfected children, with CD8+ T cells having an increased expression of TIM-3 in 
comparison to CD4+ T cells. Our findings demonstrated no association between TIM-3 and 
PD-1 expression markers with markers of disease progression in contradiction to 
observations in adults (Jones et al., 2008b, Day et al., 2006). Finally our study demonstrated a 
positive association between TIM-3 and PD-1 in an HIV-1 paediatric disease setting.  
 
Paediatric infection is characterised by elevated viral loads (Mellors et al., 1997, Dickover et 
al., 1998, Shearer et al., 1997, Rouet et al., 2003). Higher viral loads results in persistent 
antigenic stimulation which lead to immune exhaustion rendering effector cells 
dysfunctional, as documented in HIV and HCV (Khaitan and Unutmaz, 2011, Kasprowicz et 
al., 2008). TIM-3 and PD-1 have previously been found to correlate with markers of disease 
progression such as viral load and inversely with absolute CD4+ T cell count (Wu et al., 
2011, Vali et al., 2010, Jones et al., 2008b, Day et al., 2006). Our study found no association 
between clinical markers of disease and TIM-3+ expression, and a negative association 
between CD4 T cell % and PD-1+expression.  
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Children have an immature immune system with ineffective or suppressed effector function 
that contributes to the inability of cells to proliferate and effectively control HIV replication. 
It is still unclear whether CD8+ T cells in children are ineffective, and/or immature or 
completely suppressed? Our results, further confirm an elevated level of exhaustion on 
CD8+T cells compared to CD4+ T cells which could contribute to ineffective CD8+ T cell 
responses in children, or more simply could also mean that these markers better discriminate 
CD8+ T cells in comparison to CD4+ T cells. Hence, the difference between CD4 and CD8 
cell could be attributed to CD8 or CD4 compensation controls, or variation in subset 
expression and may be a true reflection of expression of these markers on CD4 and CD8 cells 
in children. The analysis of an additional timepoint would have proven beneficial to confirm 
these results. 
 
General T cell exhaustion was further corroborated by the next component that showed TIM-
3 and PD-1 to be elevated in HIV-1 infected children in comparison to uninfected children. 
Other adult studies have confirmed elevation of TIM-3 on CD4+ T cells and CD8+ T cells in 
HIV infection (Jones et al., 2008b), chronic hepatitis C virus infection (Golden-Mason et al., 
2009) and in pregnancy (Zhao et al., 2009). A recent study demonstrated PD-1 to be a 
marked negative regulator of activated T cells in children (Prendergast et al., 2011). PD-1 
expression on CD8+ T cells was found to be higher in the HIV-infected group in comparison 
to the HIV-uninfected children. Our study confirmed these findings; we documented elevated 
expression levels on CD8+ T cells in comparison to CD4+ T cells for both TIM-3 and PD-1 
inhibitory molecules. Levels of Tim-3 and PD-1 observed in this study of HIV-1 clade C 
infection were higher than those reported from previous studies in HIV-1 clade B 
infection.(Jones et al., 2008b).  
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Additionally, our study had the rare advantage of being able to document of expression of 
TIM-3 and PD-1 on T cells longitudinally over a twenty month period. The results revealed 
that TIM-3 and PD-1 expressing CD4+ and CD8+ T cells were maintained at high levels and 
tracked with HIV viral load. Due to limitation in sample size we were unable to describe 
immune responses over time which would have proven valuable as exhaustion markers have 
been implemented in the suppression of immune responses.  Our investigation of longitudinal 
data also showed a change in CD4% (increase) and HIV viral load (sharp decrease). 
However, we did not have clinical data supporting concomitant infection, treatment or 
another clinical scenario explaining the drop in HIV viral load with concomitant mild 
increase in CD4 T cell count.  The fact that CD4 count was higher as well would be 
consistent with a biological phenomenon; however a lab error in original sample acquisition 
cannot be entirely excluded. To rule out day to day assay variation all 5 timepoints were 
stained and processed for flowcytometric analysis on the same day, which makes a lab error 
at this stage less likely, given the consistent data for the other 4 time points. 
 
In vitro experiments reveal the extent to which exhaustion markers suppress effector 
functions (Khaitan and Unutmaz, 2011, Day et al., 2006, Jin et al., 2010, Ju et al., 2009, Jin et 
al.). Blocking of the PD-1 and TIM-3 pathway alone restores immune responses which 
enable the immune system to mount a more vigorous attack against foreign infections. 
However, simultaneous blockade of TIM-3 and PD-1 pathways has been documented to have 
a synergistic effect in restoring antiviral immunity and viral control compared to the blockade 
of either pathway alone (Jin et al.). Reversal of T cell dysfunction may prove valuable in 
therapeutic vaccine development. Noteworthy, Phase I clinical trials are currently being 
carried out to evaluate the efficacy of the use of PD-1 blockade therapeutically in oncology 
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and infectious disease settings (Brahmer et al., 2010, Berger et al., 2008, Sakuishi et al., 
2011). 
 
As this was a retrospective design the investigators were restricted.  The investigators were 
restricted in sample choice and availability. Given the dynamic nature of the developing 
immune system, age-related differences were noted but unavoidable and are acknowledged as 
a limitation in interpreting the data.  The investigators also acknowledge that uninfected 
children from uninfected mothers would have been an additional relevant control cohort. 
Furthermore, our study was limited by the relatively small sample size for a phenotypic study 
and flow panel constraints that restricted our investigation of co-expression of PD-1 and 
TIM-3 on a single T cell. Noteworthy, functional studies would clearly have added an 
interesting and important component to the work. However, limited availability of cells from 
these paediatric samples restricted the investigators largely to the phenotypic studies 
described here (exception:  functional Treg work in chapter 4). Furthermore, functional work 
best carried out on fresh samples. However, to our knowledge it represents the largest study 
addressing this topic matter in the literature to date. Our data is the first to report TIM-3 
expression in HIV-1 infected children and suggests that expression of both PD-1 and TIM-3 
exhaustion markers additively contribute to the failure to control viral load and to accelerate 
disease progression in this vulnerable paediatric population.  
 
We conclude that Tim-3, in concert with other inhibitory molecules such as PD-1, were  
elevated in paediatric HIV-1 clade C infection. This elevated expression on T cells from 
perinatally infected children suggests that both TIM-3 and PD-1 contribute to T cell 
exhaustion in this paediatric patient population. This could explain why younger newly 
infected children are unable to control HIV infection and show low magnitude and breadth 
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suggesting limited HIV-1 specific T cell immunity. To reiterate, our study is the first to 
describe the contribution of TIM-3 to HIV pathogenesis in HIV-1 infected children and in 
HIV-1 subtype C infection no data is available in the context of HIV-1 infection. Exploring 
negative T cell regulation provides an obvious therapeutic advantage of reversing effects of 
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CHAPTER FOUR 




Background: Generalized immune activation has repeatedly been associated with poor 
outcome in HIV-1 disease progression. To date, limited studies have been performed to 
investigate the role of Tregs and activation in HIV-1 clade C infected children. We therefore 
aimed to study the impact of Tregs and activation expression profiles on HIV-1 disease 
progression, in clade C infected children.  
Materials and Methods: Our study investigated the frequency of Tregs (CD4+CD127-
CD25+) and T cell activation (HLA-DR+ CD38+) in 46 clade C infected children, using 
multi-parameter flow cytometric assays. Treg expansion with subsequent Treg suppression 
assay confirmed functional capacity of Tregs.  
Results: We observed a statistically significant negative correlation between Treg 
frequencies and CD4+ T cell% (p=-0.0362, r=-0.3132). No significant correlations between 
Tregs and activation markers, or markers of disease progression such as absolute CD4+ T cell 
count and viral load were observed. The expression of HLA-DR+CD38+ on CD8+ T cells 
was found to be significantly higher on untreated compared to treated (p=0.002) and 
uninfected children (p=0.0177)  Similarly HLA-DR+CD38+ expression on CD4+ T cells was 
significantly higher in untreated compared to treated (p=0.0495) and uninfected children 
(p=0.0312). The expression of activation markers on CD4+ and CD8+ T cells revealed a 
positive correlation (p<0.001, r=0.6376). Markers of activation were also found to be 
significantly higher in the children aged less than 6 months in comparison to older children 
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on CD4+ (p=0.0437) and CD8+ T cells (p=0.00276). In addition to our phenotypic studies 
we were able to expand Tregs from HIV-1 infected children and demonstrated their ability to 
suppress T cell proliferation. 
Conclusion: We demonstrate that the expression of Treg and T cell activation markers are 
elevated in paediatric HIV-1 clade C infection. High Treg frequencies in perinatally infected 
children suggest that Tregs may contribute to T cell suppression in children, with highest 
frequency in the age group of < 6 months, when HIV-1 specific T cell immunity is of lowest 
magnitude and breadth.  
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4.1 INTRODUCTION 
Adults and children differ in disease progression denoting a variation in clinical outcome 
(Holland et al., 2000, Resino et al., 2002b, Resino et al., 2002a). In HIV-1 infected children, 
the levels of plasma viremia are persistently high, with declines only observed in the second 
year of life. In general, it is presumed that these young children respond ineffectively due to 
immature or defective cell functionality (Ashwood et al., 2011, Ly et al., 2009, Ochieng et 
al., 2006).  T cell efficacy can be related to cell activation, the levels of cell expression and 
cell-cell interaction. Phenotypic markers facilitate the discrimination of cell populations, 
specific subsets and their functional capabilities. It is known that the pathogenesis of HIV-1 
infection is characterized by CD4+ T cell loss in the context of generalized immune 
activation and dysregulation. (Papagno et al., 2004, Giorgi et al., 1999, Liu et al., 1998, 
Putnam et al., 2009). To date, limited research has been carried out that characterizes 
activation and regulatory T cell subsets between infected and uninfected African children.  
 
HLA-DR and CD38 are surface markers of T cell activation. In HIV uninfected individuals 
CD38 is expressed in relatively greater numbers by naïve lymphocytes, while in HIV infected 
individuals, CD38 is expressed by CD8+ memory T cells  (Benito et al., 2005). Immune 
activation is commonly characterized as either CD38+ or HLA-DR+ or dual expression of 
CD38 and HLA-DR, on T lymphocytes (Giorgi et al., 1994, Ho et al., 1993, Liu et al., 1997).  
Immune activation markers expressed on CD8+ T cells have been documented to be strong 
and independent predictors of disease progression (Liu et al., 1997).  Elevated levels of CD38 
in chronically infected individuals suggested that CD38 was the most predictive marker for 
the development of a clinical AIDS diagnosis and death. Activated T cells have also been 
shown to express HLA-DR at elevated levels (Saifuddin et al., 1998). Cross sectional and 
longitudinal studies also showed an increase of dual expression of CD38+ and HLA-DR+ 
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over the course of infection. There is a progressive increase in expression towards later stages 
of HIV-1 infection (Kestens et al., 1992, Sindhu et al., 2003, Liu et al., 1996).   
 
T cell subsets differ in infants compared to adults (Birle et al., 2003). When lymphocyte 
activation in healthy unexposed infants was compared to uninfected infants of HIV-infected 
mothers, the proportions of activated CD4+ cells were increased in uninfected infants of 
HIV-infected mothers compared to unexposed infants. (Jennings et al., 1994). Another study 
investigated co-expression levels of activation markers HLA-DR and CD38, in clade B age-
matched children. The study demonstrated that CD4+ T cells co-expressing CD38 and HLA-
DR were significantly increased in HIV infected children compared to uninfected children. 
The CD4+ cells of the uninfected and infected children exhibited a mean expression of 2 vs 
6% for < 2 years of age, 3 vs 11% for 2-3 years, 2 vs 8% for ≥4 years respectively. There was 
a significant increase in the proportion of CD8+ cells co-expressing CD38 and HLA-DR  
with a mean of 5 vs 25% for < 2 years, 10 vs 41% for 2-3 years, 6 vs 31% for ≥ 4 years 
exhibited for uninfected vs infected children (Bhatia et al., 2010, Plaeger-Marshall et al., 
1994) These findings confirm the possible effect of immune activation on immune responses.  
 
A recent study investigated activation in 194 children receiving HAART. These children 
were divided into two groups according to the viral load: 59 patients with VL ≥ 400 
copies/mL and 135 patients with VL < 400 copies/mL. The percentage of CD8+ CD38/HLA-
DR+ T cells of patients with VL ≥ 400 copies/mL was significantly higher than that of 
patients with VL < 400 copies/mL, concluding that successful HAART could significantly 
decrease immune activation in children (Jin et al., 2011).  
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As immune activation appears to play a deleterious role in both progression and acquisition 
of HIV-1 infection, immune mechanisms with the ability to decrease inflammation may be 
beneficial, and play a significant role in maintaining the fine balance of the 
immunoregulatory equilibrium, in peripheral blood and at mucosal sites (Favre et al., 2009).  
Regulatory T cells (Tregs) are a specialized subpopulation of T cells that are discriminated 
as ‘naturally arising’ CD25+CD4+ Tregs in which the frequency of the transcription factor 
forkhead box p3 (Fox3) occurs in the thymus (Curiel, 2007), or as ‘induced’ Tregs in which 
FoxP3 is induced in the periphery (Sakaguchi, 2004). Quantitative identification and viable 
enrichment of natural Tregs in humans are problematic, and warrants further investigation in 
order to understand these cells in disease. More commonly, Treg cells are defined based on 
the frequency of CD4+CD25+ and the transcription factor FoxP3+ however, alternate 
phenotypes CD4+CD25+CD127- have also been documented for use in Treg discrimination 
(Liu et al., 2006, Seddiki and Kelleher, 2008). Treg identification cannot uniquely define 
these specialized T cell subsets (Fehervari and Sakaguchi, 2004), however with methods such 
as sorting etc. the discrimination of Treg sub-populations have become more distinct.   
Studies have shown that IL-7R plays an important role in the proliferation and differentiation 
of mature T cells, and in vitro experiments show that the expression of CD127 is down-
regulated following T cell activation. CD127 expression inversely correlates with FoxP3 and 
suppressive function of human CD4+ Treg cell (Liu et al., 2006). The phenotype 
CD3+CD4+CD25+CD127- has been used to successfully define and sort functional 
regulatory T cells in previous studies. Treg cells are defined based on the frequency of 
CD4+CD25+ and the transcription factor FoxP3+ however; alternate phenotypes such as 
CD4+CD25+CD127- have also been documented for use in Treg discrimination and isolation 
of functional Tregs for suppression assays .  
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Tregs are critical regulators of immune tolerance, averting the production of self reactive T 
cells which have the potential to generate autoimmune disease in the host. Tregs suppress 
activation of the immune cells and responses, and depletion of Tregs is associated with 
immune activation in HIV (Eggena et al., 2005). The suppressive activity may limit the 
magnitude of effector response, contributing to the lack of viral control. Concurrently, it 
suppresses chronic immune activation which indicates disease progression. Treg
 
number is 




activation, and the relationship 
between
 
Treg depletion and CD4
+





absolute CD4+ T cell count (Eggena et al., 2004).  
 
Tregs have been implicated in many diseases such as lupus (Valencia et al., 2007), multiple 
sclerosis (Huan et al., 2005), HIV (Prendergast et al., 2011a, Hunt et al., 2011, Weiss et al., 
2010, Sachdeva et al., 2010, Prendergast et al., 2010), HCV (Roe et al., 2009) and, have 
emerging function in renal transplant and tumour growth (Bestard et al., 2011, Jacob et al., 
2009).  A more recent study, one of the few carried out in the HIV-1 infected paediatric 
population, evaluated the correlation between viral load, immune activation and Tregs in 
HIV-1-infected children (Freguja et al., 2011). The study investigated Treg frequency in 89 
HIV-1-infected children aged 6-14 years. The study found that the number of activated 
CD8+CD38+ T cells were increased in relation to viral load (r=0·403;  P<0·0001). In 
addition, Tregs correlated positively with HIV-1 viral load (r=0·323; P=0·002) and 
CD8+CD38+ (r=0·305; P=0·005), but correlated inversely with CD4+ cells (r=-0·312; 
P=0·004). The study showed that the suppressive activity of Treg may be unsuccessful in 
limiting immune activation (Freguja et al., 2011).  
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Tregs limit the immune response by inhibiting proliferation and activity of CD4+ and CD8+ 
effector T lymphocyte cells. Strong robust CD4+ and CD8+ effector T cell responses are 
important for control of HIV replication. After Tregs in vitro were sorted and removed, an 
increased HIV-specific effector T cell response was observed (Aandahl et al., 2004, Oswald-
Richter et al., 2004, Weiss et al., 2004). Tregs may suppress the HIV-specific cytolytic 
antiviral response of CD8+ T cells (Kinter et al., 2007).  Most of these studies examined the 
effect of Treg depletion on T cell proliferation and/or IFN- γ production, after stimulation 
with HIV antigens.  
 
The most notable evidence of the role of Tregs can be attributed to its use in human clinical 
studies. A cell expansion protocol focusing on the culture of pure Tregs, has been developed 
by the UCSF Diabetes Centre (Putnam et al., 2009). The expansion procedure enables 
enriched FpxP3 Treg cell cultures to be expanded to 1, 500 fold over a two-week period. 
Expanded Tregs can be infused back into patients to restore immune balance and possibly, 
even reverse type 1 diabetes. Successful Treg expansion may present a population of cells 
that can be expanded for use in autoimmune diseases (Putnam et al., 2009, McClymont et al., 
2011, Bour-Jordan and Bluestone, 2007). Another study showed that the targeting and 
elimination of CD25+Tregs might be sufficient to eliminate smaller tumours. By depleting 
CD25 there may be an interference with the clonal expansion of tumor antigen specific T 
lymphocytes, if used in combination with other immunotherapeutic strategies. 
 
High levels of Tregs and activation markers have been correlated with rapid disease 
progression (Shevach et al., 1998, Thornton and Shevach, 1998, Prendergast et al., 2011a, 
Macatangay and Rinaldo, 2010, Hunt et al., 2011, Weiss et al., 2010, Bernardes et al., 2010, 
Radziewicz et al., 2009, Cao et al., 2009a, Zhang et al., 2008, Langier et al., 2010, Rouse et 
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al., 2006, Sachdeva et al., 2010, Prendergast et al., 2011b).  The activation of T cells is 
influenced by the suppressive activity of Tregs (Shevach et al., 1998, Thornton and Shevach, 
1998, Prendergast et al., 2011a, Macatangay and Rinaldo, 2010, Hunt et al., 2011, Weiss et 
al., 2010, Bernardes et al., 2010, Radziewicz et al., 2009, Cao et al., 2009a, Zhang et al., 
2008, Langier et al., 2010, Rouse et al., 2006, Sachdeva et al., 2010, Prendergast et al., 
2011b).  Tregs have been documented as the suppressor arm of the immune system due to 
ability to suppress immune responses (Langier et al., 2010, Rouse et al., 2006, Macatangay 
and Rinaldo, 2010, Sachdeva et al., 2010, Prendergast et al., 2011b). A recent study 
investigated activation, regulatory and exhaustion markers in HIV-1 infected clade B children 
(Prendergast et al., 2011a). The programmed death 1 exhaustion marker (PD-1), was 
positively correlated (R=0.41, p=0.002) to be a marked negative regulator of activated T 
cells. CD8+ T cell activation (HLA-DR+CD38+) was partially driven by the magnitude of 
the HIV-specific CD8+ T cell response (Prendergast et al., 2011b). The depletion in Tregs 
was associated with increased CD8 activation (R=-0.27, p=0.068), suggesting that the decline 
in Tregs may allow immune activation to increase. The study suggested an inverse role 
between Tregs and immune activation (Prendergast et al., 2011a). It will thus prove valuable 
to look at all these components of the immune system in unison. 
 
Clade C infection has been reported to have one of the fastest rates of disease progression 
(Cohen et al., 2011, Spira et al., 2003). To date, no studies have been performed to 
investigate the role of Tregs and immune activation in children in the context of HIV-1 clade 
C infection. Given the recently published data on the interplay between exhaustion activation 
and regulatory markers, our study aimed to investigate Treg frequency association with 
generalized immune activation, and immune response in an African cohort of HIV-1 infected 
children.We aimed to answer the following research questions:  
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(1) Do Tregs and activation T cell profiles differ in HIV-1 infected children and uninfected 
children? 
(2) Are Tregs and T cell activation associated with markers of disease progression? 
(3) What is the relationship between the immunoregulatory cells, T cell activation and HIV-1 
specific T cell responses in the setting of HIV-1 infection?   
(4) Can functional Tregs be successfully expanded from HIV infected children?  
 
4.2 PARTICIPANTS, MATERIALS AND METHODS 
4.2.1 Cohort description 
In South Africa, prior to the revision and initiation of the new ART guidelines, a cohort of 
untreated HIV-1 infected mother child pairs was established. The study began recruitment in 
2006. The treatment guidelines dictated that HIV-1 seropositive mothers during the last 
trimester of pregnancy received a single dose of nevirapine during labour. The infant received 
a single dose of nevirapine within 48 hrs of birth, according to the HIVNET-012 Protocol, as 
previously described (Guay et al., 1999, Jackson et al., 2003). Treated children who had an 
undetectable viral load for at least one or more timepoints were included for analysis. 
 
The 46 study participants were recruited through clinics in KwaZulu-Natal, Durban, South 
Africa. The recruitment clinic sites included King Edward Hospital, McCord Hospital, Saint 
Mary’s Hospital and Prince Mshiyeni Hospital. Transmission pairs were screened and 
mother-child pairs who met the inclusion criteria of mother-child treatment naïve pairs and 
positive HIV-DNA PCR results from birth hospitals were recruited. The participants were 
selected for a preliminary cross-sectional analysis based on sample availability. The 
exclusion criteria for the chronically infected cohort included treated pairs (mothers and/or 
children). The untreated cohorts were part of the chronically infected pair cohort and 
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represented initially falsely diagnosed HIV negative participants. This study retrospectively 
investigated 23 HIV-1 infected, 9 HIV-1 exposed uninfected and 13 HIV-1 treated children 
(Thobakgale et al., 2009, Thobakgale et al., 2007, Mphatswe et al., 2007) from Zulu/Xhosa 
ethnic origin with HIV-1 infection. Treated children who had an undetectable viral load for at 
least one or more timepoints were included for analysis. 
 
 Written informed consent was obtained from all study participants and the research protocol 
for the study was approved by the Biomedical Research Ethics Committee of the University 
of KwaZulu-Natal, Durban, South Africa and, the Internal Review Board of Massachusetts 
General Hospital, Boston. 
 
4.2.2 Plasma viral load and absolute CD4+ T cell measurement 
Plasma was isolated from whole blood after a single round of centrifugation. Plasma viral 
loads were assessed using the Cobas Amplicor Monitor Test version 1.5: detection limit of 50 
HIV-1 RNA copies per mL of plasma, according to manufacturer instructions (Roche 
Diagnostics).  
 
Absolute CD4 T+ cell counts and percentages of CD4+ T cells were determined from fresh 
whole blood, using Multitest four colour TruCount as previously described (Gratama et al., 
2002) according to the manufacturer’s instructions, (Beckton Dickinson Technology) at the 
HIV Pathogenesis Programme, Durban, KZN, South Africa. 
 
4.2.3 Isolation of PBMCs 
Blood specimens were collected in EDTA tubes and processed within 6hrs of collection.  
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood using the 
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Ficoll-Histopaque (Sigma, St Louis, Mo) density gradient centrifugation. PBMCs were used 
fresh in ELISPOT assays. The remaining PBMCs were cryo-preserved in 90% fetal bovine 
serum (Sigma-Aldrich), 10% DMSO prior to storage in liquid nitrogen for subsequent 
multiparameter flow staining and immunophenotyping analyses. 
 
4.2.4 Multiparameter flow cytometry for Treg quantitation and investigation of T cell 
activation 
 
4.2.4.1 Antibody titrations: Antibody titrations were performed by staining (1x10
5
) PBMCs 
at a range of 2 to 25µl antibody (depending on volume and concentrations specified by 
manufacturer). Antibody dilutions were halved, covering the above range. The final optimal 
concentration was used subsequently in immunophenotyping.  The optimal concentration was 
determined by choosing the dilution of the stain where the intensity plateau for the stained 
cells was most favourable.  
 
4.2.4.2 Thawing: Frozen PBMCs were thawed using a warming method. The R10 media, 
made up of RPMI 1640 + 10% FBS, was warmed to 37°C in a 15 or 50 mL Sterilin tube. 
Firstly, 20 μl nuclease was added to 2 mL 37 
o
C R10 in a 15 mL Sterilin tube. Frozen PBMC 
vials were set aside at room temperature for approximately 5 minutes until sample was 
reaching liquid state. The cryovial was opened and the rim was swabbed with 70% ethanol 
before the cells were transferred into the 15 mL Sterilin tube containing nuclease and 2 mL of 
warm R10 media. An additional 8 mL of warm R10 was slowly added to the tubes and the 
mixture was spun down at 1,700rpm for 10 minutes. Supernatant was discarded, removing all 
of the toxic DMSO freezing solution, and the cell pellet was re-suspended. Cells were 
counted using an automated cell counting Guava viacount assay and read on the Guava cell 
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counter (Guava Technologies, Guava PCA System). Cells were finally re-suspended in R10 
at a concentration of 1 million cells per mL. 
 
4.2.4.3 Immunostaining: 1 million cells per mL were added to each experimental FACS 
tube and control Fluorescence Minus One (FMO) tubes. PBMCs were first stained for 
viability at room temperature in the dark, with 1µl of a 200 µl stock solution of 
LIVE⁄DEAD® Fixable Violet Dead Cell Stain Kit (Invitrogen). After 15 minutes the dye was 
washed off using cold PBS (phosphate buffered saline) for 10 minutes at 1,500 rpm. PBMCs 
panels were stained (extracellular) as below (Table 4.1), at 4°C for 30 minutes. 
 
4.2.4.3.1 Extracellular immunostaining (Panel 1 and 2): PBMCs were stained with 
antibodies and volumes as per Panel 1(Table 4.1), at 4°C for 30 minutes or Panel 2 (Table 
4.1). Subsequently, sample acquisition procedure was followed.  
 
4.2.4.3.2 FoxP3 Intracellular immunostaining (Panel 3): Treg staining was 
performed per manufacturer’s instruction (Ebioscience human regulatory T cell staining kit 2 
catalogue number 88-8998-40). Briefly, PBMCs were stained (extracellular) with all 
antibodies as listed Panel 2 (Table 4.1) at stipulated volumes, for 30 minutes at 4°C. Excess 
antibodies were washed off with 2 mL PBS and a 10 minute spin at 1,500 rpm. Supernatant 
was discarded and cells were re-suspended with 2 mL fixation-permeabilization buffer (1:4 
dilution). Experimental tubes were set aside to incubate for 30-60 minutes at 4°C. Thereafter, 
tubes were spun down at 1,500 rpm for 10 minutes. Supernatant was discarded and cells were 
re-suspended with 2 mL perm buffer (1:10 dilution with H2O). Once more, tubes were spun 
down at 1,500 rpm for 10 minutes. Supernatant was discarded and rat serum was added (2 uL 
rat serum per tube in 80 uL perm buffer). Tubes were left at 4°C for 15 minutes. 5uL FoxP3-
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PE was added to sample tubes while no FoxP3 added to the FMOs. Tubes were left to stain 
for 30 minutes at 4°C. Subsequently, sample acquisition procedure was followed. 
 









CD14 Pacific Blue PacB (Ebioscience, 51-0199-73) 2 
CD19 Pacific Blue PacB (Ebioscience, 51-0199-73) 2.5 
CD3 Fluorescein Isothiocyanate FITC(Ebioscience, SK7, 11-0036-42) 3 
CD4 Allophycocyanin APC (BD, 340443) 3 
CD8 Alexa Fluor 700 Alexa Fluor 700 (BD, 557945) 2 
CD38 Phycoerythrin-Cyanine 7  PE-Cy7 (BD, 335790) 5 











CD14 Pacific Blue PacB (EBioscience, 48-0149-42) 2 
CD19 Pacific Blue PacB (Ebioscience 51-0199-73) 2 
CD3 Phycoerythrin-Cyanine 5.5  PE-Cy5.5 (Ebioscience, SK7, 
MHCD0318) 
2 
CD4 Alexa Fluor 700 Alexa Fluor 700 (BD, 557922) 5 
CD8 Peridinin Chlorophyll 
Protein Complex 
PerCP(BD, 347314) 5 
CD127 Fluorescein Isothiocyanate FITC (Ebioscience,11-1278-73) 7.5 
CD25 Allophycocyanin APC(Ebioscience,17-0259-42) 5 









FoxP3 Phycoerythrin PE (Ebioscience,12-4476-42) 5 
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4.2.4.4 Acquisition: After staining of PBMCs, tubes were washed twice using cold PBS. 
Supernatant was discarded and pellet was re-suspended in PBS. Compensation beads were 
setup and read to standardize assay.  Flow data were acquired on a LSR II flow cytometer 
(BD Biosciences). For the infant cohort, a minimum of 500 000 events were collected per 
subject, and a minimum of 250 000 events were collected for adults. Acquisition templates 
were drawn during acquisition, to further confirm subset gating, prior to analysis. The FMO 
control was used as the reference gate while the LIVE⁄DEAD® Fixable Violet Dead Cell 
Stain was used as an exclusion channel to eliminate dead PBMCs. 
 
4.2.5 HIV-1 Peptides and ELISpot Assays 
A matrix of 408 overlapping peptides (10-15mers overlapping by 10 amino acids) spanning 
the entire HIV-1 clade C consensus sequence were synthesized on an automated peptide 
synthesizer (MBS 396, Advanced ChemTech). Peptides were then pooled using a matrix 
screening system.   
 
CD8+ T cell responses were determined using a matrix Interferon- ELISpot assay 
(Thobakgale et al., 2007) as described in chapter 2. 
 
4.2.6 Flow-based cell sorting and expansion of functional Tregs 
Human enriched CD4+ T cells were isolated using density centrifugation (RosetteSep, 
Stemcells technologies and Ficoll-Histopaque; Sigma-Aldrich).  CD4+ T cell enriched 
PBMCs were labeled using a combination of surface markers: anti-CD3-Phycoerythrin-
Cyanine 7 (PE-Cy7) (BD Pharmingen, clone SK7), CD4-Fluorescein Isothiocyanate (FITC) 
(eBioscience, clone RPA-T4), CD25- Allophycocyanin (APC) (eBioscience, clone BC96), 
and CD127-Phycoerythrin (PE) (BD Pharmingen, clone hIL-7R-M21). Next, the 




 Tregs and the conventional T cells CD3+CD4+CD25-CD127+ 
subsets were sorted using a FACS Aria cell sorter (BD Biosciences) at 70 pounds per square 
inch with a 70-µm nozzle. For all populations, 250 000 cells were collected in X-VIVO 15 
(BioWhittaker; Walkersville, Maryland) containing L-glutamine, gentamicin, and phenol red 
media (Lonza) supplemented with 10% human AB serum (Gemcell) and 
Penicillin/Streptomycin (50U/mL).The CD4+ Treg and conventional T (Tcon) cells were 
transferred in a flat-bottom 24-well culture plate, with 1mL of X-VIVO media 15 with human 
serum and anti-CD3/anti-CD28 coated microbeads (Invitrogen) at a 1:1 bead to cell ratio. At 
day 2, 1mL of media and exogenous IL-2 were added (300 U/mL final, NIH Aids Research & 
Reference Reagent Program). At day 5, cells were counted and transferred into a T25 cell 
culture flask at 250,000 cells/mL, with fresh X-VIVO 15 media supplemented with 10% 
human serum and IL2 (300 U/mL). At day 7, the expanded cells were assayed for their 
suppressive function and, the remaining cells were cryopreserved as observed in Fig 4.1B.  
 
4.2.7 Assessment of Treg suppressive function using CFSE T cell proliferation assay 
Suppressive Treg function was assessed using co-culture T cell proliferation assays, in which 
CD3+CD4+CD25-CD127+ T cells were used as responder cells and labeled with 
Carboxyfluorescein succinimidyl ester (CFSE) (Invitrogen) at a concentration of 9 μM for 7 
minutes at 37°C. 50x10
3
 CFSE-labeled responder T cells were transferred to 96 round bottom 
well plates with RPMI 1640 medium (Sigma) containing penicillin/streptomycin (50U/mL), 
L-glutamine (2mM), HEPES buffer (10 mM), and 10% human serum (Cellgro). Responder T 
cells were co-cultured with the sorted Treg at different ratios, in the presence of anti-
CD2/anti-CD3/anti-CD28 microbeads (Miltenyi Biotec) at a 1:1 bead to CD4+ T cell ratio. 
After 4 days of co-culture, cells were stained with anti-CD3-PeCy7 and anti-CD4-APC (BD 
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Pharmingen, clone SK3), acquired on a LSR II flowcytometer (BD Biosciences) and analyzed 
on FlowJo as observed in Fig 4.1A.  
 
Figure 4.1 Graphical representation of expansion methodology A) Gating of regulatory T 
cells and conventional T cells and B) Observed fold change of Treg days of expansion from 
day 0 to day 7 (performed in collaboration with M. Angin-manuscript in preparation). 
 
4.2.8 Statistical analysis 
Flow data was analyzed with FlowJo software version 7.5 for PC. Microsoft Excel was used 
to transfer data and subtract fluorescence minus 1 (FMO) background values. Data was 
analyzed and graphically represented using Prism software (GraphPad; version 5). The Mann 
Whitney U test and the Kruskal Wallis test and ANOVA were used for group comparisons. 
Post test analysis was performed using Dunns Multiple Comparison Test. Normalization of 
subset discrimination and gating of data was performed using FlowJo. Correlations were 





162 | C h a p t e r  4 :  T r e g s  a n d  i m m u n e  a c t i v a t i o n  
 
4.3 RESULTS 
4.3.1 Cohort Characteristics 
A total of forty six children and twelve adults were studied. As represented in Table 3.2, age 
range and clinical data show that the HIV-1 uninfected children exhibit a median absolute 
CD4+T cell count of  2,033 cells/mm
3
 and a CD4 T cell% of 34%. The infected untreated 
children had a median viral load of 55,700 copies/mL with a median absolute CD4+T cell 
count of 1,838 cells/mm
3
 and a CD4% of 30%, while the treated children had a median viral 
load of 292 copies/mL with an absolute CD4+ T cell count of 1,325 cells/mm
3
 and CD4 T 
cell% of 29% (Figure 3.1).  The median ages of the uninfected and infected untreated 
children are similar while the treated children are older in age as represented in Table 3.2. 
The adults exhibit a median viral load of 821,200 copies/mL, with a median absolute CD4+T 
cell count of 1582 cells/mm
3
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4.3.2 Flow cytometry gating for the quantification of activation and regulation 
markers on CD4+ T and CD8+ T cell subsets 
Gating schemes for the Tregs and activation experiments are represented in Fig.4.2. First we 
confirmed uniform flow rate (time plots). The live lymphocytes were then gated after 
doublets were gated out. Subsequently, gates were set to exclude dead cells (viability marker-
), monocytes (CD14+) and B cells (CD19+). The gating for viable cells was then followed by 
the gating of viable lymphocytes (CD3+), and CD4+ or CD8+. The Tregs were described by 
gating of the Treg FMO, which were used as controls. Fig 4.2A represents Tregs defined as 
CD4+CD25+CD127- Fig 4.2B represents activation expression as HLA-DR+CD38+.  
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Figure 4.2 Representative gating for the assessment of A) Treg frequencies defined by 
CD4+CD25+CD127- and B) CD8+/CD4+CD38+HLA-DR+activation for a single participant 
from study cohort.  
 
4.3.3 Elevated frequencies of Tregs in HIV-1 infected children 
We first evaluated relative Treg frequencies between sub-groups, as it has been shown in 
adults that Tregs may differ in numbers based on stage of HIV infection (Schulze Zur Wiesch 
et al., 2011). CD4+CD25+CD127- Treg frequencies (% of total CD4+ T cells) ranged from 2 
to 42% for CD4+ T cells as per Fig 4.3 When comparing the sub-groups, the median of 
absolute Tregs revealed a significantly higher frequency of Tregs in the group of untreated 
children in comparison to uninfected children (p=0.0225). Treg frequencies showed a trend 
toward elevated frequencies in HIV-1 infected children compared to their uninfected 
counterparts (p=0.056).  We found no difference in the children aged less than 6 months in 
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comparison to older children (p=0.1275). We also observed Treg frequencies in 24 adults. 
We found absolute Tregs to show a trend of increased frequencies in 13 untreated participants 
in comparison to the 11 treated adult participants (p=0.0559). 
 
Figure 4.3 Comparison of Treg frequencies of A) Tregs and B) Absolute Tregs, between sub-
groups of uninfected, treated and untreated children. 
 
4.3.4 Association observed between clinical markers of expression and frequency of 
Tregs  
We subsequently examined the relationship between frequency of Tregs and clinical markers 
of disease progression. We found a significant negative correlation between Treg frequency 
and CD4 T cell% (p=-0.0362, r=-0.3132). The relationship between Tregs and viral load 
(p=0.6295, r=-0.07866) and absolute CD4+ T cell count (p=0.4040, r=-0.1275) found no 
associations (Fig 4.4). 




















Figure 4.4 Correlation of clinical markers with frequency of Tregs: A) Viral load 
(copies/mL), B) Absolute T cell count (cells/mm
3
) and C) CD4 T cell%. 
 
4.3.5 Assessment of frequency of CD8+CD25+CD127-in HIV-1 infected children 
The investigators included CD8+CD25+CD127- cells in the analysis as a potential surrogate 
for CD8+ Tregs.  Recent data from the SIV model and in HIV suggest the presence of this 
cell type in infected subjects (Nigam et al., 2010, George et al., 2011).  In SIV infected rhesus 
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macaques CD8+FoxP3+ Tregs were expanded in gut mucosa from infected monkeys and 
correlated negatively with immune activation.  As information on CD8+ Tregs is limited, we 
next assessed the frequency of CD8+CD25+CD127- subset. The CD4+ Treg  % was elevated 
in comparison to the percentage of CD8+CD25+CD127- (unsorted). The median of 
CD8+CD25+CD127- on T cells was significantly higher in the uninfected subgroup in 
comparison to the treated children (p=0.0094) but insignificant in the treated subgroup of 









Figure 4.5 Comparison of CD8+ CD25+ CD127- frequencies within sub-groups. 
 
4.3.6 Increased expression of HLA-DR+CD38+ on T cells from HIV-1 infected 
children  
Based on a recent investigation in children that suggested that a decline in Tregs may allow 
immune activation to increase in HIV-1 infected in comparison to uninfected children, we 
first compared expression levels of HLA-DR+CD38+ expression between subgroups of 
children (Fig 4.6). A comparison of HLA-DR+CD38+ expression on CD4+ T cells and 
CD8+ T cells revealed the following: CD4 cells compared to CD8 T cells as previously 
described. HLA-DR+CD38+ expression was elevated on CD8+ T cells in comparison to 
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CD4+ T cells. When comparing the median of HLA-DR+CD38+  expression across sub-
groups HLA-DR+CD38+ on CD8+ T cells, elevated expression was observed in the 
untreated children in comparison to treated children (p=0.0002). In addition, HLA-
DR+CD38+ expression was significantly elevated in untreated children in comparison to 
uninfected children (p=0.0177), and no difference was observed between treated children 
compared to uninfected children (p=0.9151). HLA-DR+CD38+ expression on CD4+ T cells 
also revealed that untreated children exhibited a significantly higher median of HLA-
DR+CD38+  expression then in the treated children (p=0.0495) and uninfected children 
(p=0.0312). HLA-DR+CD38+ expression did not differ significantly between treated and 
uninfected children (p=0.1550) on CD4+ T cells. However, in the children aged less than 6 
months HLA-DR+CD38+ expression on CD4+ (p=0.0437) and CD8+ T cells (p=0.00276) 
was found to be significantly higher in comparison to children more than 6 months. When we 
went on to compare the median of HLA-DR+CD38+ expression to HLA-DR+CD38+ on 
CD8+ T cell in adults, elevated expression was observed in the untreated in comparison to 
the treated subgroup (p=0.0348). 
 
Figure 4.6 Comparison of expression levels of A) CD8+ HLA-DR+CD38+ and B) CD4+ 
HLA-DR+CD38+ within sub-groups. 
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4.3.7 No correlation observed between clinical markers of expression and HLA 
DR+CD38+ expression 
Based on findings from adult studies where HLA-DR+CD38+  expression correlated with 
viral load, we subsequently examined the relationship between CD8+ HLA-DR+CD38+  and 
viral load (p=0.0946, r=0.2582); absolute CD4+ T cell count (p=-0.5888, r=-0.8000) and 
CD4+ T cell % (p=0.1259, r=-0.2240) (Fig 4.7A/B/C). Upon examination of CD4+ T cells 
the following associations were revealed: CD4+ HLA-DR+CD38+ expression and viral load 
(p=0.2597, r=0.1757); absolute CD4
+
 T cell count (p=0.7127, r=-0.0546) and CD4+ T cell% 
(p=0.3529, r=-0.1371), as represented in Fig 4.7D/E/F. Additionally, our study confirmed the 
findings of other adult HIV-1 studies, showing a significant relationship between HLA-
DR+CD38+ and viral load on CD8+ T cells, in our adult participants (p=0.0217;r=0.4761).   
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Figure 4.7 Correlation of clinical markers with expression of HLA-DR+CD38+ on CD8+ T 
cells: A) Viral load (copies/mL), B) Absolute T cell count (cells/mm
3
) and C) CD4+ T cell% 
and D) Viral load (copies/mL), E) Absolute T cell count (cells/mm
3
) and F) CD4%. 
 
4.3.8 Correlation of HLA-DR+ CD38+ expression on CD4 and CD8 T cells   
We next investigated the correlation of the expression of HLA-DR+CD38+ and Tregs 
respectively, between CD4+ and CD8+ T cells in children  (Fig 4.8). There was a significant 
positive correlation of CD4+ T cells and CD8+ T cells for HLA-DR+CD38+ (p<0.0001; 
171 | C h a p t e r  4 :  T r e g s  a n d  i m m u n e  a c t i v a t i o n  
 
r=0.6376).  Based on the studies that reported an inverse relationship between Tregs and 
markers of activation, we next investigated the relationship between the expression of HLA-
DR+CD38+ and the frequency of CD4+CD25+CD127- on bulk T cells. Taking into account 
diversity in frequency of expression, no correlation was observed between 
CD4+CD25+CD127- and CD4+HLA-
DR+CD38+ (p=0.2097; r=0.2117), 
and CD8+HLA-DR+CD38+ 
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Figure 4.8 Correlation of expression of A) CD4+ HLA-DR+CD38+  and CD8+ HLA-
DR+CD38+, B) CD4+ HLA-DR+CD38+ and CD4+CD25+CD127- and C) CD8+HLA-
DR+CD38+ and CD4+CD25+CD127-. 
4.3.9 Inverse relationship between Tregs and markers of activation and cellular 
immune response 
Based on studies showing that Tregs are able to suppress immune activation and, other 
studies that have associated hyperactivation with both HIV susceptibility and disease 
progression, we investigated the relationship between expression markers and magnitude of 
CTL response (Fig 4.9) in a subset of individuals. As this was a retrospective analysis, CTL 
responses were available for a subset of individuals. Magnitude of response was assessed by 
the summation of all positive (>100SFCs) responses to pools of peptides spanning the entire 
HIV-1 genome. Of the 23 participants assessed using the ELISpot assay, ten participants 
made no responses. The remaining 13 children revealed a significant negative correlation 
between magnitude of CTL response, CD4+CD25+CD127- (p=0.4569; r=-0.1716), 
CD8+CD25+CD127- (p=0.0202; r=-0.7333) and CD8+HLA-DR+CD38+ (p=0.0408; r=-















Figure 4.9 Correlation of magnitude of response with A) CD4+CD25+CD127-, B) 
CD8+CD25+CD127-, C) CD8+ HLA-DR+CD38+ and D) age in a subset of 10 uninfected 
children. 
 
4.3.10 Longitudinal study: Treg frequencies, T cell activation expression levels and HIV 
viral load.  
To complement our cross-sectional data, we investigated expression of HLA-DR+CD38+ and 
frequency of Tregs longitudinally over a 20 month period. HLA-DR+CD38+ and frequency 
of Tregs seemed to show an inverse relationship on CD8+ T cells, at certain time points 
earlier in the investigation (Fig 4.10). Both Treg frequency and activation markers seem to 
track positively with viral load and inversely with CD4+ T cell% in the participant studied.  




Figure 4.10 Longitudinal assessment of clinical markers and activation and regulatory 
markers of A) CD8+CD25+CD127- and HLA-DR+CD38+ and B) CD4+ CD25+CD127- and 
CD4+ HLA-DR+CD38+.  
 
4.3.11 Lower frequency of Tregs when defined as CD25
high
FoxP3+ 
Based on conventional phenotyping discrimination of Tregs, we next assessed the difference 
between CD25+CD127- and CD25
high
FoxP3+. When assessing these markers in the same 
participant, we found lower frequency of CD25
high
FoxP3+ in comparison to CD25+CD127- 
Tregs. 
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However the discrepancy appeared to be due to technical difficulties with the intracellular 
cytokine staining protocol for FoxP3 and no correlation was observed between 
CD25+CD127- and FoxP3. 





4.3.12 Functional Tregs can be expanded from HIV-1 infected children  
Building on the phenotypic investigations described above, we next sought to study Treg 
function in a subset of HIV-1 infected children. We next sought to study Treg function in a 
subset of HIV-1 infected children.  These children’s samples were selected based on cell 
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viability and saturated cell counts to investigate whether the proposed methodology could 
successful expand Tregs in children. One of the key issues in Treg studies lies in the ability of 
Tregs to suppress immune responses by expansion. We investigated this suppressive 
functionality in children. We first sorted cells to isolate Treg population as represented in Fig 
4.12A. After expanding Tregs over 7 days using a CFSE proliferation assay, we found that 


















Figure 4.12 A) Gating strategy for identification of sorted CD4+CD25+CD127- Treg cells 
and B) Treg suppression assay showing CD4 proliferation in the absence of co-culture (white 
column, positive control), co-cultured with Treg (grey column) and co-cultured with 
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conventional T cells ( black column) alone of successful suppressive capability of CD4+ 




A multitude of viral, host and cellular factors may influence HIV pathogenesis. Nonetheless, 
persistent non-specific, generalized immune activation has been implicated as a major driver 
of HIV susceptibility and HIV disease progression (Paiardini et al., 2009, Hazenberg et al., 
2003, Giorgi et al., 1999, Liu et al., 1998, Liu et al., 1997). Immune exhaustion has been 
found to occur, in parallel with immune activation and a decreased expression of Tregs in 
HIV-1 progression (Sachdeva et al., 2010). Moreover Tregs have been documented to play a 
role in activation of CD4+ and CD8+ cells (Eggena et al., 2005, Prendergast et al., 2011a). 
Taken together, the mechanism underlying T cell exhaustion, regulation and activation 
remain unclear.  
 
Since their discovery in the early 1970s, the role of CD4+ CD25+ Tregs in both autoimmune 
and infectious diseases has continued to expand. Tregs actively engage in the maintenance of 
immunological self-tolerance and immune homeostasis (Sakaguchi, 2004). These 
controversial regulatory T cells (Coleman et al., 2007) have been found to have beneficial 
effects in preventing autoimmune diseases (2011, Meng et al., 2011, Mougiakakos et al., 
2010) but conversely, they have harmful effects by limiting anti-tumour and anti-microbial 
immunity (Sakaguchi et al., 2010). There has also been increasing evidence for Treg 
involvement in allograft rejection (Dummer et al., 2011, Ge et al., 2010, Tao and Hancock, 
2008, Nguyen et al., 2006, Cobbold et al., 2006, Battaglia and Roncarolo, 2006). The location 
of the Treg reservoir influences its role and function. Frequency of expression has been said 
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to differ in mucosal studies and peripheral studies (Ashwood and Wakefield, 2006). In 
addition there exists contradicting findings about the role of Tregs during HIV-1 infection, 
with some studies reporting increases (Xiao et al., 2011, Weiss et al., 2010, Kolte et al., 2009) 
and others associating depletion of Tregs with disease progression and immune activation in 
HIV in adults (Eggena et al., 2005, Sachdeva et al., 2010) and more recently, in children 
(Prendergast et al., 2011a). 
  
More commonly, Treg cells are defined based on the frequency of CD4+CD25+ and the 
transcription factor FoxP3+ however; alternate phenotypes such as CD4+CD25+CD127- 
have been documented for use in Treg discrimination and isolation of functional Tregs for 
suppression assays. The phenotype CD3+CD4+CD25+CD127- has been used to successfully 
define and sort functional regulatory T cells in previous studies.  We and others have shown a 
strong positive correlation between CD4+CD25+CD127low and CD4+CD25+FoxP3+ T 
cells.  The investigators have data on FoxP3 expression by intracellular staining for subsets of 
study participants, however technical difficulties prohibited the availability of this date  for 
the entire study cohort. FoxP3 staining would have been helpful to further demonstrate Treg 
phenotype for comparison with previous studies, We were restricted here and could not 
demonstrate the strong positive correlation that we and others have previously shown in this 
study cohort for technical reasons. 
 
The investigators included CD8+CD25+CD127low cells in the analysis as a potential 
surrogate for CD8+ Tregs.  Recent data from the SIV model and in HIV suggest the presence 
of this cell type in infected subjects (Nigam et al., 2010, George et al., 2011).  In SIV infected 
rhesus macaques CD8+FoxP3+ tregs were expanded in gut mucosa from infected monkeys 
and correlated negatively with immune activation.  In this study the CD25+ FoxP3+CD8+ 
179 | C h a p t e r  4 :  T r e g s  a n d  i m m u n e  a c t i v a t i o n  
 
were largely CD127 low and suppressive (Nigam et al., 2011). However we did not sort these 
cells in the present study and the extent to which these CD8+CD25+CD127low cells truly are 
of functional regulatory phenotype needs to be further explored in future studies. 
As children represent a vulnerable population severely affected by limitations in immune 
defense, we too sought to investigate the role of suppressive Tregs and/or activation, as 
described in adults. As this was a retrospective design the investigators were restricted. 
Samples if treated children were selected based on earliest available timepoint. Age-related 
difference was noted but unavoidable. It could be attributed to population related differences. 
Nevertheless, our study described the frequency of Tregs and activation profiles to differ in 
uninfected children, treated and infected untreated children. 
 
 We observed an inverse correlation of Tregs with CD4+ T cell % which could be a naturally 
occurring relationship in HIV-1 infected children. Our data suggest that the lower a child’s 
CD4 T cell count , the higher the percentage of Tregs.  This finding is similar to observations 
made in adults, where Treg frequency (% Treg increases) correlates with loss of absolute 
CD4 T cell numbers.  Biologically this may indicate that Tregs are either preferentially 
spared from cell death, are induced or expanded with more advanced HIV disease, possibly to 
counteract HIV associated immune activation (Shaw et al., 2011, Angin et al., 2012) 
. 
Interestingly, in a subgroup of participants, we observed a significant inverse correlation 
between immune regulation and activation on CD8+ T cells. Our findings denoting increased 
expression of markers of activation on, untreated compared to treated, compared to 
uninfected, children  were in keeping with previous investigations (Cao et al., 2009b, 
Prendergast et al., 2011a).  Our investigation further confirmed a reduced frequency of Tregs 
in comparison to activation markers. A significant difference in frequency of Tregs and 
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absolute Tregs was observed on untreated in comparison to treated children, contradicting 
findings of previous study (Prendergast et al., 2011a). This could be related to the time of 
sampling of the treated group, age and population related differences.  It is noteworthy, this 
together with our investigation was predominantly cross-sectional and this could influence 
long term changes at different stages of disease. Additionally, our study demonstrated 
changed in subsets in the context of f ARV treatment. Differential outcome may also be 
related to the selection of markers, which is controversial and differs from study to study.   
 
The exact mechanisms of suppression of effector T cells by Tregs remain unclear, but there 
are in vitro and in vivo evidences showing that these cells are able to suppress antigen-
specific responses via direct cell-to-cell contact, secrete anti-inflammatory cytokines such as 
TGF-beta and IL-10, and also inhibit the generation of memory T cells, among others 
(Dummer et al., 2011). Regulatory T cells have been documented to play a vital role in 
maintaining a balance between the induction of early virus specific immune responses and 
suppression of destructive hyperimmune activation; and have been shown to suppress the 
activity of  both CD4+ and CD8+ T cells recruited to the same APC (Sakaguchi, 2009).  
 
CD8+ T cell responses have been implicated in the effective containment of HIV in adults 
and children (Goulder, 2000). However, the direct impact of CTL seems to very controversial 
in children. Interestingly, when we investigated a group of participants tested for immune 
responses, we observed a significant inverse correlation between immune regulation and 
activation, which may provide additional evidence for rapid disease progression on children. 
Our findings are in line with another study, which described strong HIV-1-specific T cell 
responses after regulatory T cell removal in neonates (Legrand et al., 2006) and another 
finding in children that suggested  CD8+ T cell activation to be partially driven by the 
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magnitude of the HIV-specific CD8+ T cell response (Prendergast et al., 2011a). We were 
restricted in that we were unable to test for CD4+ T cell responses and their association with 
Tregs and markers of activation. Additionally, our findings may be biased as we were only 
able to assess a single cytokine (IFN-γ) secreted by CD8+ and possibly CD4+ T cells as 
ELISpot is unable to differentiate CD4 from CD8 responses. These findings may be biased as 
we were only able to assess a single cytokine (IFN-γ) secreted by CD8+ and possibly CD4+ 
T cells as ELISpot on whole PBMC specimen is unable to differentiate CD4 from CD8 
responses or less likely NK cell responses. Assays such as intracellular cytokine staining and 
tetramer staining could have differentiated between these possibilities but this was not 
possible in this study due to sample limitations. However, the ELISpot assay was optimized 
for CD8 rather than CD4 T cell responses (24h vs 48h incubation) and based on previous data 
from cohort, the majority of responses observed by ELISpot were CD8+.  Assays such as 
intracellular cytokine staining and tetramer staining could have differentiated between these 
possibilities but this was not possible in this study due to sample limitations.    
 
T cell expansion has been associated with suppression of immune responses and disease 
progression (Cao et al., 2009b). Tregs expansion experiments and murine modeling have 
shown that pharmacologic expansion of donor-derived, naturally occurring regulatory T cells 
can demonstrate a beneficial role in reducing graft-versus-host diseases (Duramad et al., 
2011). Furthermore the suppressive capability of peripheral Tregs, have been documented to 
play a role in activation of CD4+ and CD8+ cells (Lim et al., 2007). Our study is the first to 
describe successful results in expansion of functional Tregs in HIV-1 infected children. We 
are aware that these findings are restricted by a small sample size and may be biased by the 
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phenotypic marker selected, particularly taking into account the controversy that surround 
Treg markers. 
 
We conclude that an overall understanding of the exact mechanism which drive HIV disease 
pathogenesis is limited, due to the obvious multifactorial impact of the virus. Further 
functional studies that are able to dissect cause-and-effect during disease progression, will 
enhance our ability to manipulate Tregs and markers of activation in a clinically beneficial 
manner. Our study was the first to investigate the mechanism underlying Treg suppression on 
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CHAPTER FIVE 
The influence of Interleukin-10 (IL-10) Promoter Polymorphisms on HIV-1 Mother to 




Background: Interleukin-10 (IL-10) is an immune regulatory cytokine that directly affects 
HIV-1 replication.  The overall effect of IL-10 on susceptibility to HIV-1 infection and 
disease progression is not fully understood. IL-10 promoter polymorphisms influence 
susceptibility and have been reported to be associated with differential outcome depending on 
the clinical stage of HIV-1 infection. Data is lacking on the role of IL-10 and its genetic 
variants on mother-child transmission and paediatric HIV-1 acquisition. Our study 
investigated the association between two IL-10 promoter polymorphisms, with mother-to-
child HIV transmission. Subsequently, we explored the role of IL-10 promoter variants on 
HIV-1 acquisition. Finally, we assessed the association of cytokine levels with biomarkers of 
disease progression such as absolute CD4+ T cell count and viral load.  
Materials and Methods: We investigated 374 mother-child pairs from the previously 
described Mamanengane or Africa Centre Vertical Transmission (VTS) cohort and 60 
mother-child pairs from the previously described PEHSS cohort. DNA was extracted using 
the Qiagen DNA isolation kit and the Qiagen QIAamp DNA Mini Kit for dried blood spots 
(DBS). Applied Biosystems (ABI) Taqman allelic discrimination platform facilitated the 
discrimination of IL-10 promoter single nucleotide polymorphisms (SNPs) at positions -592 
and -1082, relative to the transcription start site. IFN-γ CD8+ T cell responses were screened 
using the IFN-γ ELISpot assay. Plasma IL-10 expression was measured using the Luminex 
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Millipore Multiplex MAP Human Cytokine high and regular sensitivity human high 
sensitivity assay.  
Results: We demonstrated a significant association with IL10-1082 and HIV mother-to-child 
transmission (p=0.0012). Transmitter mothers had a lower proportion of IL10 -1082A, 
compared to women who did not transmit (79.5% vs 94.5%, p=0.0012), revealing an odds 
ratio of 0.23 (95% CI 0.09 – 0.58).  No association with acquisition and IL10-592 (AA/CA vs 
CC) or IL10-1082 (AA/AG vs GG) was observed with p=0.6952 and p=0.3251. Absolute 
CD4+ T cell count and mortality revealed that for every 100 cells/µl increase children were 
6% less likely to die (p=0.0703). We found no associated influence with IL10-592 
(p=0.4279) or IL10-1082 (p=0.6361) on mortality rates of children in this cohort. Our 
investigation revealed a significant association between carriers of IL10-592 and magnitude 
of IFN-γ CD8+ T cell immune response. Carriers of IL10-592C were associated with an 
elevated magnitude of CD8+ T cell response in comparison to carriers of IL10-529A 
(p=0.0071). A positive correlation between viral loads and IL-10 plasma levels (p=0.0038; 
r=0.3872) as well as age (p=0.0199; r=0.4625) was observed. A significant negative 
correlation was observed with CD4 T cell% and IL-10 plasma levels (p=0.0007; r=-0.6190). 
No significant difference in IL-10 plasma levels according to IL10 -1082 (p=0.7148) and -
592 (p=0.1374) allelic variants.  
Conclusion: The data suggests a role for promoter IL-10 variants in HIV-1 mother to child 
transmission and disease progression. IL-10 plasma levels may play a role in immune 
dysfunction in HIV infected children. 
  
Key words: IL-10; Mother to child transmission; cytokine; children; HIV transmission; HIV 
progression  
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5.1 INTRODUCTION 
Interleukin-10 (IL-10) has been shown to play a significant role in promoting viral 
persistence by inhibiting activation and effector functions of T cells and macrophages 
(Brooks et al., 2006). IL-10 has been shown to inhibit HIV-1 replication directly in 
macrophages and monocytes (Wang and Rice, 2006, Ancuta et al., 2001) by blocking entry, 
and/or post entry through suppressing and down regulating cyclin T1 and consequently Tat 
function. Furthermore, the effects of IL-10 on HIV-1 replication may depend on the strain of 
the virus, the cell type targeted by HIV-1 and the stage of HIV-1 infection (Orenstein et al., 
1997, Ancuta et al., 2001).  
 
The lymphocytic choriomeningitis virus (LCMV) model of chronic viral infections in mice, 
demonstrate a critical role of IL-10 in the disruption of effector immune responses, in turn 
contributing to viral persistence particularly during the early phases of infection (Ejrnaes et 
al., 2006, Brooks et al., 2008). Furthermore, blockade of the IL-10 pathway allowed a DNA 
vaccine to further stimulate T cell responses and restore IFN-γ secretion, resulting in viral 
clearance. Hence, a single immunoregulatory molecule may be capable of playing a 
significant role in determining the outcome of a persistent viral infection in mice.  These 
studies need to be extended to HIV-1, the most significant persistent viral infection in the 
human population. These studies may enable a better understanding of mechanisms that 
underlie immune dysfunction in HIV-1 infection.  
 
Genetic polymorphisms in the IL-10 promoter region may influence levels of IL-10 produced 
from various cells of the immune system (Ejrnaes et al., 2006, Lazarus et al., 2006, Turner et 
al., 2002). Our investigation focused on two single nucleotide polymorphisms (SNPs) found 
in the promoter region at positions -1082 (A to G transition) and -592 (C to A transversion) 
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of the 36-kDa IL-10 gene. The IL-10 gene has been mapped to human chromosome 1, 
between 1q31 and 1q32 and its promoter. SNPs have been associated with different levels of 
IL-10 production (Kamali-Sarvestani et al., 2006, Lan et al., 2006).   Allelic variants in the 
human genome can regulate susceptibility or resistance to infection. The allelic variants -
1082A and -592A have been documented to be associated with decreased IL-10 production 
which in turn is further associated with an increased likelihood of HIV-1 acquisition and a 
rapid rate of CD4 T cell decline (Erikstrup et al., 2007, Shin et al., 2000, Shrestha et al., 
2010, Vasilescu et al., 2003). This finding suggests that the recessive allele-1082G is 
associated with increased IL-10 production and may be associated with an AIDS delaying 
effect. Several studies have investigated the contribution of IL-10 promoter polymorphisms 
to HIV-1 susceptibility or disease pathogenesis (Erikstrup et al., 2007, Shin et al., 2000, 
Shrestha et al., 2010, Vasilescu et al., 2003).  Studies suggest that allelic variants associated 
with lower IL-10 production predispose participants to higher likelihood of HIV-1 
acquisition.  Subsequently to being infected, the lower IL-10 producer alleles appear to be 
associated with rapid disease progression (Naicker et al., 2009, Shin et al., 2000).  However, 
it should be noted that all these studies have been undertaken predominantly in adults. None 
of these studies have investigated the role of IL-10 promoter polymorphisms in HIV-1 
mother to child transmission (MTCT) or HIV-1 acquisition in children. 
  
The influence of IL-10 promoter polymorphisms within HIV-1 clade C was recently 
investigated in a cohort of high risk HIV-1 negative and acutely infected South African 
women (Naicker et al., 2009). The C to A mutation at promoter position -592 was associated 
with increased risk of HIV-1 acquisition. The IL10 -1082G allelic variant showed a trend 
towards decreased likelihood of HIV-1 acquisition.  The study suggested that alleles 
associated with high IL-10 production such as IL10 -592C and IL10 -1082G may have a 
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protective effect against HIV-1 infection. However, these carriers exhibited significantly 
higher median plasma viral loads perhaps through IL-10 mediated suppression of effector 
antiviral immune mechanisms. Hence, IL-10 promoter polymorphisms may influence 
susceptibility to HIV-1 infection and may affect markers of disease progression such as viral 
load (Naicker et al., 2009). Our study described the association between genetic 
polymorphisms in the IL-10 promoter gene with the risk of HIV-1 acquisition among 
children; and the risk of transmission by mothers. Our study further described underlying 
mechanisms of IL-10 promoter polymorphisms and their interplay with cellular immune 
responses and cytokine production in an African HIV-1 clade C infected MTCT transmission 
cohort.  
 
Cytokines have been implicated in disease progression. The immunosuppressive factor, IL-
10, is a cytokine produced by lymphoid cells. Cytokine production, hyperactivation of 
antiviral T cells and the nature of the immunosuppressive environment play an influential 
role in HIV pathogenesis (Hedrich et al., 2010, Lubong Sabado et al., 2009, Song et al., 2011) 
and may provide valuable information to help understand the mechanism underlying viral 
control or the lack thereof.  
 
Elevated IL-10 plasma levels have previously been documented to correlate with poor 
prognosis in many infections (Roberts et al., 2010).  In acute HIV infection an upregulation 
of certain cytokines such as IFN-α, TNF-α (von Sydow et al., 1991) and IL-10(Norris et al., 
2006) have been reported. Furthermore another study of acute Hepatitis B and C infections 
revealed a broad array of cytokine expression lead to eventual viral clearance in a majority of 
infected participants (Stacey et al., 2009). Chronic HIV-1 infection also revealed increased 
cytokine secretions due to persistent viral replication and antigenic stimulation. Both pro-
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inflammatory and regulatory cytokines are produced during chronic immune stimulation and 
regulatory cytokines play a role in suppressing type 1 cytokines while anti inflammatory 
cytokine play a role in immune suppression (Oguariri et al., 2007).  
 
Only few studies have profiled cytokines in children. The levels of cytokine produced in 
children have been found to be an important determinant of malnutrition (Jones et al., 2005). 
The study found an increased production
 
of IL-4 and IL-10 cytokines in the CD4+ and
 
CD8+ 
cells from malnourished children in comparison to the T cells from well-nourished children. 
The results suggest that
 
malnutrition alters the capacity of T cells to produce the cytokine IL-
10, thus explaining the inability if these children to develop a specific immune response
 
and 
the predisposition to infection in these children (Rodriguez et al., 2005). Cytokine expression 
levels, absolute CD4+ T cell counts and viral load were also monitored in 12 HIV-1 infected 
children in Hong Kong. The study found alterations in cytokine profiles were not associated 
with adverse clinical events (Jones et al., 2005).  
 
More recently, a study investigated the association between plasma cytokine concentrations 
during primary acute infection with clinical markers of HIV disease progression such as 
absolute CD4 T cell counts and viral load measurements (Roberts et al., 2010). The study 
showed cytokines IL-12p40, IL-12p70, IFN-γ, IL-7 and IL-15 to be able to predict 66% of 
the variation in viral load set-point 12 months post infection. The study found IL-12p40, IL-
12p70 and IFN-γ to be significantly associated with lower viral load whereas IL-7 and IL-15 
were associated with higher viral load. The study showed that IL-7 was associated with more 
rapid CD4 loss (Roberts et al., 2010).  Our study aimed to correlate cytokine levels with long 
term biomarkers of disease progression such as absolute CD4+ T cell count and viral load. 
We assessed the median cytokine biomarker levels in age matched groups. The study also 
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described the levels of pro-inflammatory and anti-inflammatory cytokines and their influence 
on disease progression in an African clade C infected cohort of children. 
 
5.2 PARTICIPANTS, MATERIALS AND METHODS 
 
5.2.1 Cohort description 
Participants were recruited from the previously described Mamanengane or Africa Centre 
Vertical Transmission (VTS) cohort (Bland et al., 2010, Coovadia et al., 2007).  The mothers 
were enrolled during their antenatal care visits at the clinics in Umkhanyakude and the 
outlying areas of Durban, KwaZulu-Natal, South Africa. The eligibility criteria were woman 
aged 16 years of age or older, who were planning to stay in the study area for at least 3 
months after delivery, and who were able to provide written consent. As illustrated in Fig 5.1, 
our study was a sub-study of a larger study. We selected Dried Blood Spots (DBS) samples 
collected from 374 South African Mother-Child transmission pairs. The transmitter and non-
transmitter mothers were selected based on their matched viral load. The uninfected mothers 
were selected by matching the ages of the mothers to the ages of the infected mothers. 
Written informed consent was obtained from all study participants and the research protocol 
for these analyses were approved by the Biomedical Research Ethics Committee of the 
University of KwaZulu-Natal, Durban, South Africa, and the Internal Review Board of 
Massachusetts General Hospital.   


















Figure 5.1 Flow diagram of participants selected from the VTS study for the current sub-
study. 
 
We also studied the previously described PHESS study cohort (Thobakgale et al., 2007, 
Mphatswe et al., 2007) in which we investigated immune response and cytokine production 
in association with IL-10 promoter polymorphisms. The study screened and recruited 719 
HIV-1 infected mothers, 740 infants were born to the mothers; 623 infants were uninfected, 
41 were untraceable and only 76 were infected.  The study enrolled 60 infants whom met the 
study criteria. The 60 HIV-1 infected infants born to HIV-positive mothers were enrolled 
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from St Mary’s and Prince Mshiyeni Hospitals in Durban, South Africa between the periods 
of 2003-2005 (Fig 5.2). The HIV-1 seropositive mothers were recruited during the last 
trimester of pregnancy and received a single dose of Nevirapine during labour. The infant 
received a single dose of Nevirapine within 48 hrs of birth, according to the HIVNET-012 
Protocol, as previously described (Guay et al., 1999, Jackson et al., 2003).  
 
The infants were diagnosed as HIV-infected following detection of plasma HIV RNA by 
RNA-PCR (Roche Amplicor Assay). Blood was collected on day 1 and day 28 of life. A 
positive viral load test (>400 RNA copies/ml) on day 1 or day 28 was followed by a 
confirmation test. Infants with detectable virus on day 1 were defined as intra-uterine (IU) 
infected, and infants with undetectable virus on day 1 but with detectable virus on day 28 
were defined as intrapartum (IP) infected (Thobakgale et al., 2009, Thobakgale et al., 2007, 
Mphatswe et al., 2007). Written informed consent was obtained from all study participants 
and the research protocol for these analyses were approved by the Biomedical Research 
Ethics Committee of the University of KwaZulu-Natal, Durban, South Africa.   
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Figure 5.2 Flow diagram of participants selected from the PEHSS study for the current sub-
study. 
 
5.2.2 DNA extraction 
For the VTS study the DNA was extracted from DBS blood cards (S&S 903 paper card, 
Whatman® Schleicher & Schuell, Sigma-Aldrich, St. Louis, USA). The DBS cards had been 
stored for approximately 8 years at varying temperatures, first at -80
o 
C for approximately 1 
year, then at room temperature for 1 year and finally at -20
o 
C for 6 years. We isolated 
genomic DNA from a single punch from each DBS sample and followed manufacturers' 
instructions for extraction using the QIAamp DNA mini kit (Qiagen) as per Fig 5.3. This kit 
was selected based on results from a previous study that investigated the use of dried blood 
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spots for the determination of genetic variation as well as the quality of extraction of three 
commercially available kits as per Ndlovu et al, 2011; submitted). DNA was quantified on 
the Nanodrop 2000 spectrophotometer. Only DNA yield of 10-20ng of gDNA per 4.8mm 
punch of DBS card (Sjoholm et al., 2007, Singh and Spector, 2007, Wijnen et al., 2008) was 
used for genotypic analysis. DNA quality was validated by a 260/280 ratio and a purity of 
approximately 1.8.  
Figure 5.3 QIAamp DNA Mini Kit extraction protocol for dried blood spots (DBS) adapted. 
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5.2.3 Plasma viral load and CD4+ T cell measurement 
In the VTS cohort the HIV viral load and CD4+ T cell counts were determined at the Africa 
Centre Virology laboratory in Durban. Total HIV RNA was isolated from plasma using 
guanidinium-silica methods (NucliSens EasyQ HIV-1 kit) and from plasma (RNA extraction 
was using Minimag extraction by Biomeriux). The NucliSens HIV-1 QT (bioMerieux, Inc., 
Durham, NC) assay has a quantitative range of 40 to >500,000 copies/mL of plasma. CD4+ T 
cell cell counts were measured on venous blood within 24 hours of sampling using an Epics 
XL cell counter (Beckman Coulter, Fullerton, CA) and a 4-color protocol. 
 
In the PS cohort absolute CD4+ T cell counts were determined at the HIV Pathogenesis 
Programme, Durban, from fresh whole blood using Tru-Count technology on a four-color 
flow cytometer (Becton Dickinson) according to the manufacturer’s instructions. Plasma viral 
loads were measured using the Roche Amplicor Monitor Assay detection limit of 400 HIV-1 
RNA copies/ml plasma) or the Roche Ultra sensitive assay detection limit of 50 RNA 
copies/ml plasma), according to the manufacturer’s instructions.   
 
5.2.4 Allelic discrimination Assay 
The study assessed IL-10 genotyping using the TaqMan
®
 SNP Genotyping Assay kit using 
MGB primers and probes for IL-10 at nucleotide positions -592 A/C (rs 1800872) and -1082 
A/G (rs 1800896) as per manufacturer's instructions (ABI-Applied Biosystems) (Fig 5.3).  
 
The Taqman SNP genotyping assay was setup in a 96 plate format utilizing the 5`to 3` 
nuclease assay principle where each of the taqman probes annealed to a specific 
complementary sequence between a forward (5`) and reverse primer (3`). The following 
components were combined to prepare a single sample reaction (Table 5.1): 
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Note: PCR master mix (hot starter enzyme, optimized 50 mM MgCl2 (Magnesium chloride) buffer, AmpErase® Uracil N-
glycosylase (UNG) and dUTPS (2´-Deoxyuridine, 5´-Triphosphate)-protects against contamination. 
Assay mix-Minor grove binder (MGB) VICTM or FAMTM
 
labelled probes and sequences specific IL10 primer.s  
X=volume per sample of 10ng of final DNA concentration; purity 1.8-2.0(C1V1=C2V2). 
 
For negative controls no template genomic DNA was added. For positive controls genomic 
DNA samples that we previously genotyped was used as internal standards for both IL10 
SNPs -592 A/C and -1082 A/G. The standard thermocyling conditions were run on the 
Applied Biosystems Realtime PCR 7500 as follows (Table 5.2). 
 








Reagents Volume (µl) 
PCR master mix 12.5 
40x assay mix 0.625 
Genomic DNA (10ng)  X 
DNase free sterile H20  (11.875-X) 
Total 25 
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The TaqMan Allelic Discrimination assay employs a probe technology that uses the nuclease 
activity of AmpliTaq Gold® DNA Polymerase to direct 5´-3´ reactions. Two TaqMan probes 
are used for allelic discrimination. The probe hybridizes to a target sequence within the PCR 
product. The AmpliTaq Gold enzyme cleaves the TaqMan probe with its 5´–3´ nuclease 
activity. The reporter dye and quencher dye are separated upon cleavage, resulting in 
increased fluorescence of the reporter. These reactions enable PCR product detection based 








 representing heterozygous 










Figure 5.5 TaqMan Allelic probe discrimination assay. 
 
We analyzed the results using the ABI Prism
®
 Sequence Detection system 7000 software. 
The florescent probes were detected in a 96-well plate format and based on wavelength 
readout results; allelic variants were discriminated and graphically mapped as per Fig 5.5. 
The IL-10 allelic variants were analyzed as wildtype homozygous, mutation homozygous or 
heterozygous according to dominant/recessive model of mutants at each position. 











Figure 5.6 Schematic of allelic variant discrimination for 60 samples analyzed for IL-10  
-1082 (ABI Prism
®
 Sequence Detection system 7000). 
  
5.2.5 Isolation of PBMCs 
Blood was collected in EDTA tubes and processed within 6hrs of collection.  Peripheral 
blood mononuclear cells (PBMCs) were isolated from whole blood using the Ficoll-
Histopaque (Sigma, St Louis, Mo) density gradient centrifugation and used fresh in ELISPOT 
assays.   
 
5.2.6   HIV-1 Peptides 
A panel of 410 overlapping peptides (10-15mers overlapping by 10 amino acids) spanning 
the entire HIV-1 clade C consensus sequence were synthesized on an automated peptide 
synthesizer (MBS 396, Advanced ChemTech). Pepetides were used in a matrix system in 
screening assays.   
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5.2.7 ELISpot Assays 
CD8+ T cell responses were determined using an interferon-  ELISpot assay by Dr. C. 
Thobakgale (Thobakgale et al., 2007) as previously described in chapter 2.  
 
5.2.8 Luminex Cytokine analysis  
Plasma IL-10 cytokine expression levels were determined using the Luminex Multiplex MAP 
Human Cytokine high sensitivity and regular sensitivity immunoassay (Milliplex beads; 
Millipore) according to the manufacturer's instructions on a Bio-Plex 200 array system (Bio-
Rad Laboratories). Multiplex assay enables a large quantity of data to be extracted, hence 
enabling multiple analytes to be measured speedily in parallel. Immunodetection of beads 
occur in a 96-well plate format. Different bead sets are combined as a kit or by selection to 
capture antibodies into one master mix. Plasma samples (50µl) were mixed and incubated 
overnight with the bead set mix in a microtiter plate. The assay was subsequently read using 
lasers for both-bead identification and analyte quantification. Each bead was individually 
discriminated based on capture bead and based on level of florescence produced as 
wavelength outputs which are compared to standards. Analytes are analyzed in a high 
sensitivity kit measuring GM-CSF, IFN-γ, IL-10, IL-12 (p70), IL-13, IL-1β, IL-2, IL-4, IL-5, 
IL-6, IL-7, IL-8, and TNF-α. The multiplex assay can be used for the quantification of 
analytes such as MIP-1Β, EGF, Eotaxin, Fractalkine, G-CSF, IL-17, MCP-1, SD-40L, IP-10, 
TGF-Α and VEGF on a regular sensitivity kit. 
 
5.2.9 Statistical analysis 
Data was analyzed and graphically represented using Prism software (GraphPad; version 5) 
and SAS version 9.2 (SAS Institute Inc., Cary) was used for further statistical analysis. Chi-
square test compared allelic frequencies to verify that the analyzed SNPs were in Hardy-
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Weinberg equilibrium in the study population. Fisher’s exact test was used to analyze the 
association between HIV status and IL-10 promoter polymorphisms. Kruskal-Wallis test 
followed by Dunn’s post test was used to compare differences between groups. Kaplan-Meier 
survival statistics and Cox proportional hazards models were used to assess mortality of 
infants. Odds ratio was used to determine the strength of association of transmission and 
allelic variants. A linear regression model was used to in order to determine any possible 
associations of IL-10 with age, clinical markers and CTL responses. 
 
5.3 RESULTS 
5.3.1 Cohort Characteristics 
Three hundred and seventy four mothers and their children are selected as a subset of a larger 
study. After DNA extraction and TaqMan genotyping only three hundred and forty four 
mother and three hundred and sixty five children samples were evaluated. At the time of 
sampling both the mother and children received a single dose of NVP. The HIV-1 infected 
transmitter mothers were matched by viral load to HIV-1 non-transmitter mothers. The 
uninfected mothers are matched to the infected transmitter mothers by age. The study design 
was flawed in that the time of transmission was unknown.  
 
Table 5.2 Characteristics of the children of the Vertical Transmission Study cohort analyzed 
in the current sub-study. 
                                                         Infected Exposed uninfected Unexposed uninfected 
Children (n) 124 114 127 
Median Age in days (IQR) 224 (1-1,627) 550 (1-1,657) 666 (1-1,351) 








Median Viral Load (copies/ml) 176,000 - - 
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Table 5.3 Clinical characteristics of the mothers of the Vertical Transmission Study cohort 
analyzed in the current sub-study. 
 
5.3.2 Significant difference in absolute CD4+ T cell count (cells/mm
3
) in children 
As expected the uninfected sub-group of children exhibited the highest median absolute 
CD4+ T cell count of 2,215 with a range of 1,049-9,250 cells/mm
3
 in comparison to the 
infected sub-group who exhibited a median CD4+ T cell count of 1,404 with a range of 85-
2,990 cells/mm
3 
(p<0.0001). The infected sub-group exhibited a median viral load of 176,000 
with a range of 1,000-1,000,000 copies/ml. (Table 5.3&5.4; Fig 5.6).  
 
 
Figure 5.7 Comparison of Absolute 








IQR (copies/ml) 1,000-1,000,000 
                                                         Transmitter Non-transmitter Uninfected 
Mothers (n) 112 108 124 
Median Age in years (IQR) 24 (17-40) 24 (16-43) 25 (16-39) 
Median Absolute CD4+ T cell  
count (IQR) 
354 (15-1,020) 422 (35-1,419) 944 (301-1,928) 
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5.3.3 No relationship between distribution IL10 allele frequency and HIV acquisition 
in children 
Based on a previous study (Shin et al., 2000) the -1082G mutant allele has been classified as 
the recessive allele and associated with an AIDS delaying effect while the -1082A (AA and 
AG) is associated with patterns of dominance. Similarly the -592 (AA and CA) has shown to 
have a dominant effect on carriers, which is further associated with AIDS susceptibility, 
while the -592C was classified as the recessive allele and associated with an AIDS delaying 
effect. These dominant and recessive patterns formed the basis of bulk of the analysis. As 
several studies have implicated IL-10 promoter polymorphisms to HIV-1 susceptibility or 
disease pathogenesis in adults (Erikstrup et al., 2007, Shin et al., 2000, Shrestha et al., 2010, 
Vasilescu et al., 2003)we wanted to assess the association of IL-10 promoter polymorphisms 
-592 and -1082 with HIV acquisition by comparing the distribution of the allelic variants 
between HIV-1 infected and uninfected babies of HIV-1 infected mothers. The allelic 
variants were distributed similarly for both IL10 -1082 and IL10 -592. There was no overall 
association (Table 5.5) between IL10 -592 (p=0.6952) and IL10 -1082 and HIV acquisition 
(p=0.3251). 
 














AA/CA 68 (54.8%) 66 (57.9%) AA/AG 112 (90.3%) 103 (85.8%) 
CC 56 (45.2%) 48 (42.1%) GG 12 (9.7%) 17 (14.2%) 
p-value 0.6952 p-value 0.3251 
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5.3.4 No association between IL10-592 and IL10-1082and infant mortality 
A previous study in a Zimbabwean adult cohort found that mortality was lower in carriers of 
the IL-10 -1082G allele which is associated with increased IL-10 production.  We therefore 
sought to examine whether a similar trend would be found in children.  These analysis was 
only preformed on the 124 HIV-1 infected infants of whom 78 (60.9%) died. The median age 
of death was 4.4 months (IQR 2.9 – 11.9). The association between allelic variants and 
clinical markers and their association with mortality was assessed using a Cox proportional 
hazards model. Firstly, distributions of allelic variants utilized for mortality assessment were 
as follows: AA/AC 60.0% (n=41) and CC 60.7% (n=34). In IL10 -1082 the distributions the 
different alleles were as follows: AA/AG 61.6% (n=69) and GG 58.3% (n=7). In adjusting 
for both alleles, dominant and recessive patterns, there was no significant difference in 
mortality rates between dominant and recessive genes (Fig 5.7) in either IL10 -592 or -1082 



















































Figure 5.8 Mortality of children according to allelic variant: A) association with -592; B) 
association with -1082.  
 
We next analyzed the degree of influence of clinical markers on infant mortality within the 
VTS cohort. The mean log viral load (closest to birth) for those children whom died and 
those children who did not die was 3.16 (SD=1.56) and 2.50 (SD=1.38) log copies/ml, 
respectively. The mean absolute CD4 T cell count for those infants who died and those who 
did not die was 190 (SD=20.30) and 188 (SD=27.37) cells/µl, respectively. 
 
5.3.5 Proportional hazards modelling to determine the effect of IL-10 allelic variants 
and infant mortality 
The first viral load for the infants who died and the infants who surivived, were taken at a 
median of 2.5 (IQR 1-8) and 2 (IQR 1-8) days after birth, respectively. The initial absolute 
CD4+ T cell count for deaths and survival were taken at a median of 185 (IQR 183-192) and 
190 (IQR 180-195) days after birth, respectively. All infants had a first viral load 
measurement (n=128), but only 60 babies had a first absolute CD4 T cell count. A trend was 
observed demonstrating that for every 100 cell/µl absolute CD4+ T cell count increase 6% 
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children were less likely to die (95%CI). The multivariate analyses, adjusting for both IL-10 
promoter polymorphisms as well as first viral load,  revealed that there was no significant 
difference in infant mortality rates between carriers of dominant and recessive alleles for 
neither IL10 -592 nor -1082, p=0.4279 and p=0.6361 respectively. 
 
5.3.6 Association of clinical markers viral load and absolute CD4+ T cell count on 
transmission  
Several studies have suggested a contribution of IL-10 promoter polymorphisms to HIV-1 
susceptibility or disease pathogenesis (Erikstrup et al., 2007, Shin et al., 2000, Shrestha et al., 
2010, Vasilescu et al., 2003), we thus went on to investigate HIV-1 transmission in the 
mothers of the VTS cohort. The association between viral load and absolute CD4+ T cell 
count were first investigated 50 days prior to delivery in 60 women. Thirty four mothers 
transmitted HIV-1 to their children and 26 mothers did not transmit HIV-1 to their children.  
There was no association between viral load or absolute CD4+ T cell count and transmission 
with p=0.5584 and p=0.1497, respectively, adjusting for delivery. 
 
Following transmission, the transmitter and non-transmitter sub-groups were matched to 
exclude variability associated with viral load. As expected there was no difference in viral 
load with transmitter and non-transmitter mums exhibiting median viral loads of 45,000 and 
35,500copies/ml respectively (Fig 5.8). Absolute CD4+ T cell count was significantly 
different between the two groups. Transmitter mums exhibited a median absolute CD4+ T 
cell count of 354 cells/mm
3
 in comparison to non transmitter (422 cells/mm
3
) and uninfected 
mothers whom exhibit a median viral load of 944 cells/mm
3 
(p<0.0001).  No significant 
difference in viral load is observed between transmitter and non-transmitter variants within 
IL-10 promoter polymorphisms of both -592 and -1082.  


















Figure 5.9 Comparison of a) viral load (copies/ml) between transmitter, non transmitter 
mothers, and b) Absolute CD4+ T cell count (cells/mm
3
) between transmitter, non transmitter 
and uninfected mothers. 
 
5.3.7 Significant association between distribution of IL-10 -1082 genotypic frequency 
and HIV transmission 
To date, no studies have investigated the role of IL-10 promoter polymorphisms in HIV-1 
clade C mother-to-child-transmission. Therefore we next investigated the association of IL-
10 promoter polymorphisms and HIV transmission by comparing the distribution of allelic 
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variants of HIV-1 infected mothers who transmitted HIV to their babies, to those who did not 
transmit HIV to their babies. HIV-1 transmitter mums further exhibited a lower proportion of 
IL10-1082A in comparison to non-transmitter mums (79.5% vs. 94.5%, p=0.0012) (Table 
5.6). This translates into carriers of 1082A having a 77% less odds of transmitting HIV to 
their infants (odds ratio 0.23 (95% CI 0.09 – 0.58)). There was no association between IL10 -
592 and HIV transmission (p=0.4883). Noteworthy, distribution of allelic variations were 
unaffected by treatment as at the time of sampling all the infants were from a vertical 
transmission study cohort, where both the mother and children only received a single dose of 
NVP.  
 

















AA or CA 65 (58.6%) 69 (63.9%) AA or 
AG 
89 (79.5%) 103 (94.5%) 
CC 46 (51.4%) 39 (36.1%) GG 23 (20.5%) 6 (5.5%) 
p-value 0.4883 p-value 0.0012 
 
 
5.3.8 IL-10 promoter polymorphisms and CTL immune response have no effect on 
HIV-1 transmission 
Based on findings from the LCMV model of chronic viral infections that suggested a critical 
role for IL-10 in the disruption of effector immune responses and viral persistence, we next 
investigated the effect of IL-10 on cellular responses. Due to retrospective study design we 
were compelled to investigate this role in another transmission cohort (n=60) (Mphatswe et 
al., 2007, Thobakgale et al., 2009, Thobakgale et al., 2007). As an overview, the transmitter 
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and non-transmitter sub-groups were matched to exclude viral load variability with the 
transmitter and non-transmitter mums exhibiting median viral loads of 99700 and 
100000copies/ml respectively (p=0.9657). There was also no significance in absolute CD4+ 
T cell count. Transmitter mums exhibit a median absolute CD4+ T cell count of 
299cells/mm
3
 in comparison to non transmitter whom exhibit a median viral load of 
388cells/mm
3 
(p=0.1733). We found no significance in magnitude of immune response by 
looking at allelic variants previously found to be most associated with high IL-10 production 
and low IL-10 production in non-transmitter and transmitter mothers (Fig 5.9) for both IL10-























































Figure 5.10 Association of magnitude of IFN-γ CD8+ T cell responses and IL-10 allelic 
variants A) 592 and B) 1082 between transmitters and non-transmitters. 
 
5.3.9 Significant effect of IL-10 promoter polymorphisms on immune         response 
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We subsequently went on to study the association of IL10 promoter polymorphisms with 
immune responses in a subset of the children of the PS cohort. Interestingly, a significant 
association was observed between magnitude of IFN-γ CD8+ T cell immune immune 
response within the HIV-1 infected children subgroup between children whom have the 
wildtype in comparison to children whom are mutant carriers IL10 -592 AA/AC (p=0.0071). 
The carriers of the mutant allele IL10 -592A was associated with a significantly lower 
magnitude of IFN-γ CD8+ T cell in comparison to the carriers of IL10 -592C in children.  
However as demonstrated in Fig 5.10 there was no significance for IL10 -1082 (p=0.3455). 
 
Figure 5.11 Association of magnitude of IFN-γ CD8+ T cell responses and IL-10 allelic 
variants A) 592 and B) 1082 in infected children. 
 
Elevated IL-10 plasma levels have previously been documented to correlate with poor 
prognosis in many infections (Roberts et al., 2010, Lech-Maranda et al., 2006, Stanilova et 
al., 2005, Visco et al., 2004) including HIV (Norris et al., 2006, Brockman et al., 2009), 
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Twenty seven of the HIV-1 clade C children from the PS cohort (Mphatswe et al., 2007, 
Thobakgale et al., 2009, Thobakgale et al., 2007) are investigated within the cytokine 
investigation. We observed the allelic variants to be distributed as 17.2%  AA, 48.3%  AC 
and 34.5%  CC, while IL10-1082 was distributed as 55.2% (AA) and 44.8% (13) AG. We 
found no associations between allelic variants and levels of IL-10 (p=0.7932) and IFN-γ 
(p=0.6834) cytokines in-592 (Fig 5.11).  
 
Figure 5.12 Comparison of plasma IL-10 and IFN-γ cytokine levels with allelic variants A) 
IL-10 -592 and B) -1082 infected children. 
 
5.3.10 Correlation of clinical markers of disease progression with cytokine expression 
levels in children  
Based on previous findings the allelic variants -1082A and -592A have been documented to 
be associated with decreased IL-10 production have thus associated with an increased 
susceptibility to HIV. A linear regression model was fitted to IL10 expression data in order to 
determine possible associations. In spite of the log viral load being significantly associated 
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seems to be a confounder. However, there was a significant negative association between 
viral load and age (p=0.0050), thus as age increases per month, viral load decreases at a rate 
of 0.02940 log copies/ml (SE=0.00962). At the same time age was also associated with IL10 
expression (p=0.0014) with IL10 expression levels decreasing at a rate of 0.01028 log units 
per month increase of age. The younger aged children were associated with higher viral load, 
and lower age were associated with higher IL10 expression, thus this relationship makes it 
seem as if the higher viral load was associated with higher IL10 expression. Adjusting for 
age, using a multiple linear regression models, excluded viral load association to conclude 
that age was a confounder. 
Figure 5.13 Correlation of IL-10 cytokine levels (pg/ML) with A) Viral Load B) CD4 T cell 
%. 
Correlation of viral loads and cytokine levels revealed positive correlations for IL-10 
(p=0.0380) and TNF-α (0.0065). As per Fig 5.12 correlation of absolute CD4 T cell % and 
cytokine levels revealed positive correlations for IL-10(0.0007); TNF-α (p=0.0188); IL-5 








































219 | C h a p t e r  5 :  I L - 1 0   
 
5.3.11 Comparison of IL-10 cytokine levels within age matched babies 
Grouping the babies by age reveals no significant changes in median levels of the IL-10 
cytokine with age (Fig 5.13). An increase in viral load was inversely with absolute T cell 
count for children aged 1 to 3months of age. However a gradual stabilization in viral load 
coupled with an elevation in absolute CD4+ T cell count was observed 4 months of age and 










Figure 5.14 Stratification of: A) IL10 
cytokine levels; B) Viral load and C) CD4 
T cell % by age of children. 
 
 
5.3.12 Comparison of cytokine levels cross sectionally by function and longitudinally 
over time 
Expression levels are further investigated.  Median levels of chemokines and cytokines were 
grouped by function. Pro-inflammatory cytokines are classified as IL-1β, IL-5, IL-6, TNF-α, 
MCP-1 and IL-12 (p70). 
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Growth factors are classified as EGF, TGF-Α and VEGF; while haematopoietic classified as 
IL-7, GM-CSF and G-CSF.  The anti-inflammatory function was only represented by 
cytokine IL-10. Chemokines are represented by IL-8, IP-10, MIP-1Β, Eotaxin and 
Fractalkine. Adaptive function are classified as   SD-40L, IL-2, IL-13, IL-4, SD, IL-17 and 
IFN-γ.  As some cytokines are ubiquitously expressed without negative controls results 
proved difficult to interpret. It appears that chemokines are expressed at higher levels in 
comparison to other groups of cytokines within first month of life, which may or may not be 
related to age. Proinflammatory and adaptive function seems to be limited in comparison to 
the anti inflammatory cytokine IL-10 (Fig 5.14A).   
 
Figure 5.15 Expression levels of Cytokines/chemokines (pg/ML) A) Cross sectionally by 
function in children less than a month of age and B) longitudinally over time. 
 
The study went on to investigate the individual cytokine and chemokine levels of expression 
over time from five months to forty two months of age. Chemokines (Eotaxin and IP-10) and 
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growth factors (EGF and VEGF) are expressed at highest levels throughout all 42 months of 
life. Anti-inflammatory cytokine IL-10 was expressed at increased levels to TNF-α. 
Interestingly chemokine IL-8 expression level decreased to undetectable levels over time. 
Expression levels of IL-7 and IL-13 remained stable over time. The study further investigated 
pro-inflammatory and anti-inflammatory function in one transmission pair over time. The 
mother and child are treatment naive and exhibited CD4 T cell % of 29-40% with a stable 
viral load. The child has a higher overall expression levels in comparison to the mother over 
time. The anti-inflammatory cytokine was expressed at a higher levels compared to pro-
inflammatory cytokines in the child compared to the mother. 
 
Within this cohort the children aged 1month or younger express lower IL-10 cytokine levels 
and exhibit lower viral loads that increased and then to be maintained at high levels with 
time. The children aged 1 month or younger exhibit a higher initial CD4+ T cell % which 
were found to decrease with age. The CD4+ T cell % seemed to stabilize after 3 months of 
age within this cohort.       
 
5.4 DISCUSSION 
The multifunctional role of IL-10 has sparked interest in understanding the mechanisms that 
underlie the function of IL-10 in signal transduction (Sarkar et al., 2011, Begue et al., 2011), 
cellular immune response (Tsilidis et al., 2009, Wang et al., 2009, Bialecka et al., 2008, 
Lazarus et al., 2006, Brooks et al., 2008), cellular activation (Hedrich et al., 2010, Sarkar et 
al., 2008, Hoiden and Moller, 1996), epigenetics (Saraiva et al., 2005, Chang et al., 2007) and 
cytokine production (Maurer et al., 2000, Hoiden and Moller, 1996, Mosmann, 1991). IL-10 
has been shown to play an important role in the immune dysfunction and viral persistence in 
chronic viral infections (Brooks et al., 2008, Brooks et al., 2006).  Immune dysfunction 
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associated with IL-10 appears to be reversible with IL-10 receptor blockade to restoring 
robust IFN-γ CD8+ T cell immune responses, promoting viral clearance and enhancing 
vaccine induced immune responses.   
 
A study in an adult African cohort found that the carriers of alleles associated with high IL10 
production in promoter polymorphisms were less likely to acquire HIV-1, however, this 
mechanism was reversed as the virus progressed suggesting a paradoxical role for IL-10 
promoter polymorphisms in different stages of HIV-1 infection in adults (Eskdale et al., 
1998, Naicker et al., 2009, Shrestha et al., 2010). This impelled us to investigate the role of 
IL-10 polymorphisms in HIV-1 mother-child transmission. Studies describing the role of IL-
10 and its genetic variants on mother-child transmission and paediatric HIV-1 disease 
progression are limited. This study investigated association between two IL-10 promoter 
polymorphisms and mother to child HIV transmission and clinical outcomes. Our study 
explored some possible mechanisms underlying the role of IL-10 promoter variants on HIV 
pathogenesis. Furthermore, we assessed the association of cytokine levels with biomarkers of 
disease progression such as absolute CD4+ T cell count and viral load. 
Absolute CD4+ T cell count is important clinical marker for disease progression in adults 
while the CD4+ T cell % is a more accurate indicator in children. As expected uninfected 
mothers and children exhibited higher absolute CD4+ T cell counts. Interestingly, in 
confirmation with other studies, we observed a significantly higher positive correlation of 
viral load with IL-10 levels, and an inversely a significant negative correlation with CD4+ T 
cell % in this particular cohort of children (Orsilles et al., 2006, Srikanth et al., 2000, Bebell 
et al., 2008, Imami et al., 1999). These results further confirm the strong role of IL-10 as a 
marker of disease progression. Despite the immature immune system and highly variable 
viral burden in these young children, IL-10 is able to predict disease as well the clinical 
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marker viral load and the marker CD4+ T cell %, which is used to dictate treatment 
guidelines in children.    
 
Our study was the first to investigate IL-10 association in mother to child acquisition and 
transmission. We found no association between any allelic variants and HIV-1 acquisition in 
children. As the route of transmission and acquisition in children differ from that of adults, 
variations in findings were anticipated. Our results contradict studies in adults that found 
carriers of the IL10-592A to be more likely to acquire HIV-1 infection. Hence the allelic 
variants associated with low IL-10 production was significantly more likely to become HIV-1 
infected. These results further contrast studies in adult South African and North American 
cohorts that found the carriers of the -592A allelic variant, linked to low IL-10 production, to 
be at a higher risk of HIV-acquisition (Naicker et al., 2009, Shin et al., 2000).  
 
When Cox proportional hazards model was used to assess mortality or time to death there 
was no association between allelic variants and mortality in children which has been 
observed in studies in other infections (Liu et al., 2011). However, these results contradict 
observations in adults that linked -592A to increased risk of mortality (Erikstrup et al., 2007, 
Huebinger et al., 2010). When investigating time to death our study found 58% of 
participants to be carriers of the -1082G. The children whom carried the -1082G, an allele 
linked to increased IL10 production,  were more likely to die within first 21months of life, in 
comparison to children with other allelic variants who survived as long as 12 additional 
months. These results are in contrast to other observations in adults which found carriers of -
1082G to be associated with protection (Erikstrup et al., 2007). Survival rate in many carriers 
were approximately doubled (Erikstrup et al., 2007). The multivariate analyses, when 
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adjusted for both viral load and promoter polymorphism, showed no difference in clinical 
outcome irrespective of the allele being carried.  
 
We next investigated the role of IL-10 promoter polymorphisms on HIV-1 mother to child 
transmission.  This study is the first of its kind as IL-10 polymorphisms have not previously 
been documented within mother to child transmission. Many studies have indirectly 
implicated IL-10 expression levels, not allelic variants, in vertical transmission. It must be 
noted, that within this sub-study as the time of transmission was unknown mothers were 
matched by their viral loads and age of mothers. This may bias results if viral load is a 
confounding factor. 
 
 A study investigated IL-10 secretion levels in pregnant woman and found pregnant woman 
to express higher levels of IL-10 to help control HIV-1 replication and possibly reduce risk of 
transmission (Bento et al., 2009).  Our study found significant differences in allelic frequency 
with the carriers of the IL10-1082G, the HIV-1 infected mothers who transmitted HIV to 
their babies (20.5%) in comparison to those mothers who did not transmit HIV to their babies 
(6%) in relation to IL10 promoter polymorphisms. There was no association between IL10 -
592 and HIV transmission (p=0.6255).The non-transmitter mums were matched to control 
viral load for uniformity in our acquisition investigation of their children, but this may also 
bias the effect viral load has on the distribution of promoter polymorphisms during different 
stages of HIV-1 infection. Naicker et al. suggest a paradoxical role for IL-10 promoter 
polymorphisms on HIV-1 pathogenesis (Naicker et al., 2009).  The study documented that 
IL-10 polymorphisms associated with higher IL-10 production were also associated with high 
viral load during the acute infection phase of HIV-1 infection.  However, with the onset of 
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HIV-1 infection as the virus progressed towards the chronic stage of infection the association 
between viral load and allelic variants either disappeared or reversed (Naicker et al., 2009).  
 
The LCMV model showed that IL-10 played an influential role in inhibiting adaptive T cell 
immune responses (Brooks et al., 2008, Ejrnaes et al., 2006). T cells have been shown to play 
an important role in viral control hence the lack of strong robust immune responses aggravate 
increased viral persistence (Brooks et al., 2006, Ejrnaes et al., 2006, Kiepiela et al., 2004, 
Kiepiela et al., 2007). In a vivo LCMV IL-10 blockade of the IL-10 receptor resulted in an 
enhancement of T cell immune response in persistently infected mice (Ejrnaes et al., 2006). 
Interestingly Brooks et al., document IL-10 to not just play a significant role in viral control 
but in complete viral clearance in a LCMV model after the genetic removal of IL-10. This 
removal of IL-10 enabled robust effector T cell response and subsequent elimination of virus 
(Brooks et al., 2008). Due to our study design we were not able to conduct these types of 
blockade experiments (Brockman et al., 2009). A deficit in IL-10 at birth translated into 
immune dysregulation has also been found to be associated with leukemia in children (Chang 
et al., 2011). However, these studies are currently underway in another cohort.  
  
Polymorphisms in cytokine genes such as the anti-inflammatory cytokine IL-10 have further 
been implicated in clinical outcome perhaps through modulation of host adaptive response in 
humans via influence on cytokine levels (Vollmer-Conna et al., 2004). A study investigating 
woman with sexually transmitted disease detected higher levels of  IL-10 in non-ulcerative 
STD and bacterial vaginosis in endocervical secretions suggested that these infections may 
alter susceptibility to HIV-1 infection in women (Cohen et al., 1999). When investigating the 
allelic variants of IL10 promoter polymorphisms the -592 A allelic variant is associated with 
lower IL-10 production which can be associated with strong anti-inflammatory function and 
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the presence of robust adaptive immune responses (van Exel et al., 2002, Naicker et al., 
2009). Furthermore, previous studies have documented that carriers of the IL10-1082G allele 
to be linked to higher IL-10 production and hence a suppression of T cell immune responses 
(Naicker et al., 2009, Shin et al., 2000, Yanamandra et al., 2005).Our investigation confirmed 
that the carriers of -1082 G was associated with higher IL-10 production in comparison to the 
carriers of IL10 -1082A. A study of acute Hepatitis B and C infections showed that 
expressing an enormous cascade of cytokines lead to eventual viral clearance in a majority of 
infected individuals (Stacey et al., 2009).  
 
We also investigated a broad array of cytokines and observed levels correlated positively 
with IFN-γ levels which represent immune responses. Proinflammatory and adaptive function 
seems to be less in comparison to the anti inflammatory cytokine IL-10 in children within this 
cohort. The carriers IL10-592A, which is generally associated low IL-10 production in adults, 
however who showed no association in our children cohort, was significantly associated with 
a lower magnitude of response. It has been documented that multiple cell types contribute to 
IL-10–mediated immune suppression in the presence of uncontrolled HIV viremia. The 
proliferative capacity of HIV-specific CD4 and CD8 T cells in individuals with ongoing viral 
replication differ which could attributed to why allelic polymorphisms did not correlate with 
plasma IL-10 levels (Brockman et al., 2009). Moreover, as the success of ART influences 
viral replication and thus cell proliferation it may also affect cytokine levels.  Notably, due to 
the controversial role of IL-10 in maintenance of immune responses and the contradiction 
between our data in children in comparison to findings in adults, an understanding of the 
underlying mechanisms that regulate immune control is crucial.  
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This study did pose limitations worth highlighting. First, the sample size was relatively small 
for a genetic association study. The mother and children also received a single dose of NVP 
which could modify exposure outcomes. Furthermore, we matched viral load of transmitter 
and non-transmitter participants to allow for similar transmission setting, which could 
indirectly the effect of other factors that are driven by viral load that may influence IL-10. 
Moreover, in our investigation of cytokine levels and their association with IL-10 allelic 
variants and chronological measurements, we lacked a comparative uninfected control group 
which limits our data interpretation. Finally the cohort for the cytokine analysis was not a 
homogenous population due to varying age and hospital visits. Most importantly, we were 
unable to compare cytokine observations to a cohort of uninfected children to validate 
findings.  
 
In conclusion the association of IL-10 polymorphisms vary in HIV-1 infection, and as we 
have described with age. We suggest that the mechanisms underlying the function of IL-10 
may vary between adults and children. As our MTCT study was the first of its kind and our 
cohort represented a very rare untreated children’s cohort. . A meta-analyses of all reported 
IL-10 promoter polymorphism studies within HIV-1 infection, as recently executed in cancer 
research (Zhu et al., 2011), will prove beneficial for a better understanding of the mechanism 
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CHAPTER SIX 
6.1 GENERAL DISCUSSION 
At the onset of the current millennium the international community established eight 
Millennium Development Goals (MDGs) to be achieved by 2015. The two goals at the heart 
of the memorandum was MDG 4, which seeks to reduce child mortality by 75% and MDG 5, 
which aims to improve maternal health resulting in reducing infant mortality (UNICEF, 
2011). Many countries have made progress to reduce maternal, perinatal mortality and the 
mortality of children less than 5 years of age. However, it seems unlikely that South Africa 
would be able to adhere to this timeline. In particular, according to Stats SA (2011) and 
KwaZulu-Natal’s (KZN) annual performance plan (http://www.kznhealth.gov.za/app2011-
14.pdf), the province of KZN has reported high infant (55,8/1000 live births), child 
(87,5/1000 ) and  maternal (210/100,000 live births) mortality rates. Furthermore, the 
government member of the executive council (MEC) of health has remarked on the damage 
the AIDS epidemic has inflicted on disease burden with unacceptable high morbidity and 
mortality rates in the province of KZN. (http://www.kznhealth.gov.za/app2011-14.pdf). The 
past decades of HIV research has brought substantial advances, but unfortunately mothers 
and children still remain vulnerable to the world’s leading infectious health crisis 
 
The paediatric population is vulnerable to HIV owing to the immaturity of their immune 
system. In the absence of antiretroviral therapy, HIV-1 infected children die within the first 
two years of life (Bobat et al., 1999, Bobat et al., 1990, Goulder et al., 2001b, Newell et al., 
2004, Ruiz Contreras, 1998, Prendergast et al., 2007, Mphatswe et al., 2007). A better 
understanding of immune control in slow progressor survivors naturally containing viral load, 
may direct us to the underlying determinants of protective immunity. The broad scientific 
goal of our study was to explore HIV pathogenesis in genetically matched transmission pairs 
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and/or children, in order to further contribute to understanding of the correlates of successful 
immune control in paediatric HIV-1 infection. We carried out this investigation by 
comprehensively dissecting HIV-1 immunopathogenesis into the following investigational 
components: the transmitted virus, the cellular immune response to the virus, the 
functionality of elicited T cells, regulation of T cells, and finally host genetic determinants by 
investigating IL-10 gene variants within a mother-child transmission setting.  We observed 
that CD8+ T cell responses and viral fitness did not explain differences in disease progression 
in the investigated transmission pairs within this cohort; activation and regulatory markers 
were shown to influence immune response or vice-versa. Our data showed a significant 
association between IL10 -1082 and HIV transmission and an association of high viral 
replication with increased IL-10 plasma levels which may contribute to immune dysfunction 
in paediatric HIV infection.  
 
These findings are discussed in detail in the context of existing literature in the sections to 
below. 
 
6.2 CD8+ T CELL RESPONSES, HLA AND VIRUS REPLICATIVE CAPACITY 
Following the inability of the innate system to protect the host against some invaders, the host 
has evolved to include a second defense system. The adaptive arm of immunity includes 
dendritic cells, antibodies, CTLs, and T helper cells. The effect of both CD4+ and CD8+ T 
cell responses on disease progression in paediatric HIV infection has proven controversial 
(Feeney et al., 2003, Goulder et al., 2001b, Huang et al., 2008, Prendergast et al., 2011a, 
Salimi et al., 2000, Thobakgale et al., 2007, Lohman et al., 2005). Our study investigated 
CD8+ T cell antigen specificity using an IFN-γ ELISpot screening assay. Many children did 
not respond when we screened responses using peptide pooling methodology (Addo et al., 
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2003, Kiepiela et al., 2004, Kiepiela et al., 2007, Luzuriaga et al., 1991). The inability to 
control viremia may be attributed to the lack, delay or ineffectiveness of T cell immune 
responses (Margolick et al., 1995). Subsequently, we stratified responses from our pooled 
peptide assay (cut off 100 SFCs) to discover that the non-responder children were ideally 
making low level responses. The viral regions targeted by these children in order of 
frequency of response were Nef (49%), Gag (17%), Env (14%) and Acc/Reg/Pol (6%). 
Children differ in that their immune system is less developed and their T cell responses may 
not be as detectable or effective in viral containment as observed in adults (Luzuriaga et al., 
1991). These findings may be biased as we were only able to assess a single cytokine (IFN-γ) 
secreted by CD8+ and possibly CD4+ T cells as ELISpot on whole PBMC specimen is unable to 
differentiate CD4 from CD8 responses or less likely NK cell responses. Assays such as 
intracellular cytokine staining and tetramer staining could have differentiated between these 
possibilities but this was not possible in this study due to sample limitations. However, the 
ELISpot assay was optimized for CD8 rather than CD4 T cell responses (24h vs 48h 
incubation) and based on previous data from cohort, the majority of responses observed by 
ELISpot were CD8+.    Furthermore, the study was limited in that the investigation was 
carried out cross-sectionally and hence the long term benefits of T cell specificity could not 
be assessed.    
 
Our responder children confirmed findings of previous studies showing the viral region Nef 
to be dominantly targeted in children 3 months to 10 years of age (Thobakgale et al., 2007, 
Huang et al., 2008) while acutely infected children predominantly target Env (Thobakgale et 
al., 2007). In adults, Env-specific responses have been associated with higher viremia. 
Following vertical transmission, the viral loads in children do not decline and do not reach 
viral set point until a few years after HIV infection (Goulder et al., 2001b) unlike primary 
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infection in adults. The viral kinetics following infection is different to what is noted in adults 
(Holland et al., 2000, Resino et al., 2002b, Resino et al., 2002a); most children typically 
progress to AIDS or death within the first 2 years of life in the absence of antiretroviral 
treatment (Prendergast, 2007). We found no difference in viral load (Huang et al., 2008, 
Lohman et al., 2005). The functional assessment of T cell polyfunctionality suggested that it 
may be the quality of CD8+ T cell response rather than the quantity of responses that 
influences clinical outcome (Betts et al., 2006, Thobakgale et al., 2011).    
 
We were unable to directly assess the effect of CD4+T helper cells as previously described in 
children (Huang et al., 2008, Thobakgale et al., 2007, Wasik et al., 2000). CD4+ T cells have 
also been shown to play a role in suppression of functional capacity in young children (Kolte 
et al., 2011) and young nonhuman primates (Hartigan-O'Connor et al., 2007).  CD4+ Tregs, 
mediated by the CTLA-4 pathway have been found to play a role in CD8+ T cell suppression 
in vivo (Sakaguchi et al., 2009). Furthermore, a simultaneous blockade of TIM-3 and PD-1 
pathways has been documented to have a synergistic effect in restoring T cell antiviral 
immunity (Jin et al., 2010).Interestingly in mice, blockade of the IL-10 pathway further 
stimulate T cell responses and restored IFN-γ secretion, resulting in eventual viral clearance. 
(Brooks et al., 2006). We were unable to test functional capabilities using blockade 
experiments. However taken together, regulating pathways, paediatric age, the peptides 
screened in relation to consensus sequence, cytokine used to measure CD8+ T cell responses 
contribute to our understanding of the mechanisms underlying T cell immunity in children.  
 
Host and maternal factors are known to influence disease progression (Andiman, 1999, 
Bloland et al., 1995, Colognesi et al., 1997, Kuhn et al., 2004, Newell et al., 2004, Palomba et 
al., 1999). Our assessment of viral burden following vertical transmission revealed that 
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transmitter mothers had higher viral loads compared to non-transmitter mothers. Based on 
other studies that showed that HIV-1 infected adults (Goepfert et al., 2008, Matthews et al., 
2009) and children (Feeney et al., 2005, Thobakgale et al., 2009) may benefit from exhibiting 
HLA-B restricted Gag-specific responses and from receiving transmitted escape mutations- 
we next investigated the interplay between HLA, CD8+ T cell and virus in MTCT 
transmission pairs.  As HLA-B*27 (Goulder et al., 2001a, Schneidewind et al., 2007) and 
HLA-B*57 (Altfeld et al., 2003, Brockman et al., 2007, Crawford et al., 2009, Goulder et al., 
2000, Leslie et al., 2004, Miura et al., 2009b, Feeney et al., 2005, Thobakgale et al., 2009) 
restricted Gag-specific responses have been documented to play a protective role in slow 
disease progression and within transmission pairs (Feeney et al., 2005, Thobakgale et al., 
2009, Goepfert et al., 2008), we focused on these HLA alleles. We did not find any 
association between Gag-specific CD8+ T cell response and slow progression in the selected 
children in our cohort in line with other studies in children (Froebel et al., 1997, Huang et al., 
2008). An alternative explanation for our findings could be sample size limitations as we 
examined a small number on children. 
 
Studies have also associated HIV-1 fitness with the rate of transmission and disease 
progression (Biesinger and Kimata, 2008, Chopera et al., 2008, Duda et al., 2009, Miura et 
al., 2009a, Miura et al., 2009c, Plaeger-Marshall et al., 1994, Wright et al., 2010, Wright et 
al., 2011). We found no association with the absence of Gag responses and sequence 
variations in Gag. Even though many infants did respond to other viral regions, we were 
unable to sequence other regions of the virus due to funding restrictions. Furthermore, we were 
unable to associate CTL escape mutations with roles in attenuating the fitness of the virus, 
contrasting another study that demonstrated that replicative capacities differ in slow and rapid 
progressor children (Prado et al., 2010). Furthermore, the precise timing, occurrence and 
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location of escape mutations in the viral genome indicates the efficacy of certain CTL 
specificities and suggest a cost to the virus that may be important in vaccine design (Goulder 
and Watkins, 2004).  
 
We were limited by the fact that we could not follow up all these transmission pairs in more 
detail over from birth. For example, the timing or the mode of transmission could not be 
determined in our study, contrasting to previous studies that demonstrated that in utero 
infected children rapidly progress to disease (Mphatswe et al., 2007). Details of other co-
infections were also unknown. As the study was run through clinic sites many children were 
recruited as they were visiting sites due to symptoms related to ill-health. Genetically, we 
may have overlooked missing genetic links associated with the genetic environment of the 
father, as CD8+ T cell responses may be compromised both by the transmission of maternal 
escape variants and by MTCT of escape variants that originally arose in the father (Pillay et 
al., 2005). All in all, we did not find any association between HLA, CTL responses, 
transmission of escape variants with overall viral fitness in the selected transmission pairs. 
This may be related to study design or show that HLA and CTL data alone is not sufficient in 
determining what mediates control.  
 
 6.3 MARKERS OF EXHAUSTION: TIM-3 AND PD-1 
HIV-1 pathogenesis is characterized by the rapid loss of CD4+ T cells leading to generalized 
immune dysfunction, including an exhausted CD8+ T cell phenotype. As previously 
mentioned- it may be the quality and not the quantity of response that influences the 
effectiveness of T cell immunity. An understanding of the underlying factors that drive the 
functional quality and effective antiviral T cell responses would inevitably improve 
therapeutic strategies to contain and possibly clear infection. 
240 | C h a p t e r  6 :  D i s c u s s i o n  a n d  C o n c l u d i n g  r e m a r k s  
 
We investigated progressive cell exhaustion of TIM-3, in concert with PD-1. A synergistic 
effect of PD-1 and TIM-3 blockade has been found to revere T cell exhaustion. Based on the 
panel restrictions we were not able to correlate co-expression on identical cell. We found that 
these exhaustion markers were expressed at significantly higher levels in HIV-1 infected 
children in comparison to uninfected children in keeping with adult studies (Jones et al., 
2008, Jin et al., Fourcade et al., Day et al., 2006). Our investigation revealed that PD-1 
expression on CD8+ T cells was higher in the HIV-infected children in comparison to the 
HIV-uninfected children in keeping with recently described reports (Prendergast et al., 
2011c). We documented elevated expression levels on CD8+ T cells in comparison to CD4+ 
T cells for both TIM-3 and PD-1 inhibitory molecules. Our findings demonstrate no 
association between TIM-3 and PD-1 expression markers with markers of disease 
progression in contradiction to adult HIV-1 studies (Jones et al., 2008, Day et al., 2006). Our 
study demonstrated a positive association between TIM-3 and PD-1 in an HIV-1 paediatric 
disease setting. PD-1 seemed to be a marked negative regulator of activated T cells in 
children (Prendergast et al., 2011c). Longitudinal investigation revealed that TIM-3 and PD-1 
expression levels on T cells were maintained at high levels and tracked with viral load.  
 
Taken together, our findings may explain why younger newly infected children are unable to 
control HIV infection and show low magnitude and breadth suggesting limited HIV-1 
specific T cell immunity. Data on co-regulation of PD-1 and TIM-3 in a LCMV model 
showed that blocking of these pathways restored immune responses, suggesting that the 
immune system is able to mount a vigorous attack against foreign infections. Furthermore, a 
simultaneous blockade of TIM-3 and PD-1 pathways has been documented to have a 
synergistic effect in restoring antiviral immunity and viral control compared to the blockade 
of either pathway alone (Jin et al., 2010). Reversal of T cell dysfunction may prove valuable 
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in therapeutic vaccine development.  It is noteworthy, Phase I clinical trials are currently 
being carried out to evaluate the efficacy of the use of PD-1 blockade therapeutically in 
oncology and infectious disease settings (Brahmer et al., 2010, Berger et al., 2008, Sakuishi 
et al., 2011). 
 
Our study did pose limitations worth highlighting. We were limited by the relatively small 
sample size for a phenotypic study and flow panel constraints that restricted our investigation 
of co-expression of PD-1 and TIM-3 on a single T cell. We were further limited in that we 
were unable to describe these phenotypes in relation to T cell functionality. Nevertheless, to 
date no studies have been performed to investigate the role of TIM-3 in HIV-1 infected 
children, our data is the first undertake this investigations in clade C HIV-1 infection. It 
remains imperative not to extrapolate but rather to investigate the mechanisms underlying 
paediatric infection. 
 
6.4 REGULATION AND ACTIVATION 
Immune exhaustion seems to occur concomitantly with immune activation and decrease in 
regulatory T cells in viremic chronically HIV-1-infected adults (Sachdeva et al., 2010). 
Adults and children differ in disease progression denoting a variation in clinical outcome 
(Holland et al., 2000, Resino et al., 2002b, Resino et al., 2002a). In general, it is presumed 
that young children respond ineffectively due to immature or defective cell functionality 
associated with high viral burden (Ashwood et al., 2011, Ly et al., 2009, Ochieng et al., 
2006).  To date, no studies have been performed to investigate the role of Tregs and immune 
activation in children in the context of HIV-1 clade C infection. Our study was the first to 
investigate the mechanism underlying Treg suppression on generalized immune activation 
and immune response in this African cohort of HIV-1 clade C infected children. 
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Persistent non-specific, generalized immune activation has been implicated as a major driver 
of both susceptibility to HIV and HIV disease progression (Paiardini et al., 2009, Hazenberg 
et al., 2003, Giorgi et al., 1999, Liu et al., 1998, Liu et al., 1997). Tregs have been 
documented to play a role in activation of CD4+ and CD8+ cells during different stages of 
HIV-1 infection (Eggena et al., 2005, Prendergast et al., 2011b). Clade C infection has been 
reported to have one of the fastest rates of disease progression (Cohen et al., 2011, Spira et 
al., 2003). Our study showed that Treg frequency and activation expression profiles to differ 
between uninfected children and treated clade C infected children. We observed a significant 
inverse correlation of Tregs and CD4+ T cell%. Interestingly, in a group of participants tested 
for immune responses we observed a significant inverse correlation between immune 
regulatory and activation on CD8+ T cells.  
 
Immune exhaustion seems to occur concomitantly with immune activation (Sachdeva et al., 
2010)- we thus next investigated their role in paediatric HIV-1 infection. Our study 
investigated the frequency of Tregs using CD4+CD127-CD25+ and T cell activation using 
the markers HLA-DR+CD38+. It is noteworthy, that the selection of these markers is 
controversial and differs from study to study.  CD127 expression inversely correlates with 
FoxP3 and suppressive function of human CD4+ Treg cell (Liu et al., 2006). The phenotype 
CD3+CD4+CD25+CD127- has been used to successfully define and sort functional 
regulatory T cells in previous studies.  We and others have shown a strong positive 
correlation between CD4+CD25+CD127low and CD4+CD25+FoxP3+ T cells.  We have 
data on FoxP3 expression by intracellular staining for a subsets of the study participants, 
however we encountered technical difficulties which prohibited having this data available for 
the entire study cohort.  More commonly, Treg cells are defined based on the frequency of 
CD4+CD25+ and the transcription factor FoxP3+ however; alternate phenotypes such as 
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CD4+CD25+CD127- have also been documented for use in Treg discrimination and isolation 
of functional Tregs for suppression assays . 
  
In contrast to adults (Sachdeva et al., 2010), we found no correlation between Tregs or 
activation markers and markers of disease progression such as absolute CD4+ T cell count 
and viral load. However, this may be attributed to the unstable high persistent viral loads 
children exhibit. The expression of HLA-DR+CD38+ was found to be significantly higher on 
untreated compared to treated and uninfected children on CD8+ T cells and similarly on 
untreated compared to treated and uninfected children on CD4+ T cells. The markers of 
activation on T cells were also found to be significantly higher in the children aged less than 
6 months in comparison to older children, probably further related to the higher viral load 
observed on infants following transmission (Richardson et al., 2003).  
 
Interestingly when we investigated the involvement of immune response we observed a 
significant negative correlation between magnitude of CTL response and both Treg and 
activation markers, in keeping with other studies (Prendergast et al., 2011c, Day et al., 2006). 
In addition to our phenotypic studies were able to expand functional Tregs from HIV-1 
infected children, confirming the presence of functional Tregs, which could further explain 
CD8+ T cell suppression in children. As previously discussed, we were limited by sample 
size. In addition time and mode of transmission was unknown and we were thus unable to 
describe these subset frequencies in the context of MTCT. A larger scaled longitudinal 
investigation was not possible due to participants defaulting and retention of study 
participants.  We were unable to test the effects of other cytokines apart from IFN-γ. 
Paediatric samples are limited and thus we were unable to run all experiments using fresh 
samples. However, a preliminary test indicated minor differences between samples tested.  
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In summary, we demonstrate that the frequency of Tregs and activation markers are elevated 
in paediatric HIV-1 clade C infection. High Treg frequencies, suggest that Tregs may 
contribute to T cell suppression in children, with highest frequency in the age group of < 6 
months, where HIV-1 specific T cell immunity is of lowest magnitude and breadth. Further 
functional studies are needed to dissect the cause and effect during disease progression and 
will enhance our ability to manipulate Tregs and markers of activation in a clinically 
beneficial manner.  
 
6.5 HOST GENETICS: IL-10 
A multitude of viral, host and cellular factors may influence HIV pathogenesis. 
Polymorphisms in cytokine genes such as the anti-inflammatory cytokine IL-10 have been 
implicated in clinical outcome perhaps through modulation of host adaptive response in 
humans via influence on cytokine levels (Vollmer-Conna et al., 2004). The overall effect of 
IL-10 on susceptibility to HIV-1 infection and disease progression is not fully understood. IL-
10 promoter polymorphisms have been shown to influence susceptibility and have been 
reported to be associated with differential outcome based on stage of HIV-1 infection 
investigated, however data is lacking on the role of IL-10 and IL-10 genetic variants on 
mother-child transmission and paediatric HIV-1 disease progression.  
 
Our study explored possible mechanisms underlying the role of IL-10 promoter variants on 
HIV pathogenesis. Our investigation confirmed that the carriers of allelic variant-1082G were 
linked with higher IL-10 production in comparison to the carriers of IL10 -1082A and in turn 
associated with transmission. The stratification of investigated cytokines revealed that 
proinflammatory and adaptive function were limited, in comparison to the anti inflammatory 
cytokine IL-10 in children within this cohort. The carriers of IL10 -592A, which is generally 
245 | C h a p t e r  6 :  D i s c u s s i o n  a n d  C o n c l u d i n g  r e m a r k s  
 
associated with low IL-10 production in adults, however who showed no association in our 
children cohort, which was significantly associated with a lower magnitude of response. 
Notably, due to the controversial role of IL-10 in maintenance of immune responses and the 
contradiction between our data in children in comparison to findings in adults, an 
understanding of the underlying mechanisms that regulate immune control is crucial.  
 
The association of IL-10 polymorphisms vary in HIV-1 infection and with plasma IL-10 
levels. This may vary with age, treatment and cell types. The population under investigation 
was a very heterogenous group which could account for variations. IL-10 polymorphisms 
alone cannot account for IL-10 levels. Other cells may further contribute to IL-10 production 
such as macrophages. Other cytokines may also affect IL-10 production. IL-10 levels may 
also be impacted by co-infections. Further work will need to be done to understand better the 
role of IL-10 and IL-10 genetic polymorphisms in HIV pathogenesis. A meta-analyses of all 
reported IL-10 promoter polymorphism studies within HIV-1 infection, as recently executed 
in cancer research (Zhu et al., 2011) and acute Hepatitis B and C infections (Stacey et al., 
2009), will prove beneficial for a better understanding of the mechanism driving IL-10 
regulation.  
 
6.6 THE WAY FORWARD...... 
We are constantly being exposed to infectious agents and yet, in most cases, we are able to 
resist infections. Unlike most infections, HIV infected individuals require ARV to prolong 
their survival, are unable to clear their infection, or develop a natural immunity to subsequent 
infection.  The evaluation of protection against HIV is normally undertaken in exposed 
uninfected cohorts, elite, long term non-progressors and acute seroconvertors. The failure of 
the MERCK STEP vaccine trials (Bradac and Dieffenbach, 2009) and clues form the Thai 
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trial has increased the urgency to extend HIV-1 research to investigate viral, host, cellular and 
adaptive research concurrently. 
 
As HIV preferentially targets CD4 cells and depletion of these cells characterizes HIV 
pathogenesis most researchers are on a quest to identify correlates of protection against HIV, 
which can be implemented into HIV vaccine design and efficacy trials. Only a few potential 
HIV vaccines have been clinically approved for testing, of which the recent T cell based 
RV144 vaccine has shown partial protection against HIV (Rerks-Ngarm et al., 2009).  Further 
studies that focus their investigation on therapeutic vaccines that are able to boost quality 
immune response, provide protection and help in the containment of viral load will prove 
valuable. Efforts need to focus more towards CD4+ T cell responses which have more 
recently been implicated in viral containment in children (Prendergast et al., 2011a). 
 
In macaques CD8+ T cell depletion have been associated with a rise in viremia (Jin et al., 
1999, Metzner et al., 2000). T cells play a pivotal role in the host antiviral adaptive response 
to HIV infection. However, HIV does not only affect the cell mediated branch of the adaptive 
response but also influences the humoral arm of adaptive immunity. Ideally a successful 
vaccine should be able to induce effective cellular as well as humoral responses. Currently, 
researchers are trying to identify monoclonal antibodies that could elicit broad potent 
neutralizing antibodies that could prevent infection at sites of infection (Munier et al., 2011, 
Wu et al., 2011, Singh et al., 2011).    
 
On the other hand, the host adaptive response is the body’s second line of defence and 
requires time to react to an invading organism, whereas the innate immune system provides 
immediate defence and is ready to be mobilized upon infection. Second, the adaptive immune 
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system is antigen specific and reacts only with the organism that induced the response. In 
contrast, the innate system is not antigen specific and reacts equally well to a variety of 
organisms. Ideally both components of the immune system, have demonstrated central roles 
in antiviral immunity by shaping the quality of the adaptive immune response to viruses and 
by mediating direct antiviral activity(Koblin et al., 2011). Vaccine initiatives may also need 
to focus on natural killer T cells (NKT), which play an intermediary role in bridging the 
innate and acquired immune system enhancing both systems respective functions. 
 
Pathways of exhaustion and regulation should also be further investigated. PD-1 and CTLA-4 
have been found to be positively associated with viral load (Kaufmann et al., 2007, Day et al., 
2006). PD-1 together with TIM-3, have been synergistically proven to improve CD8+ T cell 
responses and viral control in the LCMV model (Jin et al., 2010).   Interestingly, CD8+ T 
cells expressing both inhibitory receptors produced the suppressive cytokine IL-10.The 
inhibition of the IL-10 pathway has also been shown to restore T cell function and result in 
eventual viral clearance (Brooks et al., 2008, Brooks et al., 2006, Ejrnaes et al., 2006). Tregs 
play a dual role and have been implicated in T cell suppression. Treg studies were limited by 
the need to identify markers that adequately predict frequency and function of Treg subsets. 
In addition, low frequencies of Tregs in HIV controllers have been found to contribute to an 
effective adaptive immune response, but may also contribute to generalized immune 
activation, potentially contributing to CD4 depletion (Eggena et al., 2005, Cao et al., 2009, 
Hunt et al., 2011, Prendergast et al., 2011b, Xiao et al., 2011). Our ability to expand 
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Vertical Transmission 
 It remains unclear why some infants become infected while others do not, despite their 
considerable exposure to HIV-1 in utero, during delivery and while breastfeeding. The 
mechanisms underlying vertical transmission are thought to be elevated viral loads, genital 
secretions and breast milk. The immune responses, polyfunctionality of T cells, and the 
presence of selective escape variants impact viral load levels. Furthermore, neutralising 
antibodies have been found to successfully reduce infection rates. Both humoral and cellular 
responses are necessary to reduce vertical transmission. Taken together, reduction in 
transmission and suppression of HIV-1 may be possible and could be achieved by 
enhancement and manipulation of the potential pathways. 
 
6.7 CONCLUSION 
Our HIV-1 MTCT study was established prior to the revision of PMTCT guidelines and 
represents a rare cohort of untreated children. Due to the much welcomed revision of PMTC 
guidelines, our initially envisioned detailed study design changed, creating the need to 
broadly investigate paediatric HIV-1. However, there still exists a need to describe these roles 
in more detail in future investigations. Nevertheless these findings, much of which has not 
been assessed particularly role of Tregs, PD-1, TIM-3 and IL-10, contribute to our 
understanding and existing knowledge and understanding of paediatric HIV-1 infection.  
 
Possible eradication of paediatric HIV-1 infection lies in the development of an infant 
vaccine that can be administered at birth that would theoretically provide protection from 
infancy, through the adolescence period, and into adulthood. An overall understanding of the 
exact mechanism that drives HIV-1 disease pathogenesis is restricted due to the apparent 
multifactorial impact of the virus.  
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APPENDIX 






RESEARCH CONSENT FORM FOR UNINFECTED PARTICIPANTS (CHILDREN) 
Protocol Title: MECHANISMS OF HLA-ASSOCIATED CONTROL AND LACK OF CONTROL OF HIV INFECTION.  
BREC REFERENCE NUMBER E028/99 
PHD SUBSTUDY CELLULAR IMMUNITY, IMMUNE ACTIVATION AND REGULATION IN HIV-1 INFECTED 
MOTHER-CHILD PAIRS: WHAT ARE THE DETERMINANTS OF PROTECTIVE IMMUNITY?  
Principal Investigator:  Professor Thumbi Ndung'u and Ms. Eshia Moodley 
Study Clinician:   Dr Fundisiwe Chonco and Dr Gurpreet Kindra 
Description of Study Population:   Children Uninfected with HIV  
_________________________________________________________________________ 
Information to Patients- English  
This study will be conducted at 4 clinical sites as follows: 
1) Prince Mshiyeni Memorial Hospital. 
2) St Mary’s Memorial Hospital 
3) McCords Hospital 
4) King Edward Hospital  
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Dear Parent and/or Caregiver, 
You have been told that your child is HIV Negative.  You have been informed about the study by the 
clinician and nursing staff of the HIV Pathogenesis Program (HPP). 
If you agree to participate, you will be given a signed copy of this document. We would like to take some 
blood (5ml<2yrs, 10ml<12yrs) from your child to see the difference between immune responses made 
by children infected with HIV and those who are not infected.  We will also study the genetic make-up of 
the donated blood cells. People with different genetic make-up respond differently to viral infections 
and our study will help us to understand the response to HIV. This is a research study that has no 
immediate benefits to the child.  It is important as it will help us understand immune responses in young 
children and help us to develop a vaccine for HIV so that in future people will not be infected.  The blood 
will be taken from your child every 3-6 months until the study is closed (estimated between 1 – 3 years).  
 
USE AND STORAGE OF SAMPLES 
We shall store your child’s cells and they will be used to define his/her immune status and his/her 
genetic make-up. Your child's samples will be stored at laboratories that are specially designed to keep 
stored samples safely.   Samples left-over from this study may be used in other approved studies in the 
future. These samples will not be used for studies not approved by the ethics committee. If we want to 
use the samples for a research purpose not described in this consent form, we will send our request to 
an Institutional Review Board or the UKZN Ethics Committee. The committee protects the rights and 
welfare of research subjects.  They will determine if we need to contact you and ask your consent to do 
the research.   
 
 The samples will neither be used for any commercial interests, nor will they be sold or used in products 
that make money for the researchers.  You will not receive payment or entitlements for any beneficial 
outcomes of these studies. 
  
The blood may be analyzed in laboratories outside of South Africa.  This is because we do not have the 
expertise to do all the testing here in South Africa.  Only approved researchers working on this project 
will be able to access your samples. The people who work at these laboratories will have access to the 
samples when they store them and keep track of them, but they will not know the name of the child as 
they will be stored by number. There is no time limit on how long the samples may be stored. You will 
not forfeit your rights over these cells and you can request at any time that they be destroyed.  The 
blood sample and personal information will be stored without the child’s name or other information to 
identify him/her as a participant in this study to protect their privacy.  
 
You will be given R75 on every scheduled clinic visit to cover transport costs.  Participation is completely 
voluntary, and you may choose not to have your child participate.  If you choose not to have your child 
participate, your care at the clinic will not be affected in any way.  If you choose for your child to 
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participate, you may withdraw your consent at any time without any penalty if you so choose.  Your 
child’s participation will be treated with strict confidentiality. 
Site-Investigator’s Contact details: Professorf T Ndung’u on 0823587204 or Dr Fundisiwe Chonco on 
0826871535.   
 
Contact details of Research Ethics Committee administrator and Chair-for reporting of 
complaints/problems.  
email:  brec@ukzn.ac.za or phone: 031 260 4769.   
Physical address: The Biomedical Research Ethics Committee,  Room N40, Govan Mbeki Research 
Centre, Westville Campus, University of Kwazulu-Natal, Durban, South Africa. 
 
Thank you for your help. 
 
Doctor/Sister ________________________ of the Hospital Research team has explained to me that I am 
attending a clinic where HIV is being treated and studied.  I have read the above document and I consent 
for my child to be involved in the study. 
 
 
Date : _______________________ 
 
Client Name : ______________________    Client Signature : _________________________ 
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SAMPLE EXPORT 
We ask your permission to send some of your blood to scientists outside of South Africa for 
investigations related to this study. We work closely with other scientists in the US and Europe who are 
able to do tests that we are not yet able to do  here in South Africa. Your blood or your DNA (a product 
from your blood) will be sent without your name or other identifying information to protect your 
privacy.  We will seek ethics approval and your consent before any new studies are done on the 
samples. 
 
Date : _______________________ 
 
Client Name : ______________________    Client Signature : _________________________ 
 




We ask your permission to store processed blood products for future testing. Your blood products will 
not be stored with any identifying information that can link your specimen to you as a participant in this 
study. We will seek ethics approval and your consent before any new studies are done on the samples. 
 
Date : _______________________ 
 
Client Name : ______________________    Client Signature : _________________________ 
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RESEARCH CONSENT FORM 
 
Isihloko:  HIV Specific CD8+ T cell responses in chronically HIV infected children 
Indawo: St Mary’s Hospital, King Edward Hospital, Prince Mshiyeni Memorial Hospital, McCord Hospital 
Umcwaningi omkhulu:   Dr Philip Goulder 
Abacwaningi abaseduze:  Dr Fundisiwe Chonco; Srs Thandi Cele; Thandi Sikhakhane 
 
Uhlobo lwabantu oludingekayo: Izingane ezitheleleke ngegciwane lengculazi isikhathi    
  esingange minyaka emithathu 
 
Ulwazi oluqondiswe kuziguli- IsiZulu 
 





Ubusutsheliwe ukuthi umntwana wakho utheleleke ngegciwane lengculazi. Egazini lengane yakho  
kunezakhi zomzimba (T –cell) ezikwazi ukulwa nezinhlobo zezifo ezingamuhlasela, kubalwa negciwane 
lengculazi. Ucwaningo lukhombisa ukuthi uma lezizakhi zomzimba ziqinile futhi zisebenza kahle zenza 
ukuthi ingculazi ingasheshi ikugulise. Lokhu kuhambelana nohlobo lwegciwane lengculazi elihlasele 
umntwana wakho. 
 
Singathanda ukuthatha igazi Kumntwana wakho elilingana nespuni (5ml<2,10ml<12) ukuze sihlole 
uhlobo lwegciwane nendlela igciwane elizibonakalisa ngayo kumntwana. Lolucwaningo alunanzuzo 
esheshayo kuwe. Lubalulekile ngoba wussizo ekwakheni umgomo wegciwane lengculazi kubantu 
bakusasa abangathelelekile. Igazi lomntwana wakho liyothathwa njalo emva kwezinyanga ezintathu 
kuya kweziyisithupha.  Sizolilondoloza igazi lomntwana wakho, siyolisebenzisa kuphela uma sihlola isimo 
samasotsha omzimba kanye nohlobo lwezakhi zomzimba ezenza ufuzo (HLA) zakhe. ( HLA- imele 
Leukocyte antigen yomuntu- okuyizinhlayiyana ezincane egazini okusiza umzimba ungangenwa yizifo.  
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Uhlobo lweHLA uluthola kubaba nomama wakho. Sikholwa ukuthi abantu abanezinhlobo ezahlukene ze 
HLA bangakwemukela  ngezindlela ezahlukene ukumelana negciwane lengculazi. Kuyinhloso yethu 
ukuthi uma sesiqedile ngocwaningo emva kweminyaka emithathu kuya kwemihlanu ( 3-5 years) leli gazi 
eligciniwe sibulale izakhi ezikulo, ngeke asetshenziselwe ukuhweba noma olunye ucwaningo 
olwehlukile. Ngaphezu kwalokhu awulahlekelwa ngamalungelo akho ngaleligazi uma uthanda ungacela 
ukuthi abulawe. 
 
Uyonikezwa imali yokugibela engamashumi amahlanu amarandi (R50) ngesikhathi   uvakashele 
emtholampilo ukuyothathwa igazi. Ukubandakanya umntwana wakho kuyilungelo lakho 
awuphoqelekile, ungakhetha futhi ukungazibandakanyi. Uma ungazibandakanyanga lokho ngeke 
kuthikameze amalungelo akho njengesiguli emtholampilo. Ungakhetha ukuphuma kulolucwaningo uma 
ungasathandi. Ukuzibandakanya kwakho kuyogcinwa kuyimfihlo. 
 
Siyabonga ngo sizo lwakho 
 
 
UDokotela/uMhlengikazi omkhulu ________________________ wase St Mary’s  Hospital ungichazelile 
ukuthi ngivakashela emtholampilo lapho kwelashelwa khona isandulela ngculazi bese kwenziwa 
nocwaningo. Ngiwufundile lo mbhalo ongenhla futhi ngiyavuma ukuthi umntwana wami abandakanywe 
ocwaningeni. 
Usuku : _______________________ 
 
Igama lesiguli: ______________________    Isishicilelo sesiguli: _________________________ 
 
Igama Likameluleki: ___________________  Isishicilelo sikameluleki: ____________________ 
Abacwaningi ongathintana  nabo nezinombolo zabo zocingo: Srs Thandi Cele & Thandi Sikhakhane: 
0836451759 noma u Prof T Ndung’u pm 0823587204. Ungaxhumana noSihlalo we Research Ethics 
Committee uma ufuna ukubika izikhalo zakho nezinkinga onazo. Ungakhona futhi ukuxhumana nosihlalo 
we Biomedical Research Ethics committe ( Dr Jack Moodley) kanye noNkosikazi S. Buccas kulenombolo: 
(031) 260 4769; email address: buccas@ukzn.ac.za 
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I address lakhona:  The Biomedical Research Ethics Committee, University of KwaZulu-Natal, 719 Umbilo 
Road, Congella 4013, Durban 
B) Sequencing PCR (Chapter 2) 
Reagents for first round PCR.  
Reagent Volume (µl) 
H2O 















PCR amplification conditions for first round (Leslie et al., 2004) .  
Step number Temperature (C) Time 
1 99 2 minutes 
2 94 15 sec 
3 62 30 sec 
4 72 1 minute 
5 restart step 2,20 times  
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6 94 15 sec 
7 59 30 sec 
8 72 1 minute 
9 restart step 6, 20 times  
10 72 7 minutes 
11 4 for ever 
Reagents for second round PCR.  
Reagent Volume (ul) 
H2O 













PCR product 5.0 
Total 50.0 
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PCR amplification conditions for second round.  
Step number Temperature (C) Time 
1 99 2 minutes 
2 94 15 sec 
3 56 30 sec 
4 72 1 minute 
5 Restart step 2, 20 times  
6 94 15 sec 
7 54 30 sec 
8 72 1 minute 
9 Restart step 6, 20 times  
10 72 7 minutes 







Viral replicative assay MWM confirming Gag-Protease insert 
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C) HLA 
Clinical characteristics of participants of ARV naïve study cohort (Chapter 2)  
Mothers Age CD4 VL A A B B C C 
CP1M- 001  35 347 13,400 02 3002/3010/3012 35 44 04 1601 
CP1M- 002  30 301 82,600 33 68 07 41 07 17 
CP2M- 001  22 173 173,000 24 3402/3404 08 1516 07 1402/1403 
CP3M- 004 24 905 170,000 30 6602 39 45 1203 1601 
CP3M- 005 28 246 185,000 3004/3006 3004/3006 27 5802 0202/0205 0602/0607/0610 
CP3F- 005       03 03 08 08 07 07 
CP3M- 006 33 259 40,100 nd           
CP3M- 007 17 418 376,000 68 68 07 1510 03 07 
CP3M- 009 25 288 4,700 03 03 5802 5802 06 06 
CP3M- 010 42 247 41,800 2301 6602 1402/1404 44 07 08 
CP3M- 011 36 291 130,000 01 32 4207/4201 8101/8102 17 1801/1802 
CP3M- 014 28 641 5,690 24 3002/3012 07 14 07 08 
CP3M- 015 27 448 37,600 03 34 1503 44 02 04 
CP3M- 016 23 225 223,000 29 3001/3018/3019/3014 5802 5802 06 06 
CP3M- 018 36 287 69,600 30 68 4201 5802 06 17 
CP3M- 019 25 281 127,000 03 74 1503 5802 02 06 
CP3M- 020 29 200 286,000 0205/0208 68 1503 18 02 04 
CP3M- 021 30 317 253,000 3 66 13 1510 NA NA 
CP3M- 023 29 211 31,200 02 68 07 5802 06 07 
CP3M- 024 32 210 692,000 29 6601/6604 4201 5802 06 17 
CP3M- 026 33 344 75,900 01 03 35 81 04 18 
CP3M- 027 32 279 48,900 3001 6602 4201 44 07 17 
CP3M- 028 40 397 30,200 30 32 1510 4201 08 17 
CP3M- 033 22 201 111,000 02 3002/3010/3012 08 5802 06 07 
CP3M- 034 32 176 1,170 23 66 5801 5802 06 07 
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CP3M- 036 36 217 7,080 30 30 1503 4201 1701 1801 
CP3M- 039 28 526 4,790 3004/3006 74 1503 41 02 17 
CP3M- 040 23 381 58,200 03 68 07 1510 03 07 
CP3M- 041 30 113 726,000 23 3402/3404 08 08 07 07 
CP3M- 042 29 450 4,790 23 3002/3007/3010/3012 4201 5802 06 17 
CP3M- 043 34 176 60,900 0205/0208 33 4201 5802 06 17 
CP3M- 044 30 647 1,790 2 03 08 5801 07 07 
CP3M- 045 21 430 65, 500 1 68 44 44 04 07 
CP3M- 046 25 450 10, 400 23 3402/3404 1503 4201 02 17 
CP3M- 047 31 550 6,200 3002/3010/
3012 
3402/3404 08 44 04 07 
CP3M- 049 22 428 63613 2 66 45 5802 06 16 
CP3M- 050 28 821 4392 24 66 07 5802 06 07 
CP3M- 051 21 269 3822 2 03 1510 45 03 1601/1607/1608 
CP3M- 052 33 580 1202 24 74 07 5702/5703 07 07 
CP3M-064 23 584 28,161 3 23 1510 5802 16 ? 
CP4M- 001  26 616 139,000 26 74 41 45 1601 17 
CP4M-002  34 347 328,000 3402/3404 6802 07 44 04 07 
CP4M-003  32 669 322,000 02 3002/3012 5802 5802 0602 602 
CP4M-004 23 704 18,100 3001 3402/3404 4201 44 04 17 
CP4M-005  34 147 39,800 24 6802 07 14 07 0802/0807 
CP4M-006  32 244 75,300 2301 29 1510 15 03 1601 
CP4M-007  37 345 54,200 3002/3012 74 1402 5703 07 08 
CP4M-008 28 306 68,500            
CP4M-009  37 412 48,800 30 3402/3404 3910/3920 44 04 12 
CP4M- 010 25 24 125,000 0205/0208 3004/3006 1401 5802 0602 08 
CP4M-011 35 134 750,000 30 29 18 58 3 07 
CP4M-012 31 253 249,000 29 6802 07 1510 0304/0305 07 
CP4M-013  30 226 660000 4301 6802 1503 5802 0202/0210 0602/0607/0610 
CP4M-014  26 143 750000 02 68 35 49 04 07 
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CP4M-016 29 nd 39,600 34 68 1503 49 2 4 
CP4M-017 24 320 26,700 3 74 13 49 2 6 
CP4M-018 24 515 205,000 3002 74 1503 49 0202/0210 0602/0607/0610 
Children                   
CP1C- 001  2.7 22 1,320 3402/3404 3002/3010/3012 35 44 04 1601 
CP1C- 002 child 
2 
3 23 76,100 0205/0208 68 07 5703/5702 07 07 
CP1C- 002 child 
1 
5 46 4,130 2 6802 07 5703/5702 07 07 
CP2C-001  0.6 13 2765360 N/A           
CP3C-004 3 17 148,000 30 34 44 45 04 16 
CP3C-005 0.8 37 303,000 03 30 08 5802 06 07 
CP3C-006 0.5 20 750,000 03 68 0807/08 1509/1510 07 08 
CP3C-007 0.3 39 750,000 68 68 07 5702 07 1801/1802 
CP3C-009 0.4 17 750,000 03 3001/3018/3019 4201 5802 06 17 
CP3C-010 0.3 38 750,000 2301 33 1402/1404 4201 08 17 
CP3C-011 0.3 42 201050 2301 33 1402 4201 0802/0807 17 
CP3C-014 0.7 21 328,000 24 68 07 58 07 07 
CP3C-015 8 15 62,800 24 3402/3404 08 44 04 07 
CP3C-016 0.5 30 7281580 0304/0305 3001/3018/3019 1510 5802 0304/0305 06 
CP3C-018 2 22 178,000 3004/3006 68 07 5802 06 07 
CP3C-019 0.4 24 750,000 3402/3404 74 1503 44 02 04 
CP3C-020 0.5 14 322,000 02 02 18 45 02 16 
CP3C-021 0.4 13 740000 03 30 13 39 06 17 
CP3C-023 0.3 22 405,000 0202/0210 03 1503 5802 0202/0210 06 
CP3C-024 0.6 37 537,000 30 66 27 5802 02 06 
CP3C-026 0.3 16 750,000 01 30 42 81 17 18 
CP3C-027 0.3 19 750,000 30 30 08 44 07 07 
CP3C-028 0.5 18 292,000 23 30 1503 4201 02 17 
CP3C-033 0.3 17 750,000 29 3002/3010/3012 44 5802 06 07 
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CP3C-034 1.8 12 579,000 23 68 1510 5801 07 08 
CP3C-035 0.8 24 750,000 02 23 08 15 03 08 
CP3C-036 0.4 24 1477305 30 30 08 4201/4208 07 17 
CP3C-039 0.4 38 557,000 3004/3006 30 07 41 02 17 
CP3C-040 0.6 31 750,000 6601/6604 68 07 5802 06 07 
CP3C-041 1 31 750,000 23 3002/3007/3010/3012 08 39 07 12 
CP3C-042 0.3 33 627,000 3002/3010/
3012 
3402/3404 1503 5802 02 06 
CP3C-043 1.5 32 104,000 0205/0208 68 1510 5802 03 06 
CP3C-044 0.9 22 260,000 0205/0208 02 1401/1407 5801 07 08 
CP3C-045 1 24 530, 000 1 66 44 5802 06 07 
CP3C-046 0.4 33 750, 000 34 34 1503 44 02 04 
CP3C-047 0.4 38 7135185 3002/3010/
3012 
32 08 5801 07 07 
CP3C-049 0.3 30 3,902,668 2 30 45 45 16 16 
CP3C-050 0.4 33 82,227 23 24 07 08 07 07 
CP3C-051 0.5 24 62,185 1 02 45 81 1601 18 
CP3C-052 0.4 40 558,889 24 3402/3404 07 44 04 07 
CP3C-064 0.5 30 1,000,000 23 30 1510 45 16 16 
CP4C-001  3.3 28 59,900 0205/0208 26 1401 41 08 17 
CP4C-002  3 34 529,000 24 3402/3404 07 44 04 07 
CP4C-003  4.2 21 189,000 30 30 45 5802 06 1601/1602 
CP4C-004  1.5 37 301,000 3001 6802 07 4201 07 17 
CP4C-005  2.5 25 335,000 24 3001 1402 4201 0802/0807 17 
CP4 C-006  3.1 25 246,000 2301 6801 1510 5801 03 06 
CP4C-007 3 33 97,600 2301 74 1510 5703 07 1601 
CP4C-008  2 26 348,000 02/0250 6802/6901 1401 5802 0602 08 
CP4C-009  2.1 11 750,000 3402/3404 6601/6604 44 5802 04 06 
CP4C-010  9 22 167,000 3004/3006 6802 1402 5802 0602 08 
CP4C-011 2 11 439,000 30 30 13 18 6 7 
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D) ELISpot-peptides routinely tested  
HLA Protein Code Clade-C Sequence OLP# 
B7 P24 B7-SV9(p24) SPRTLNAWV #20 
  P24 B7/42/81-TL9(p24) TPQDLNTML #25 
  P24 
B7/42/81-HA9 
(p24) HPVHAGPIA #29, #30 
All these peptides should 
be tested for B7/42/81 
P24 B7/42/81-GL9(p24) GPSHKARVL #48 
Nef B7/42/81-FL9(Nef) FPVRPQVPL #76 
Nef 
B7/42/81-RM9 
(Nef) RPQVPLRPM #76 
  nef 
B7/42/81-
RGF9(nef) RPMTFKGAF #77 
  nef 
B7/42/81-
TL10(nef) TPGPGVRYPL #84 
  RT B7/42/81-SM9(RT) SPAIFQSSM #187 
  vpr B7/42/81-FL9(vpr) FPRPWLHGL 
#281, 
#282 
  gp120 
B7/42/81-
RI10(gp120) RPNNNTRKSI #328 
  gp41 
B7/42/81-
IA9(gp41) IPRRQGFEA #401 
  vif B7/42/81-HI10(vif) HKRVSSEVHI 
#407, 
#408 
  Int B7/42/81-LI9(Int) LPPIVAKEI #244 
  Pro 
B7/42/81-
TL11(Pro) TPVNIIGRNML #163 
  RT B7/42/81-YL9(RT) YPGIKVKQL 
#202, 
#203 
  REV B7/42/81-RL10 RPAEPVPLQL #102 
  P17 B7/42/81-RLY10 RLRPGGKKHY #3 
  RT B81/42/81-SL10 SPIETVPVKL #166 
  RT B7/42/81-VM9 VPVKLKPGM #166 
  RT B7/42/81-VL9 VASCDKCQL #245/246 
  RT B7/42/81-RQL11 RPPLVKLWYQL #221 
  PROT B7/42/81-TM10 TPVNIIGRNM #163  
  Vif B7/42/81-KL9 KPKKIKPPL #422 
  RT B7/42/81-TL11 TPGIRYQYNVL #184 
CP4C-012  10 38 164,000 29 3402/3404 1510 44 0304/0305 04 
CP4C-013  7 16 177,000 29 4301 18 5802 602 704 
CP4C-014  4 32 331,000 3002/3010/
3012 
68 35 5802 04 06 
CP4C-016 7 nd 71,300 3 34 1503 5802 2 6 
CP4C-017 6 31 120,000 1 74 1503 45 2 16 
CP4C-018 5 24 292,000 3002/3010/
3012 
6802/6818/6827 1510 5802 0304/0305 0602/0607/0610 
CP4C-019 5 27 30,900 29 68 1503 5801 2 4 
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  RT B7/42/81-GL9(RT) GPKVKQWPL #168 
     
B27 P17 B27-IK9(p17) IRLRPGGKK #3 
  P24 B27-KK10(p24) KRWIILGLNK #36 
  nef B27-KV10(nef) KRQEILDLWV #81 
  gp41 B27-GR10(gp41) GRSSLRGLQR #393 
  RT B27-KY9 KRKGGIGGY #265 
          
B57 p17 B57-WF9(p17) WASRELERF #5 
  P24 B57-ISW9(p24) ISPRTLNAW #20 
Run B57 peptides  
P24 B57-KF11(p24) KAFSPEVIPMF #22 
p24 B57-DW10(p24) DTINEEAAEW #28 
for all B5801/5802/5803 P24 B57-TW10(p24) TSTLQEQIAW #33, #34 
  P24 B57-QW9 (p24) QATQDVKNW #42 
  nef B57-HW9(nef) HTQGYFPDW #82 
  Rev B57-QY10(Rev) QAVRIIKILY #96 
  RT B57-IW9(RT) IQLPEKDSW #199 
  RT B57-IAW9(RT) IAMESIVIW #216 
  Int B57-SW10(Int) SAAVKAACWW #257 
  Int B57-KF9(Int) KTAVQMAVF 
#263, 
#264 
  Vpr B57-AW9(Vpr) AVRHFPRPW #281 
  Env B57-KW11(Env) KAYETEVHNVW #296 
  Vif B57-VF9(Vif) VSRRANGWF #405 
  nef B57-KAF9(Nef) KAAFDLSFF #78 
  RT B57-AF10 QATWIPEWEF #220 
  RT B57-FF9 FSVPLDEDF #181 
  RT B57-EY9 ETKIGKAGY #226 
  RT B57-KI13 KAGYVTDRGRQKI #226 
  GP120 B5802-QL11 QTRVLAIERYL #365 
  Vif B57-LW9 LGHGVSIEW #411 
  gp41 B57-TWS10 TTAVPWNSSW #369 
  RT B57-LL9 LGIPHPAGL #178 
  RT B57-FW11 FAIKKKDSTKW #174 
  POL B57 KR10 KAGYVTDRGR #226 
  POL B57 VI9 VTDRGRQKI #226 
          
 
